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Abstract 
Comprehensive evidence on the comparative effects of various oral antithrombotic agents 
on the prevention of saphenous vein graft failure (SVGF) for patients undergoing 
coronary artery bypass is lacking. A systematic review and frequentist random-effects 
network meta-analysis of 18 RCTs (n=3,413 patients) comparing the effect of 
antithrombotic agents on SVGF and clinical outcomes was performed. Based on 
moderate quality evidence, among the six eligible interventions, dual-antiplatelet therapy 
with aspirin and clopidogrel was superior to aspirin monotherapy in reducing SVGF (OR: 
0.63; 95% CI: 0.41-0.97). No statistical differences were found for major bleeding, 
mortality, and myocardial infarction between antithrombotic agents, owing to low 
number of events for most comparisons. Though significant heterogeneity or incoherence 
was not found, the quality of network evidence for these outcomes ranged from very low 
to moderate. Adequately-powered multi-arm RCTs are needed to ascertain the effects of 
antithrombotic therapies to help clinicians and patients achieve optimal treatment 
decisions. 
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Coronary artery bypass, saphenous vein graft failure, antithrombotic therapy, network 
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Preface 
Among antithrombotic agents, aspirin monotherapy has been recommended as the 
mainstay of prevention of saphenous vein graft failure (SVGF) in patients undergoing 
coronary artery bypass graft (CABG) surgery, as supported in many clinical practice 
guidelines.1-7 The scientific basis for this recommendation was evidence gathered from 
individual studies (randomized controlled trials (RCTs) and observational studies) and 
pairwise meta-analyses. However, there remain gaps in the evidence base for the 
guideline recommendation for prevention of SVGF after CABG. Although the 
conventional pairwise meta-analysis of well-designed RCTs (a quantitative method of 
synthesizing results from independent but similar RCTs to provide greater statistical 
power) is widely considered to be the highest level of evidence, this approach does not 
allow for a coherent assessment of more than two treatment strategies. This is 
problematic as clinicians and patients are challenged to choose from multiple 
antithrombotic drugs. Clinical-decision making is even more challenging because some 
of the medications have not been compared directly in RCTs. To date, no studies have 
been published that assess the comparative efficacy of all relevant antithrombotic agents 
on SVGF prevention among CABG patients in a unified analysis. Therefore, we designed 
a systematic review and network meta-analysis (NMA) in order to include all sources of 
evidence derived from RCTs comparing antithrombotic drugs in a single analysis to 
better inform clinical decision-making and guide further research in this area.  
The following outline provides the overall framework for this thesis. The first chapter 
describes the clinical background regarding the current information related to CABG and 
oral antithrombotic agents as well as the rationale behind the present thesis work and 
discusses thesis objectives. Chapter 2 provides information on the methodological 
background to familiarize readers with the concepts and terminology of pairwise meta-
analysis and NMA. Chapter 3 outlines the methods and statistical analyses used to answer 
our objectives. The results of the systematic review, quality assessment, and NMA are 
provided in Chapter 4. Finally, Chapter 5 discusses the interpretations of our findings, 
strengths and limitations, directions for future research, and overall conclusions.  
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Chapter 1  
 
1 Literature Review 
This chapter provides background clinical information relevant to the thesis. We provide 
a brief description of cardiovascular disease and the importance of coronary artery bypass 
surgery, including its inherent limitations as a treatment modality. We then summarize 
current knowledge about pharmacotherapies used to prevent saphenous vein graft failure, 
highlight notable gaps in the literature, and outline how the present study can expand the 
existing scientific knowledge. 
1.1 Cardiovascular Disease Burden 
Cardiovascular disease (CVD) is an umbrella term for all acute and chronic diseases that 
affect circulatory system in the heart, brain, and other parts of the body. CVD can be 
broadly divided into two types: atherosclerotic CVDs and other CVDs. Atherosclerosis is 
an inflammatory disease in which fatty material and cholesterol are accumulated in the 
walls of blood vessels. Atherosclerotic CVDs include coronary artery disease or CAD, 
which occurs when atherosclerotic plaque narrows the coronary arteries; cerebrovascular 
disease, which occurs when the plaque is in the blood vessels feeding the brain; and 
peripheral vascular disease, which occurs when the plaque reduces blood flow to the 
peripheral arteries. Other CVDs include congenital heart disease, rheumatic heart disease, 
deep vein thrombosis, and pulmonary embolism. 
In 2015, CVD, the leading cause of global mortality, claimed the lives of more than 17 
million (31%) individuals; of which, 80% of deaths occurred in developing countries.8 
Although the mortality burden of CVD was mostly concentrated in developing countries, 
the overall burden remains high in developed countries including United States (US) and 
Canada. In US, nearly 37% of adults have a CVD and one of every three deaths occurs 
due to CVD,9 which is similar to the CVD-specific mortality rate in Canada.10 Despite 
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improved management and medical care, the number of deaths is expected to rise to more 
than 23.6 million by 2030 wordwide.11 
Not only does CVD take a toll on the health of individuals, it poses a substantial 
economic burden. It was estimated that the 2010 global total cost attributed to CVD was 
approximately US$ 863 billion. The global economic burden of CVD will continue to 
increase owing to population aging and clustering of cardiovascular risk factors.12 13 
Consequently, an increase in the global cost is expected with an annual total cost of US$ 
1,044 billion estimated by 2030 and a cumulative total cost of US$ 20,032 billion 
between 2010 and 2030.14 In the US, the annual direct and indirect costs of CVD were 
estimated to be $ 316 billion in 2012 and the annual total direct medical costs are 
projected to double by 2030.9 A similar trend is also forecasted to occur in developing 
countries such as China in which an increase from US$ 721.58 million in 2012 to US$ 
1.71 billion in 2030 is expected.15 To address these global health challenges, there is a 
global initiative by World Health Organization to reduce premature deaths by 25% by 
2025 via preventive measures, which may translate to a 34% reduction in premature 
deaths attributable to CVD, and ultimately, a decrease in overall global health and health 
care expenditures.16 17 The importance of reaching this goal highlights the need to 
improve medical prevention strategies, in addition to primary prevention strategies. 
1.2 Coronary Artery Disease 
Among atherosclerotic CVDs, CAD (also known as ischemic heart disease) is the most 
prevalent type of CVDs. CAD occurs when the coronary arteries, which supply blood to 
heart tissues, become narrowed and stiff due to the accumulation of atherosclerotic 
plaque. Left to its natural history of ischemic heart disease, these cholesterol-rich plaques 
can lead to myocardial infarction (MI), blockages of the artery that lead to the death of 
heart tissue, angina (chest pain), and ultimately death. Globally, CAD is the leading cause 
of CVD-specific mortality.11 In the US, CAD accounts for 45% of all CVD deaths.9 
Treatment strategies for CAD depend on various factors including anatomical factors 
(e.g., the severity of CAD), clinical factors (e.g., presence of comorbidities such as 
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diabetes), technical factors (e.g., whether revascularization is complete or incomplete), 
and patient-specific factors (e.g., patient values and preferences).18 As the first line 
therapy, medical management is used to control symptoms of disease in patients with 
stable CAD. Stable CAD is generally characterized by episodes of chest pain that are 
reversible but persist over time.19 The required pharmacological therapy, among others, 
includes antiplatelet therapy and statins, which should be given to all CAD patients. In 
patients with comorbidities such as chronic kidney disease, hypertension, diabetes, or 
impaired left ventricular ejection fraction (LVEF), an angiotensin-converting-enzyme 
inhibitor is also recommended to improve prognosis.20 However, if symptoms persist 
despite medical therapy, coronary artery revascularization is required to treat the 
disease.18 21 Coronary artery revascularization can be achieved via percutaneous coronary 
intervention (PCI), or coronary artery bypass graft (CABG). PCI is a non-surgical 
procedure where a stent is placed in the narrowed vessel via a catheter, whereas CABG is 
open heart surgery that places bypass grafts by anastomosis (i.e., joining two blood 
vessels) to the heart around the diseased native arteries. Due to advanced technology in 
PCI and CABG, determining the optimal revascularization strategy is not always 
straightforward. In general, revascularization by PCI is recommended for the following 
types of patients: those with single-vessel CAD, multivessel CAD without proximal left 
anterior descending (LAD) involvement that is amenable to PCI and those deemed to 
have prohibitively high surgical risk.21 On the other hand, CABG is indicated for patients 
with lesions that are not amenable to PCI and who have coronary anatomies suitable for 
surgery. More specifically, suitable candidates for CABG are defined as patients with left 
main disease with >50% diameter stenosis, three-vessel disease with left ventricular 
dysfunction, or two-vessel disease with proximal LAD artery disease.21 22 
1.3 Coronary Artery Bypass Graft (CABG) 
CABG was first introduced in the 1950s. Now, CABG is one of the most frequent 
surgical operations performed in the world. In the US in 2012, more than 200,000 
patients underwent CABG with a rate of 64.6 per 100,000 population, which is similar to 
that of the same year in Canada (69 per 100,000).23 24  
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CABG is used to restore blood flow to the heart with the goal of relieving angina 
symptoms and improving survival rates. Recent meta-analyses have observed that 84% of 
CABG patients remain angina-free within the first five postoperative years and that there 
is a 2.7% absolute risk reduction in mortality with CABG compared to PCI in patients 
with multivessel disease.25 26 The long-term success of CABG, however, depends on the 
patency of the grafts, of which there are two main types: arterial and venous conduits. 
The arterial grafts include (left or right) internal mammary artery, radial artery, and rarely 
gastro-epiploic artery. Among arterial grafts, left internal mammary artery (LIMA) to 
LAD coronary artery anastomosis has been recognized as a method of choice followed by 
right internal mammary artery and radial artery.4 21 27 28 Furthermore, compared to venous 
grafts, arterial grafts are the preferred conduit given their excellent long-term patency 
rates. However, total arterial revascularization is underused where <10% of CABG 
patients receive total arterial grafts.29 In practice, arterial grafts are mostly used in 
combination with saphenous vein grafts (SVGs). 
1.3.1 Importance of assessing saphenous vein graft failure 
SVGs remain the most commonly used grafts during CABG because of the benefits 
afforded by the sufficient length to accommodate many anastomoses and ease of harvest. 
Unfortunately, the concern regarding thrombus formation and progression of 
atherosclerosis is predominantly related to SVGs. Compared to arterial grafts, SVGs are 
more vulnerable to thrombotic/atherosclerotic occlusion due to their wall structure, 
biochemical composition, and responses to high pressure in an arterial environment.30 Up 
to 25% of SVGs occlude at one year, 15% to 35% at five years, and 29% to 68% at ≥10 
years, while most (up to 95%) of LIMA grafts remain patent even after 10 years post-
CABG.21 
Though consistent evidence is limited, some argue that the occurrence of adverse 
cardiovascular events post CABG may be explained by the presence of SVG failure 
(SVGF, defined as occlusion that blocks blood supply to the heart through the SVG). The 
mechanism of SVGF starts with the formation of thrombus that involves the localization 
of platelet adhesion and the activation of coagulation cascade system on the vein luminal 
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surface.31-36 This formation is the major pathological process of SVGF within the first 
month of CABG. Between one to 12 postoperative months, intimal hyperplasia is the 
main reason for SVGF, which occurs when smooth muscle cells migrating from the 
media to the intima of veins continue to proliferate and undergo apoptosis.34-36 Beyond 12 
months, atherosclerosis takes over the process of SVGF. Compared to that in native 
diseased arteries, atherosclerosis in SVGs is more likely to rupture and dislodge which 
may result in life-threatening blockages of blood vessels potentially leading to MI, 
angina, or even death.34 A subgroup analysis of patients who returned for catheterization 
within one- and three- postoperative years showed that SVGF was associated with early 
and late angina.37 In addition, another subgroup study of a clinical trial showed that 
patients with SVGF were more likely to experience MI or death than those without 
SVGF.38 It is important to note that these studies are subject to bias because of a high rate 
of loss to follow-up and a failure to adjust for confounders. After controlling for potential 
confounders, the differences in death or MI rates between those who had SVGF and those 
who did not were no longer apparent at four to five years after CABG.39 Moreover, 
although an observational analysis by Halabi et al40 showed that early SVGF (one to 18 
months) was associated with an increased 10-year risk of major cardiovascular events, 
this occurrence was mainly driven by repeat revascularization, “a faulty endpoint for 
clinical trials” that is associated with referral bias as the procedure is more likely to be 
performed in symptomatic patients.41 42 This significant difference can be expected 
because of the high incidence of repeat revascularization relative to MI or death post 
CABG providing greater statistical power to detect differences. Using separate 
multivariable analyses, Lopes et al39 showed a significant association between repeat 
revascularization and SVGF but not with other patient-relevant outcomes (i.e., MI or 
death) at four years after CABG. Whether there is a causal relationship between SVGF 
and clinical outcomes and whether repeat revascularization should be part of the 
composite clinical outcomes, they remain unclear.43 Nonetheless, SVGF is still 
considered an important indicator to guide the decision-making process regarding the 
management of subsequent treatments. If graft failure is detected, it is recommended to 
perform repeat revascularization (PCI or rarely re-do CABG) to treat restenosis.21 
However, repeat revascularization is not without hazards. It is known that PCI places 
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CABG patients at risk of MI, mortality, and additional repeat revascularizations, and that 
re-do CABG is associated with a higher mortality rate compared to initial CABG.21 It is 
therefore of clinical interest to prevent graft failure, especially SVGF given its frequent 
occurrence, to avoid unnecessary invasive procedures and their inherent complications. 
Importantly, emerging evidence suggests that SVG patency rates can potentially be 
improved by pharmacological therapy. Since platelets and coagulation factors contribute 
to the pathophysiology of SVG disease, antiplatelet therapy and anticoagulant therapy 
should, in theory, prevent SVGF as these agents inhibit clotting factors of platelet and 
coagulation.31-36 
1.3.2 Determinants of saphenous vein graft failure 
There are several factors that can affect the development of SVGF either at the patient-
level or graft-level. The well-known patient-level risk factors include traditional 
cardiovascular risk factors such as diabetes, hypertension, dyslipidemia, and smoking.44 
45 46 47 Although females tend to have poorer clinical outcomes following CABG, it is 
unclear whether sex is predictive of SVGF.48 
In addition to patient-level factors, native vessel diameter and surgical technique are the 
graft-related features that predict SVG patency. It was shown that there was a 90% 
patency rate for SVGs that were grafted to vessels >2.0 mm in diameter versus 52% for 
vessels ≤2.0 mm.49 In terms of surgical factors, the ‘no-touch’ technique of harvesting 
SVGs, whereby the vein is harvested along with its surrounding tissue to avoid creating 
spasm, is found to be linked to a reduction of SVGF.50 Another graft-level predictor of 
graft failure is blood flow competition between the native coronary artery and the graft, a 
phenomenon that occurs when a bypass graft competes with a native vessel to supply 
blood to a distal heart vessel. A high competitive flow, especially through a native 
coronary artery with stenosis <70%, accelerates the process of atherosclerosis in the 
grafts.51-53 However, this occurrence happens predominantly in arterial grafts, and the 
association between competitive flow and SVGF remains uncertain.54 
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Other factors that may be associated with the patency of SVGs include use of 
cardiopulmonary bypass (CPB), time to surgery (urgent or elective), antifibrinolytic use, 
and antithrombotic therapy use. A meta-analysis of 12 randomized controlled trials 
(RCTs) showed a statistically significant 41% increase in risk of occlusion of SVGs in 
those who underwent CABG without CPB (known as off-pump CABG or OPCAB) than 
those with CPB (known as on-pump CABG or CCAB).55 Moreover, though there is little 
evidence to show an association between SVGF and time to surgery, it has been 
suggested that compared with elective surgery, patients undergoing urgent surgery were 
likely to receive fewer internal mammary artery grafts and more SVGs.56 57 Moreover, the 
relationship between antifibrinolytic therapy and SVGF remains unclear due to 
conflicting results. A RCT showed that aprotinin increased 10-day occlusion of SVGs,58 
whereas the use of tranexamic acid did not significantly increase the short-term rate of 
SVGF.59 Lastly, the use of pharmacotherapy including lipid-lowering drugs and 
antithrombotic agents was associated with improved SVG patency. 34 36 60 
1.3.3 Prophylactic pharmacotherapy options for saphenous vein 
graft failure 
It has been established that antithrombotic therapy and lipid-lowering drugs are the 
medical therapies used to inhibit the process of SVG disease.34 36 
1.3.3.1 Lipid-lowering agents 
The main goal of lipid-lowering drugs is to reduce blood low-density lipoprotein (LDL) 
cholesterol, a fat-like substance in vein graft atherosclerosis that influences the process of 
SVG disease.45 Lipid-lowering agents include statins and fibrates. Of these, statins are the 
most commonly prescribed drugs.  
Epidemiological studies have shown that statins slow the development of SVG disease. 
In a RCT of 1,351 patients who had prior (1 to 11 years) CABG, the aggressive lovastatin 
(40 to 80 mg/day) therapy was shown to reduce the incidence of SVGF and progression 
of SVG atherosclerosis at four years post randomization compared to the moderate 
lovastatin (2.5 to 5 mg/day) therapy.61 Moreover, a recent multivariable analysis of a 
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RCT showed that among 113 CABG patients who were on statins, those who achieved 
LDL levels <100 mg/dL had a lower occurrence of SVGF than those who did not.62 
Currently, preoperative statins are recommended for patients undergoing CABG and 
should be restarted early after surgery.3 4 6 
1.3.3.2 Antithrombotic therapy 
The main goal of antithrombotic agents is to prevent the formation of thrombus, which 
consists of fibrin and platelets, and the progression of thrombosis. Oral antithrombotic 
therapy is identified in two main categories: oral antiplatelet therapy (aspirin, indobufen, 
dipyridamole, ticlopidine, clopidogrel, ticagrelor, and prasugrel) and oral anticoagulation 
therapy (warfarin, acenocoumarol, phenprocoumon, dabigatran, rivaroxaban, and 
apixaban). In terms of adverse effects, all of these agents put patients at varying risk of 
bleeding. Though they share the same main goal and common side effect, they have 
different mechanisms of action. Antiplatelet agents prevent the activation of platelets, 
reducing the aggregation of platelets on the injured vascular wall by inhibiting receptors 
on platelets. By contrast, anticoagulation therapy prevents clots by interrupting the 
coagulation cascade.34  
Antiplatelet therapy. Aspirin prevents platelet adhesion to the vein wall by decreasing the 
production of thromboxane A2, a hormone released by activated platelets that stimulates 
other platelets and augments platelet aggregation, with the goal of improving graft 
patency and clinical outcomes. Compared to placebo, aspirin administered early after 
CABG for one year was shown to improve 60-day and one-year SVG patency.63 64 In 
terms of clinical outcomes, a recent meta-analysis of RCTs showed that the beneficial 
effect of preoperative aspirin was also apparent in the reduction of cardiovascular events 
in CABG patients.65 Given its favourable effects, it is not surprising to have multiple 
guidelines recommending the use of pre- and post- operative aspirin for the prevention of 
SVG occlusion and the secondary cardiovascular prevention.1-7 
Clopidogrel, ticlopidine, prasugrel, and ticagrelor selectively inhibit adenosine 
diphosphate receptors, causing platelet dysfunction. Clopidogrel, ticagrelor, and prasugrel 
are more potent than aspirin. The combination of these antiplatelet agents with aspirin has 
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been studied in many clinical settings with the expectation of synergistic antithrombotic 
effects, especially in patients with aspirin resistance i.e., patients who do not completely 
respond to aspirin and continue to suffer from the clinical manifestations of thrombosis.66 
For non-responders, the use of a second antiplatelet agent may therefore be justified to 
maximize SVG patency as patients who had occluded vein grafts are more likely to be 
non-responders than those who did not.67 However, one side effect of antiplatelet therapy 
is increased bleeding risk. Using dual or poly antiplatelet agents may potentially improve 
effectiveness but at the expense of a much higher risk of bleeding. 
Dipyridamole and indobufen are antiplatelet drugs that inhibit the activity of platelet 
cyclooxygenase and cyclic guanosine monophosphate phosphodiesterase type V enzyme, 
respectively.5 68 Unlike other antiplatelet agents mentioned previously, these drugs are 
often not used in current practice, especially for SVGF prevention, because of their side-
effects and the fact that they have been preferred over more effective and safer agents 
such as aspirin. 
Anticoagulation therapy. Warfarin, acenocoumarol, and phenprocoumon are vitamin-K 
antagonists, which inhibit blood clot formation by reducing the vitamin-K dependent 
coagulation factors.69 Unlike other antithrombotic agents, vitamin-K antagonists need 
frequent laboratory monitoring to minimize bleeding complications associated with the 
drugs. To address this problem, direct oral anticoagulant agents (DOACs) including 
apixaban, rivaroxaban, and dabigatran have been developed. 
1.4 Gaps in the Current Literature and Rationale of the 
Thesis 
Clinical practice guidelines play a role in providing current summaries of best available 
evidence to health policy-makers, clinicians, researchers, patients, and other healthcare 
providers with the goal of improving patient outcomes and promoting appropriate use of 
optimal therapy.1-7 70 In many guidelines,1-7 70 the strength of recommendations and the 
level of evidence are presented to assist healthcare providers in making informed clinical 
decisions. The strength of recommendations of a specific therapy is graded based on the 
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size of treatment effect ranging from Class I to Class III, where Class I indicates that the 
therapy should be administered, Class II denotes that additional studies are helpful to 
strengthen the recommendation, and Class III suggests that the therapy is harmful or has 
no benefit. The level of evidence, on the other hand, is weighted according to the quality 
of evidence (risk of bias and precision of treatment effect) ranging from Level A to Level 
C, where Level A indicates that data were obtained from high quality of evidence (meta-
analysis or multiple RCTs), Level B means that data were sourced from lower quality of 
evidence (a single RCT or observational studies with conflicting results), and Level C 
suggests that data were from poor quality of evidence (case studies or expert opinions). 
Today, there are many clinical guidelines that have been developed focusing on the 
prevention of SVGF after CABG. The majority of existing guidelines have strongly and 
consistently emphasized the importance of aspirin (alone) administration before and early 
after CABG in improving graft patency (Class of recommendation: I).1-7 However, the 
scientific basis for this recommendation primarily relies on the available direct evidence 
of varying quality. The majority of earlier guidelines, including American College of 
Cardiology/American Heart Association (ACC/AHA)1-3 and American College of Chest 
Physicians5 guidelines, developed recommendations for SVGF prevention based on 
multiple observational studies and underpowered RCTs. In recent guidelines by AHA 
(2015),6 recommendations were based on higher quality evidence (Level of Evidence: I). 
In these guidelines, the writing group appraised and used multiple RCTs and a meta-
analysis of RCTs published by Fremes et al.71 to evaluate the benefit of various oral 
antithrombotic agents in SVGF prevention. However, this meta-analysis included an 
intervention (i.e., dipyridamole) that is not being widely used today and rarely for the 
prevention of SVGF. This is potentially problematic as the conclusions made based on 
studies with irrelevant comparators may not be applicable in the current practice, where 
aspirin monotherapy is the standard prophylactic treatment. Moreover, since the 
publication of this meta-analysis, important evidence from RCTs with newer agents has 
emerged, enriching the totality of evidence to better inform decision-making. Therefore, 
revising guidelines with inclusion of more updated information and more relevant 
interventions is crucial. 
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In 2016, ACC/AHA developed and published more recent guidelines for SVGF 
prevention.70 Unlike many other existing guidelines that highly recommended the use of 
aspirin monotherapy, these guidelines proposed a different recommendation. The 2016 
guidelines suggested that the addition of clopidogrel to aspirin (known as dual-
antiplatelet therapy with aspirin and clopidogrel) may be reasonable for SVGF 
prevention. However, this recommendation requires additional studies to strengthen the 
recommendation (Class of recommendation: IIb) and is based on lower quality of 
evidence (Level of evidence: Level B – Non-Randomized). Using this recommendation 
poses several challenges: 1) the recommendation based on lower quality of evidence may 
not be very helpful in guiding clinical decision making, especially when the intervention 
involves risks to the patients. 2) Although the 2016 ACC/AHA guidelines considered 
prophylactic treatments that are used in current practice, these guidelines primarily 
focused on two treatments, aspirin monotherapy and dual-antiplatelet therapy with aspirin 
and clopidogrel and failed to place recommendations for other relevant alternatives to 
prevent SVGF. The focus on two clinical therapies may lead to uninformed clinical 
decisions regarding the optimal prophylactic treatment for CABG patients. 3) In addition 
to the narrow focus in the practice guidelines on aspirin monotherapy and dual-
antiplatelet therapy with aspirin and clopidogrel, in the absence of an appropriate 
statistical analysis, objective assessments of optimal therapy are not possible.  
Clinicians and patients are constantly challenged to make an optimal choice from among 
the multiple antithrombotic regimens proposed for potential prevention of SVGF. Despite 
the importance of providing optimal prophylactic treatments to CABG patients, most 
available antithrombotic agents have not been compared directly in randomized trials, 
and furthermore no studies have been published that assess the comparative effects of all 
oral antithrombotic agents in the prevention of SVGF after CABG. There are a number of 
ways to assess the efficacy of multiple antithrombotic agents, including designing a 
multi-arm head-to-head RCT, performing a series of pairwise meta-analyses, and 
conducting a network meta-analysis (NMA, also known as multiple treatment 
comparison). However, well-designed RCTs comparing all relevant interventions have 
not yet been performed, and conducting such RCTs can be challenging due to the high 
cost and time required for studies of adequate power to detect differences between active 
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comparators. Furthermore, several other pairwise meta-analyses comparing a subset of 
relevant antithrombotic therapies have been recently published.72 73 Although a pairwise 
meta-analysis of well-designed RCTs is widely considered to be the highest level of 
evidence, this approach does not allow for a coherent assessment of more than two 
antithrombotic therapies nor allow for comparison of therapies that have not been directly 
compared in RCTs. Naively comparing across treatments with a series of pairwise meta-
analyses is also not recommended because of a failure to appropriately handle the study 
effect (i.e. the effect of patient/study characteristics that equally contribute to the 
intervention and comparator). Only the treatment effect (and not the study effect) of each 
RCT should be compared to obtain an unbiased estimate from an indirect comparison.74 
Among the aforementioned options, NMA of RCTs may represent a better option to 
determine the efficacy of all relevant antithrombotic agents as it can compare multiple 
treatments simultaneously even when the treatments have not yet been compared directly, 
while preserving the within-study randomization. Hence, in the present study, we used a 
NMA approach, to conduct multiple treatment comparisons. 
1.5 Thesis Objectives 
This thesis addresses two main research objectives: 
Objective 1 – Systematic Review 
To systematically review the literature to identify RCTs that assessed the efficacy of 
various antithrombotic therapies for the prevention of SVGF in patients undergoing 
CABG. 
Objective 2 –Meta-analysis 
a) To conduct a pairwise meta-analysis of relevant RCTs to provide a summary of direct 
estimates of the effects of antithrombotic agents (alone or in-combination with other 
antithrombotic agents) versus placebo/control or other antithrombotic agents on graft 
patency and clinical outcomes of interest in patients undergoing CABG. 
b) To perform a NMA of relevant RCTs to evaluate the comparative efficacy of 
antithrombotic agents (alone or in-combination with other antithrombotic agents) 
13 
 
versus placebo/control or other antithrombotic agents in the prevention of SVGF 
among patients undergoing CABG. 
c) To perform a NMA of relevant RCTs to evaluate the effect of antithrombotic agents 
(alone or in-combination with other antithrombotic agents) versus placebo/control or 
other antithrombotic agents on clinical outcomes in patients undergoing CABG. 
d) To generate a treatment ranking for each outcome of interest. 
e) To assess the quality of direct and network evidence provided by included RCTs. 
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Chapter 2  
 
2 Literature Review for Methodological Background 
This chapter provides a brief background on quantitative and qualitative methodology 
used in this thesis. Specifically, we introduce the concepts with a detailed review of the 
underlying assumptions of pairwise meta-analysis and NMA and explain the importance 
of the Grading of Recommendation, Assessment, Development, and Evaluation approach 
in assessing the quality of randomized evidence for outcomes reported in evidence 
synthesis. 
2.1 Pairwise Meta-Analysis 
2.1.1 Introduction 
According to the Cochrane Collaboration,75 a systematic review is defined as “a review 
of a clearly formulated question that uses systematic and explicit methods to identify, 
select, and critically appraise relevant research, and to collect and analyze data from the 
studies that are included in the review.” In a review, studies that address a similar 
research question can be pooled together to provide a meaningful summary. When 
sufficient data are available, the findings of included studies can also be quantitatively 
synthesized through meta-analysis to obtain a more precise single summary estimate.76  
There are a number of summary estimates that can be used to present the study findings. 
The selection depends on the available data and the type of outcome of interest. When 
means and standard deviations are available from the original studies, the standardized or 
unstandardized mean difference or response rate are the common effect sizes. For binary 
outcomes where the number of events and non-events in two study arms are reported, the 
risk ratio (RR), odds ratio (OR), and risk difference (RD) are the preferred effect sizes. 
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For studies that report a correlation between two continuous variables, a correlation 
coefficient can be calculated and used as a summary estimate.76 
2.1.2 Heterogeneity 
On average, randomization balances the distributions of any prognostic factors across 
study groups in a RCT. In the absence of systematic errors, the difference in event rates 
(or any outcome measures) between the groups is the effect of the treatment on the 
outcome of interest relative to a comparator (known as the treatment effect). Despite the 
benefit of randomization, treatment effect may vary between groups of participants in a 
RCT. This is expected as some people with certain characteristics that are effect 
modifiers (i.e., characteristics that modify the treatment effects) may respond to 
treatments differently. The true variation in treatment effects within a RCT is called 
within-study heterogeneity.77 For instance, a RCT of statins may include a mixture of 
participants with and without prior exposure to aspirin. 
In a meta-analysis comparing two interventions, the distribution of study and patient 
characteristics may not be balanced across RCTs because randomization does not occur 
at study level (i.e., participants are not randomized to different studies). As a result, a 
between-study variation in these characteristics is expected. If these characteristics are 
effect modifiers, then this variation is called between-study heterogeneity. For example, 
if some of the trials comparing treatment A with C, are not comparable in terms of 
distribution of effect modifiers (e.g., severity of disease, selection of patients, or 
regimens) and, hence, their observed effect sizes are not similar, then between-study 
heterogeneity is present. In a pairwise meta-analysis of individual patient-level data, there 
are two sources of heterogeneity: within-study heterogeneity and between-study 
heterogeneity. Without individual patient-level data, we can only assess between-study 
heterogeneity in an aggregate pairwise meta-analysis.77 In a meta-analysis, between-study 
heterogeneity may arise from three sources: clinical, methodological, and statistical. 
Clinical heterogeneity: Clinical heterogeneity is assumed to occur when studies included 
in the review are not sufficiently similar in clinical characteristics, such as baseline 
patient characteristics, intervention characteristics, and outcome measurements.  
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Methodological heterogeneity. Methodological heterogeneity occurs when the included 
studies are not comparable in terms of risk of bias and study design (e.g., clustered RCTs 
versus non-clustered RCTs. Compared with non-clustered RCTs, clustered RCTs produce 
less precise estimates). 
Combining studies that are clinically and methodologically diverse may increase the 
generalizability of findings; however, the combination can have a negative impact on 
internal validity. The more diverse a targeted population, the greater the chance of 
heterogeneity.75  Furthermore, evaluating similarity among studies is based on qualitative 
assessment of study and patient characteristics, which can be subjective. The involvement 
of clinical experts and methodologists is therefore strongly recommended in the process 
of making decisions about combining studies in order to produce a meaningful and valid 
summary of estimates.78 
Statistical heterogeneity: statistical heterogeneity refers to variability in treatment effect 
size estimates across studies, including magnitude and/or direction of effect that is 
beyond the expected play of chance. The source of this heterogeneity may arise from the 
combined impact of clinical and methodological heterogeneity, biases, or random 
chance.75 
Statistical heterogeneity can be detected using statistical tests such as Cochran Q-
statistic,79 Generalized Q-statistic, and Cochran Q-statistic adjusted for small-study 
effects.80 Of these, the Cochran Q-statistic is the most commonly used test and it 
performs well in controlling the type I error rate (false positive rate).81 The extent of 
statistical heterogeneity can then be quantified using statistical measures such as H2 
index,82 I2 statistics,83 D2 index,84 and G2 index.80 Among these measures, I2 statistic is 
the most common.85 The I2 statistic describes the percentage of variation in study 
estimates amongst studies that is attributable to heterogeneity and beyond what chance 
alone could explain.86 An I2 of 75% indicates that 75% of the observed variance comes 
from true differences across individual studies, and thus there is substantial 
heterogeneity. When between-study heterogeneity is detected, it is important to explore 
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its potential sources by performing subsequent analyses such as meta-regression, 
subgroup analyses, and/or sensitivity analyses.  
Subgroup analysis: The variation in effect sizes across different subgroups (studies of 
similar characteristics) can be explored using subgroup analysis. For example, a meta-
analysis comparing dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin 
monotherapy included a mixture of RCTs with low and high aspirin doses (with no 
variation in doses within RCTs). Subgroup analysis by dose may be performed to explore 
the impact of dose on the treatment effect. These subgroups may be patient-level 
variables if individual-patient level data are available or study-level variables if only 
aggregate patient data are available. It is important to note that the subgroup effects are 
often misleading and should be considered hypothesis-generating rather than 
conclusive.87  
Meta-regression: If the source of heterogeneity is a categorical or continuous variable, 
then meta-regression can be used instead of subgroup analysis. Meta-regression is used to 
explore the relationship between study-level variables and treatment effects. Some 
examples of study-level variables used in meta-regression include treatment doses and 
year of publication. There are several limitations inherent in subgroup analysis and meta-
regression.  
First, when we perform subgroup analysis or meta-regression, randomization is broken in 
cases where the original trial did not stratify randomization based on the subgroup 
variable of interest. These analyses therefore are observational by nature and suffer the 
limitations of any observational studies such as confounding. Second, the statistical 
power by which to detect a difference among subgroups (in subgroup analysis) or to 
detect a significant association between covariates and effect size (in meta-regression) is 
usually low.76 Third, if study-level covariates vary between patients within a study, then 
the analyses are subject to ecological bias such that an association may exist at the study 
level, but may not be true at the patient-level.88 Lastly, in practice, these analyses are 
often performed multiple times with a number of covariates or subgroups. Though there 
is no consensus on how to handle the issue of multiple testing in meta-analysis, 
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investigators should be mindful of its consequence, in particular as it relates to the 
inflation of risk of type I errors (>5%).76 
Sensitivity analysis: If subgroup analysis and meta-regression cannot be performed, 
sensitivity analysis is particularly useful to explore the potential heterogeneity. For 
example, sensitivity analyses can be done by excluding studies that had very different 
baseline risks from most included studies. 
2.1.3 Statistical models 
The choices of statistical models in a meta-analysis are fixed-effects and random-effects 
models. 
2.1.3.1 Fixed-effects pairwise meta-analysis 
In the fixed-effects, all included studies are assumed to share a common effect size and 
any variation in observed effects is a result of sampling error.89 In other words, a fixed 
effects meta-analysis is based on the assumption that there is no between-study 
heterogeneity. The observed effects Yi from individual studies included in a meta-
analysis are sampled from a distribution with one true effect size, μ and variance σ2. The 
observed effect Yi is: 
Yi = 𝜇 +  𝜀𝑖       
where 𝜀𝑖 is the within-study error of the i
th study and assumed to be normally distributed, 
𝜀𝑖 ~N(0, 𝑣𝑖). 𝑣𝑖 denotes the within-study variance of the i
th study. 
2.1.3.2 Random-effects pairwise meta-analysis 
It may not be realistic to assume that the effect sizes are identical across studies.82 In fact, 
it is reasonable to expect slight variation between studies that we characterize as 
between-study heterogeneity. The studies are required to be similar to ensure internal 
validity but not identical. A random-effects model assumes that there is a common 
normal distribution of true effect estimates.89 In other words, the true treatment effects 
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may vary from study to study. In this model, we need to consider two levels of sampling. 
First, the true effect size 𝜃𝑖 in the i
th study is distributed about 𝜇, the mean of all true 
effects, with a variance 𝜏2. The difference between 𝜃𝑖 and μ refers to between-study error 
(𝑠𝑖). Second, the observed effect Yi in the i
th study is distributed about 𝜃𝑖, the true effect 
size in the ith study, with a variance 𝜎2. The difference between Yi and 𝜃𝑖  refers to 
variability due to sampling error, within-study error (𝜀𝑖). The summary estimate 
represents the population mean of all true effects. In a random-effects model, the 
observed effect Yi of the i
th study is: 
Yi = 𝜇 +  𝑠𝑖 +  𝜀𝑖     
where  𝑠𝑖 ~ N(0, 𝜏
2) and 𝜀𝑖 ~N(0, 𝑣𝑖). 𝑣𝑖 denotes the within-study variance for the i
th 
study and 𝜏2 denotes between-study variance. In a fixed-effects model, 𝑠𝑖 = 0. 
2.2 Network meta-analysis 
2.2.1 Introduction 
A pairwise meta-analysis is useful when the pooled information is derived from studies 
comparing two interventions. However, clinicians and patients are often challenged to 
choose from multiple treatment options. Clinical decision-making becomes even more 
challenging when head-to-head comparisons are not available for some of the 
alternatives. NMA, also known as mixed treatment comparison (MTC), is a promising 
method that overcomes these issues. NMA synthesizes evidence from direct comparisons 
(between two treatments, A and B, without the need of a common comparator) and 
indirect comparisons (between two treatments, A and B, via a common comparator, C) 
and simultaneously combines both sources of evidence via mixed comparisons to obtain 
treatment effect estimates for all relative pairwise comparisons for a particular outcome 
of interest, even when the treatments have never been compared head-to-head.90  
The effect of treatment A relative to treatment B can be obtained directly through a head-
to-head comparison. When direct evidence does not exist, indirect evidence can be 
estimated by deriving direct comparisons between treatment A versus C and treatment B 
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versus C, where C is a common comparator.91 The simplest way to obtain indirect 
estimates in a closed loop within the network is to use Butcher’s method, the adjusted 
indirect comparison.91 
Figure 1. Direct and indirect comparisons. 
 
Each node represents a treatment, solid lines represent pairwise direct comparisons, 
and a dash line represents an indirect comparison. 
 
In Figure 1, we can calculate the probability of an event if patients receive treatment A 
versus treatment B using Butcher’s method. The indirect treatment effect of A versus B 
can be estimated by (computations are carried out on a log scale using the odds, 𝑂𝑑𝑑𝑠 =
𝑝
1−𝑝
 , as a function of probability, 𝑝) 
𝑙𝑜𝑔𝑂𝑅𝐴𝐵 = 𝑙𝑜𝑔𝑂𝑅𝐴𝐶 − 𝑙𝑜𝑔𝑂𝑅𝐵𝐶  
The variance: 
𝑉𝑎𝑟(𝑙𝑜𝑔𝑂𝑅𝐴𝐵) = 𝑉𝑎𝑟(𝑙𝑜𝑔𝑂𝑅𝐴𝐶) + 𝑉𝑎𝑟(𝑙𝑜𝑔𝑂𝑅𝐵𝐶) 
The 95% CI for the indirect estimate can be calculated 
95% 𝐶𝐼 (𝑙𝑜𝑔𝑂𝑅𝐴𝐵) = 𝑙𝑜𝑔𝑂𝑅𝐴𝐵 ± 1.96√𝑉𝑎𝑟(𝑙𝑜𝑔𝑂𝑅𝐴𝐵) 
For the purpose of this example, odds ratio is used, however, the method can be extended 
to other outcomes. Butcher’s method is limited as it is used to estimate an indirect effect. 
21 
 
NMA is an extension of Butcher’s method and can produce direct and indirect estimates, 
and combine (mix) them to gain precision. 
In terms of statistical models, the same considerations for pairwise meta-analyses are 
applied when choosing between a fixed-effect and a random-effects model in the NMA. 
If investigators believe that the included studies are reflective of a single population and 
expected to have an identical treatment effect and the generalizability of the findings are 
not of interest, then the fixed-effect model may be used.92 Fixed-effect models are more 
likely to be considered appropriate in cases where studies are conducted by the same 
investigators under the same protocol or if studies are very similar in all important factors 
clinically, methodologically, and statistically. However, this rarely happens in real 
practice as it is reasonable to expect some degree of variation between studies. As a 
result, the random-effects model is more commonly used as it incorporates known and 
unknown heterogeneity.92 
Synthesizing the totality of evidence in a NMA improves the statistical power by which 
to detect effects and therefore increases the precision in the network estimates.90 This 
statistical method can also produce a ranking for all treatment options, which may assist 
policy makers or clinicians with decision-making.93 NMA is especially valuable when 
study data are pooled from RCTs as randomization (balance in prognostic factors and 
other important characteristics between treatment groups) within a RCT is maintained.94 
However, NMA is not without drawbacks. Even though within-study randomization is 
preserved in direct comparisons of RCTs, interventions were not randomized across 
studies in NMA.94 As a result,  indirect comparisons are observational by nature and may 
bear some of the limitations of observational studies, such as bias due to confounding77 90 
and selection bias.95 Confounding bias arises when the imbalance in the effect modifiers 
between direct comparisons confound treatment effects. Additionally, selection bias 
occurs when researchers selectively choose treatment comparators based on the 
expectation of magnitude and direction of treatment effects, which can be minimized by 
including all relevant comparators or random selection. To ensure unbiased indirect 
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estimates, there are two main assumptions that need special care: homogeneity and 
transitivity, with its statistical extension, known as coherence. 
2.2.2 Assumptions 
2.2.2.1 Homogeneity 
Recall, within-study heterogeneity is observed within a study whereas between-study 
heterogeneity occurs when there is substantial variation in effect modifiers across studies 
of the same treatment contrast (defined as a comparison between two treatment agents). 
Since a NMA can analyze multiple treatment comparisons, there is an additional source 
of variation in treatment effects to be considered in a NMA, which is between-
comparison heterogeneity. Between-comparison heterogeneity arises when the 
distribution of the effect modifier is imbalanced across treatment comparisons. A 
consequence of this imbalance is a biased indirect estimate.77 
2.2.2.2 Transitivity 
Even if studies of the same treatment comparison are comparable (or homogeneous), the 
imbalance distribution of study characteristics that modify treatment effects across 
treatment comparisons will lead to biased indirect estimates.77 For example, if sex is an 
effect modifier and more females were included in comparisons involving newer 
treatments than those in older treatments, then the indirect treatment effect is biased by 
sex. This is known as a violation of the transitivity assumption. There are five possible 
ways to interpret the transitivity assumption, also known as similarity or 
exchangeability.94 First, treatment C is not systematically different between A-C and B-C 
studies in terms of effect modifiers. Second, arms in each study are missing at random 
and the choice of interventions is not associated with the treatment effects. Third, 
distribution of effect modifiers is balanced across treatment comparisons within the 
network irrespective of the degree of between-study heterogeneity. Fourth, subjects are 
eligible to take any of the competing treatments, and could, in principle, be randomized 
to any of them. Fifth, the effects of treatment A and C estimated directly and indirectly 
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come from the same distribution. In other words, any (known and unknown) differences 
between relative effects of A-C and B-C are attributable to heterogeneity. 
The transitivity assumption cannot be evaluated using statistical tests.94 Therefore, it is 
important to qualitatively identify potential violations of the transitivity assumption to aid 
in interpreting NMA results by considering the five expressions. However, in the 
presence of a closed loop (a path that begins and ends at the same treatment (node)), 
coherence, a synonym for transitivity, can be statistically tested. Transitivity requires a 
conceptual evaluation, whereas coherence is a statistical manifestation of transitivity 
across a closed loop.96 
2.2.2.3 Coherence 
When both direct and indirect estimates are available, the combination of sources of 
evidence produces a more precise estimate, known as a mixed estimate. The mixed 
estimate becomes reliable when there is statistical agreement between direct and indirect 
evidence. When there is a conflict between the two sources of evidence in a closed loop, 
the use of mixed evidence may not be reliable; the disagreement suggests a violation of 
the coherence assumption. 
Incoherence can be globally investigated (in the entire network) and locally (in a specific 
closed loop of evidence). Methods for assessing statistical local incoherence include: 
• Loop-specific approach: This method estimates incoherence by generating an 
inconsistency factor (IF, the difference in absolute terms between indirect and direct 
estimates for a specific treatment contrast in a closed loop, which is expressed in the 
logarithmic scale) and its corresponding 95% confidence interval (CI).97 
• Composite test for incoherence: Unlike the loop-specific approach, this approach 
incorporates information from all direct comparisons that contribute to a specific 
indirect comparison. In other words, the estimated indirect summary effect is 
obtained from two or more different closed loops, and not from one specific loop.98 
• Node-splitting approach: This approach assesses incoherence by comparing direct 
evidence to indirect evidence via removal of a single direct pairwise comparison from 
the network.99 Once the direct comparison is removed, the network is re-calculated to 
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obtain an indirect effect. The direct effect estimated before the removal is then 
compared with the indirect effect estimated after the removal using a Z-test.  
The following are available methods for assessing incoherence globally: 
• Lu and Ades Model: This approach is an extension of the loop-specific approach, 
where all IFs in the entire network are considered simultaneously. The null 
hypothesis that all IFs are zero is evaluated using the χ2 test to identify the presence of 
global incoherence.97  
• Design-by-Treatment interaction model: The summary estimate of A versus C from 
two-arm studies of A versus C (AC design) may differ from the estimate obtained 
from three-arm studies of A versus B versus C (ABC design).100 It is therefore 
important to consider the study design as another potential source of incoherence. 
Unlike the Lu and Ades model, the design-by-treatment interaction method can assess 
incoherence globally in the presence of multi-arm studies.100 
• Q-statistic in NMA: Krahn et al provided an equation to calculate the weighted 
distance between the network summary estimates and the direct summary estimates 
for a particular comparison.101 The weighted distance refers to the Q-statistic for 
incoherence. Hence, to statistically test incoherence, the null hypothesis that 
coherence is present is evaluated using the χ2 test. 
The fulfillment of transitivity and coherence assumptions results in reliable indirect 
evidence.102 However, the coherence assumption should be interpreted with caution. The 
number of studies contributing to a direct estimation is often small, yielding an 
underpowered statistical test. Therefore, the absence of statistically significant 
incoherence does not necessarily equal coherence. The likelihood of detecting 
incoherence is even lower in the presence of heterogeneity because of the wider 95% CI 
of an indirect estimate that overlaps with that of direct estimates, or vice versa.94 103 
2.2.3 Statistical framework 
Frequentist and Bayesian approaches can be used to fit data to a model in order to make 
inference about the true value of a parameter of interest. The frequentist inference is a 
statistical inference that evaluates parameters based on a sampling distribution, where the 
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parameter of the population is assumed to be an unknown fixed constant. Consequently, 
probability statements cannot be made because the parameter is not a random, but fixed, 
quantity. To calculate probabilities, a random sample of observations is drawn from a 
sampling distribution of all possible random samples. These probabilities therefore are 
conditional on these random samples (and not actual data). Based on this sampling 
distribution, frequentist statistics performs inference on the parameter.104  
There are several different inference types about the parameter that frequentist 
approaches consider including hypothesis testing and interval estimation. Hypothesis 
testing is focused on what data from an analysis can explain by testing the null hypothesis 
that there is no difference between groups, Ho: 𝜋 = 𝜋0, against the alternative hypothesis 
that there is a significant difference, Ha: 𝜋 ≠ 𝜋0, at a level of significance, α. The 
observed effect is tested under null hypothesis. The key question is, how likely is the 
observed effect, if the null hypothesis is true. If we fail to reject the null hypothesis, we 
would not accept the alternative hypothesis nor conclude that the null hypothesis is true. 
We can say that there is insufficient evidence of difference or the observed effect can be 
explained by chance alone. If we reject the null hypothesis, we would accept the 
alternative hypothesis that there is a significant difference.104 Thus, analysis of study data 
is conditional on the null hypothesis being true. Direct probability statements about the 
true value of a parameter are not possible within the hypothesis testing framework of 
frequentist statistics. Another inference type is known as interval estimation. The 95% CI 
indicates that 95% of intervals calculated from repeated samples will be expected to 
include the true population effect and 5% of intervals will not. Analysis of study data 
using interval estimation is also conditional on the null hypothesis being true. The 95% 
CI does not provide a range of values for the true parameter, although it is often 
mistakenly interpreted this way. The only correct way of interpreting the 95% CI is to 
indicate that 95% of intervals so constructed will contain the true parameter value, 
conditional on the null hypothesis being true.  
This contrasts with Bayesian statistics where parameters are assumed to be random. Since 
the parameters are random, probability statements can be made. In the Bayesian 
framework, the inference about parameters are updated with prior knowledge (known as 
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prior). To calculate probabilities, we form a posterior distribution by combining the prior 
information with the evidence from the actual data (formally, posterior ∝ prior × 
likelihood). In the Bayesian interpretation of the inference, the 95% credible intervals are 
estimated which indicates that there is a 95% probability that the true population effect 
lies within the interval.104 
In the context of a NMA, both approaches can be used.  The Bayesian approach permits 
treatment rankings, i.e., the probability that a particular intervention for a particular 
health condition is best, second best, and so on. In addition, Bayesian posterior 
distributions can serve as inputs into probabilistic cost-effectiveness analyses.93 However, 
the Bayesian approach requires appropriate prior distributions for model parameters and 
careful considerations to make selections. Even though it is recommended to use the non-
informative priors to minimize the subjective selection of priors, sensitivity analyses with 
different priors are helpful to assess whether the results are stable and robust. With the 
exception of the most simple Bayesian analysis, complex computing algorithms are 
required to define the posterior distribution through sampling. The most commonly 
employed algorithm is Markov Chain Monte Carlo simulation. In Bayesian statistics, we 
need to ensure convergence of the Markov Chain Monte-Carlo algorithm to the posterior 
distribution; otherwise, the parameter estimations are not reliable. Similar to Bayesian, 
recently developed approaches within frequentist statistics allow for treatment ranking.105 
However, unlike Bayesian approaches, the frequentist approach does not rely on the use 
of prior information. The selection of priors can be based on subjective judgment, and it 
is likely that different priors produce different results.106 For example, the between-study 
variance can be varied markedly across different prior distributions when the number of 
studies in a meta-analysis is small.107 Since the frequentist approach does not consider 
any priors, this method provides more objective results relative to the Bayesian 
method.104 
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2.3 Grading of Recommendation, Assessment, 
Development, and Evaluation (GRADE) 
2.3.1 Introduction 
Quality of evidence is highly variable as it depends on how well studies are conducted 
and whether appropriate designs/analyses are used. Inadequate research methods can 
produce biased study findings. Pairwise meta-analysis and NMA are quantitative 
approaches that do not evaluate the quality of evidence. The estimates derived from these 
approaches will reflect any biases inherent in the included studies or even increase the 
risk of bias if the study selection process is not systematic. Therefore, it is crucial to 
appraise the quality of each study included in a (pairwise or network) meta-analysis, in 
order to better understand the strength of the resulting evidence. The Grading of 
Recommendation, Assessment, Development, and Evaluation (GRADE) working group 
has developed a widely used tool to rate the quality of evidence, known as the GRADE 
approach.108 109 
2.3.2 GRADE’s approach to rating quality of evidence 
The GRADE approach is a systematic method used in health care to guide in the process 
of making recommendations reflective of the certainty (confidence) in evidence. There 
are five concepts that need to be considered in GRADE when assessing the quality of 
evidence.110  
Risk of bias: This concept focuses on the limitations of individual studies for a specific 
outcome that may threaten internal validity. There are many tools that have been 
developed to assess risk of bias including Cochrane Collaboration risk of bias (RoB) tool, 
Jadad scale, Delphi List, Newcastle-Ottawa Scale, Downs and Black, just to mention a 
few.111 Of these, the Cochrane RoB tool is a commonly used tool to assess risk of bias of 
RCTs.112 This tool assesses six different bias domains: 
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• Selection bias, which produces incomparable groups and imbalanced sample sizes 
leading to overrepresentation of groups of patients with certain characteristics. This 
bias domain is split into two groups: 
o Selection bias due to inappropriate random sequence generation, where the 
process of allocating interventions to participants is not random (e.g., quasi-
random allocation based on patient identification). 
o Selection bias due to failure to conceal random allocation, where the 
investigators randomizing the participants are aware of the study intervention 
to which the next participant will be allocated (e.g., non-sequentially 
numbered, non-opaque, or non-sealed envelopes; or an open random 
allocation schedule). 
• Performance bias, which results in behavior change or co-interventions, which occur 
differentially between treatment groups due to failure to blind participants and 
personnel. 
• Detection bias, which overestimates or underestimates the treatment effect due to 
failure to blind outcome assessors. 
• Attrition bias, which results in differential missing outcome data, i.e., the proportions 
of missing participants and reasons for missing data are not similar across treatment 
groups. This type of bias occurs when there is a high rate of loss to follow-up or a 
failure to follow the intention-to-treat (ITT) analysis with substantial departure from 
allocation. It is important to note that although the goal of ITT analysis is to preserve 
balance in the distribution of prognosis between study groups, it does not necessarily 
minimize bias introduced by large amounts of missing data. 
• Reporting bias, which results in overestimation or underestimation of meta-analytic 
summary effects due to selective outcome reporting (e.g., reporting only statistically 
significant results) 
• Other sources of bias that are beyond the specific domains mentioned above such as 
fraud, termination of study that is related to outcome data, and considerable changes 
in the protocol. 
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Once the risk of bias within a study is evaluated, the quality of evidence can be rated 
down or up for risk of bias treating all studies as a body of evidence. If most studies are at 
low risk of bias, then the evidence is of high quality. If studies at moderate risk of bias 
are a primary source of evidence, then the quality is rated down by one level. If most 
studies are at high risk of bias, then the evidence is rated down by two levels.112  
Inconsistency: This concept focuses on variation (heterogeneity) in treatment effects 
across studies. If large statistical heterogeneity is detected, then, it is suggested to down-
rate the quality of evidence for inconsistency.113 
Indirectness: This concept focuses on differences in population, interventions, and 
outcomes between the included studies and those of interest. In other words, do patients 
or treatments or outcomes of interest differ from those in the included studies?114 In the 
context of NMA, the concept of indirectness has been expanded to include the risk of bias 
from indirect comparisons by assessing the coherence between indirect and direct 
estimates.115 
Imprecision: This concept focuses on 95% CIs around the treatment effect.116 If the 95% 
CIs are wide and cross the clinical decision threshold (or line of no effect), the quality of 
evidence is down-rated for imprecision. If the 95% CI does not cross the threshold but 
both number of events and sample size are small or the optimal information size (OIS) is 
not met, then the quality of evidence is rated down.117 
Publication bias: This concept focuses on studies that are not published, especially those 
that were deliberately not reported due to non-significant results.118 Egger’s test and 
funnel plot are examples of methods that examine the precision and distribution of 
published effect sizes to explore the potential publication bias.75 
Based on these five concepts, the quality of evidence is rated separately for direct 
evidence, indirect evidence, and network evidence for each treatment comparison for a 
particular outcome of interest. As a first step, direct evidence is rated. Using GRADE the 
quality of direct evidence is rated as high, moderate, low, and very low. High quality 
evidence suggests that the degree of our confidence in effect estimates being close to the 
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truth is high, whereas very low-quality evidence indicates very little confidence in the 
summary estimates being close to the truth. The initial quality of randomized evidence 
starts as high-quality evidence and each concept is then considered to help in rating down 
or rating up the quality. The quality is rated down by one or two points for each concept 
depending on how serious the problem is. The quality can be rated up if the effect size is 
large or dose-response relationship is present.119 A second step involves rating the quality 
of indirect evidence. The quality of the indirect estimate is rated according to the ratings 
of the two direct comparisons contributing to that specific indirect estimate, where the 
rating of the comparison that contributes the most will be chosen, and based on the 
presence of intransitivity. Lastly, if both direct and indirect estimates are present, the 
quality of the network estimate is rated based on the rating of the source of evidence with 
the higher quality. Otherwise, it is rated based on the available source of evidence (i.e., 
direct or indirect estimates only).115 
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Chapter 3  
 
3 Methods 
This chapter includes a description of the methods undertaken to conduct the present 
thesis work. We describe the study selection process, including the eligibility criteria, 
information sources, and search strategy; the data extraction and analysis; and the 
assessment of study quality. The protocol of the present study was registered 
(PROSPERO no.: CRD42017065678) and has been submitted for publication,120 and any 
post-hoc differences between protocol and NMA are highlighted in this chapter. This 
study is reported in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) extension for NMA guidelines.121 
3.1 Search Strategy 
A pre-specified comprehensive and systematic literature search strategy was created 
before the start of the study in collaboration with an experienced medical librarian to 
identify relevant studies related to our research question. Five electronic databases 
(MEDLINE, EMBASE, CINAHL, Cochrane Library, and Web of Science) were 
searched for studies published as a journal article from inception until November 13, 
2016, with no restriction by language or publication date placed on any searches. For 
each database, we structured a search strategy into relevant search concepts according to 
population, intervention/comparator, outcome, and study design (PICOS) using the 
following key terms: “coronary artery bypass”, “antithrombotic”, “graft occlusion or graft 
failure or repeat revascularization or percutaneous coronary intervention”, and 
“randomized controlled trial”. A complete detail of the search strategy can be found in 
eTables 1 to 5. Weekly auto-alerts for electronic databases during the course of this study 
were also set up to receive notifications for newly relevant published reports. To ensure 
all relevant studies were identified, we performed a grey literature search of trial 
registries (ClinicialTrials.gov, International Clinical Trials Registry Platform, 
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AstraZeneca, Bayer, and Bristol-Myers Squibb), USA Food and Drug Administration, 
electronic theses online service, and Gray Matters (eTable 6). We also manually screened 
reference lists of eligible studies and previous systematic reviews and pairwise meta-
analyses to identify any additional relevant studies. 
3.2 Eligibility Criteria 
The study eligibility criteria were designed a priori in consultation with a team of clinical 
and statistical experts (RB and JM) to assure the most pertinent studies for the NMA and 
were specified in terms of PICOS. Eligible studies were selected based on the following 
criteria: 
Patient Population: We included adult patients (aged 18 years or older) undergoing 
CABG surgery with at least one SVG who were eligible to receive any of the oral 
antithrombotic agents that are used in current practice for SVGF prevention (listed 
below), regardless of comorbidity, clinical setting (elective or urgent surgery), previous 
antithrombotic exposure, whether perioperative heparin or antifibrinolytic was 
administered, and whether CPB was used.  
Interventions: The antithrombotic treatments included in this study are listed as follows: 
aspirin monotherapy, clopidogrel monotherapy, dual-antiplatelet therapy with aspirin and 
clopidogrel, dual-antiplatelet therapy with aspirin and ticagrelor, and vitamin-K 
antagonists (warfarin, acenocoumarol, or phenprocoumon). The decision about grouping 
warfarin, acenocoumarol, and phenprocoumon together was made in consultation with a 
clinical expert (RB) because these agents are members of the same drug class with 
similar mechanisms of action. Participants must have received at least one of these agents 
as a study medication within seven days pre- and/or post-CABG, regardless of drug 
regimen, timing of drug initiation (before or after CABG), and duration of treatment. A 
seven-day period was chosen arbitrarily but taking into consideration the lifetime of 
platelet cells (eight to nine days).122 Other antithrombotic agents were considered in the 
protocol, but not included in our NMA because of a lack of data (e.g., prasugrel and 
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DOACs) or because they are rarely used in current practice for the prevention of SVGF 
(e.g., dipyridamole and ticlopidine). 
Comparator: The comparator could be placebo/inactive control or a different oral 
antithrombotic agent, regardless of drug regimen, duration of treatment, and timing of 
drug initiation. Placebo/control was defined as per study author definition. The 
comparator however could not be the same antithrombotic agent at a different dose as 
comparing the effects of drug dosages is beyond the scope of this study. Similar to the 
intervention group, participants must have received at least one of the products as a study 
medication within seven days before and/or after CABG. 
Outcomes: Eligible studies must have reported the incidence of SVG occlusion (defined 
below) in intervention and comparator groups, as SVGF was the primary outcome of this 
NMA. There were no restraints on the units of analysis, methods or time of imaging 
assessment, and definitions of outcome. The lack of a universal definition for SVGF 
leads to a variety of definitions being reported in the literature, which results in 
inconsistencies in the reporting of events across studies and increased heterogeneity.43 If 
several definitions were presented in the same study, to reduce heterogeneity in the 
analysis, we extracted SVGF data according to our preferred definition. Our preferred 
definition of SVGF was total occlusion in one or more SVGs detected angiographically 
and expressed on a per-patient basis. 
If a study did not provide data using our preferred definition, we originally planned to use 
a predefined hierarchy, based on unit of patency analysis, percentage of stenosis in the 
graft lumen, and need for repeat revascularization to treat restenosis. However, due to the 
inadequate description of outcome measures in most included studies, we selected 
outcome data in the following order of preference: a) patients with at least one occluded 
SVG; b) repeat revascularization (repeat CABG or SVG-related PCI); and c) number of 
occluded SVG. The new definition of occlusion was no longer based on degree of 
stenosis, but rather on study author definition. We excluded studies with an unclear 
definition of repeat revascularization as it would be difficult to judge, without adequate 
descriptions, whether the procedure was performed to treat restenosis or different lesions. 
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Our pre-specified secondary outcomes included all-cause mortality, cerebrovascular 
accidents (CVA: stroke or transient ischemic attack [TIA]), MI (fatal or non-fatal), major 
adverse cardiac and cerebrovascular event (MACCE), major bleeding, minor bleeding, 
intracranial bleeding, heart failure, red blood cells (RBCs) transfusion, and admission to 
hospital due to cardiovascular cause. These outcomes were chosen based on their clinical 
importance. In our protocol, we planned to use Thrombolysis in Myocardial Infarction 
(TIMI) criteria for major bleeding. However, there were several studies that were 
published before the existence of TIMI criteria in the research. For fair comparisons, we 
decided to use the study author’s definition. As per protocol, the remaining outcomes 
were defined by the study authors. Studies were included based on the availability of 
SVGF data and not on our secondary outcomes. 
Study design: We included all parallel-group RCTs comparing one of the aforementioned 
oral antithrombotic agents as the intervention with a different antithrombotic agent or 
placebo/control as the comparator. RCTs with multiple eligible comparators (i.e. multi-
arm studies) were included. Non-English language studies, observational comparative 
studies, non-comparative studies, editorials, secondary studies, subgroup analyses of 
eligible RCTs, and RCTs without extractable outcome data were excluded from the 
analysis. If duplicates were identified, we did not include them in this study because 
analyzing the same information more than once in meta-analysis may lead to 
overestimation of treatment effect.123 In this case, studies with the most complete reports 
were selected. There were no constraints on sample size or publication date. 
3.3 Screening 
Once the literature search was performed, all citations were imported into Covidence 
Systematic Review Software (https://www.covidence.org/) for screening. A three-level 
screening procedure was used to ensure the most inclusive studies for the review. In level 
one screening, two reviewers (KS and AH, a cardiology fellow) independently screened 
titles and abstracts based on the pre-specified study eligibility criteria. The purpose of this 
step was to include as many studies as possible that were potentially relevant to our 
NMA. Prior to the screening of all titles and abstracts, screening was piloted to ensure 
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consistency between reviewers in using the screening criteria. Duplicates and irrelevant 
abstracts were excluded, but relevant abstracts published in non-English languages were 
kept at this stage. Any discrepancies were resolved by discussion with an experienced 
cardiologist (RB). In level two screening, the same reviewers independently screened the 
same set of full texts of reports included in level one. In this stage, non-English citations 
were excluded if the full-texts were not available in English. Again, a third reviewer (RB) 
was consulted to resolve any disagreements. The first two levels of screening were done 
independently and in duplicate to minimize the risk of measurement errors. Lastly, after 
completing the first two levels of screening, one reviewer (KS) checked reference lists of 
eligible studies and relevant reviews to find eligible studies that were not identified from 
the electronic searches, and a third reviewer (RB) was asked to confirm the study’s 
eligibility. Reasons for exclusion were recorded. 
3.4 Data Extraction for Descriptive Statistics 
After the screening, we extracted information from the eligible studies. Data were 
extracted using a comprehensive data extraction form, which was pilot-tested on ten 
randomly-selected eligible studies by one reviewer (TC, an interventional cardiology 
fellow) and refined by another reviewer (KS) accordingly. One reviewer (KS) then 
extracted data from all included studies using the final version of the data extraction form 
and secondary reviewers (AH and TC) checked the extracted data for accuracy and 
completeness. Any disagreements were resolved by consulting a third reviewer (RB). The 
following information was collected for descriptive purposes:  
Study characteristics: Inclusion and exclusion criteria, number of randomized patients 
per study arm, accrual period of the study, study setting (e.g., single or multicenter), 
clinical setting, CABG type (on- or off- pump), heparin or antifibrinolytic use during 
CABG, antithrombotic status prior to CABG, country of conduct, Cochrane risk of bias, 
and length of follow-up. 
Patient characteristics: Mean age, mean number of bypass grafts per patient, mean of 
LVEF, proportion of male patients, and proportion of patients with diabetes mellitus, 
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hypertension, prior MI, prior CVA, or dyslipidemia. Data on chronic kidney disease, and 
heart failure at baseline were collected as per protocol, however these were not reported 
in this NMA due to limited or no data. 
Intervention characteristics: Type, dose, and frequency of antithrombotic agents, 
definition of placebo/control, duration of treatment, and timing for the start of treatment. 
Outcomes: Clinical event rates (number of patients with MACCE, major bleeding, CVA, 
MI, minor bleeding, intracranial bleeding, repeat revascularization, heart failure, or re-
exploration for bleeding; number of patients that were hospitalized due to cardiovascular 
cause, number of deaths) per study arm; number of patients with at least one occluded 
SVG per study arm; number of occluded SVGs, number of total SVGs, and average 
number of SVGs analyzed per patient per study arm; rates of loss to follow-up (with 
reasons), time and method of outcome assessment, study author definitions of outcomes, 
and number of patients analyzed per study arm. 
Publication details: Year of publication and first author. 
Included studies had to have at least two eligible study arms. If studies had two or more 
eligible intervention arms of the same product but at different doses, we included the 
study arm that had the most complete follow-up data. If a study presented results from 
more than one time point separately in multiple publications, we kept all publications and 
treated them as a single study.  
It is important to obtain data on these baseline characteristics as it allows us to visually 
assess the distributions of clinical characteristics of patients and methodological 
characteristics of studies both across included studies and across treatment comparisons, 
to understand the baseline risk profile of patients in each study, to appreciate changes (if 
any) in clinical practice over time, and to identify potential sources of heterogeneity. 
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3.5 Data Extraction for Meta-Analysis and Network Meta-
Analysis 
There are two different types of input data for meta-analysis and NMA: arm-level data 
(the observed outcomes are reported for each study arm) and contrast-level data (the 
relative effect measures are reported in a study). We extracted arm-level data from all 
included studies due to the availability of arm-specific data. As a base case, we included 
outcome data with the longest follow-up for studies that reported results at more than one 
time point as per Cochrane guidelines.75  
Our outcomes of interest were all binary. If enough studies (i.e., at least two studies per 
outcome) with direct comparisons were available, we performed pairwise meta-analysis 
and at least 10 studies per outcome for NMA. Outcomes included for pairwise meta-
analysis were SVGF; number of deaths; number of patients with MI (fatal or non-fatal), 
CVA (any stroke or TIA), re-exploration for bleeding, major bleeding, MACCE and 
minor bleeding. Outcomes included for NMA were SVGF, major bleeding, all-cause 
mortality, and MI. We attempted to collect data on heart failure, admission to hospital 
due to cardiovascular cause, and need for RBC transfusions, but did not include them in 
the meta-analysis due to limited data. 
It is important to obtain information about potential effect modifiers as it allows us to 
make comparisons between treatment contrasts and to evaluate whether the included 
studies were sufficiently similar. A similar distribution of these variables between studies 
suggests that homogeneity is likely to be present, and a similar prevalence of effect 
modifiers between treatment comparisons suggests that the transitivity assumption is less 
likely to be violated and that NMA is possible (details in Chapter 2.2.2). We therefore 
pre-specified several potential effect modifiers in our protocol as sources of heterogeneity 
and incoherence. Potential effect modifiers included antifibrinolytic use during surgery, 
timing for the start of treatment, CABG type, and clinical setting. These variables were 
chosen based on clinical expectations that they may influence SVG patency (see Chapter 
1.3.2). Other potential effect-modifiers were SVG flow, diameter of diseased artery, 
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comorbidities, and sex. However, they were not included in our list as individual patient-
level data is required. 
3.6 Risk of Bias Within Individual Studies 
To assess the methodological quality of eligible studies, one reviewer (KS) performed a 
risk of bias assessment which was doubled checked by secondary reviewers (TC and 
AH).75 There are several quality assessment tools available for randomized studies.110 124-
128 In this NMA, we evaluated the risk of bias of each included study using the Cochrane 
Collaboration RoB tool,110 which is the standard approach for quality assessment of 
randomized trials.129 Unlike other existing tools, the Cochrane Collaboration RoB tool 
does not use checklists nor a numerical quality assessment scale based on the rationale 
that numeric scores are not sufficiently discriminatory to identify studies with high risk of 
bias beyond qualitative assessment alone.130 Instead, this standard tool uses the domain-
based rating system, which incorporates six bias domains (see Chapter 2.3.2). For each 
domain, we assessed the risk of bias related to trial results (i.e., internal validity) on an 
outcome level and whether potential sources of bias were addressed in the included 
studies.110 The judgement about risk of bias was made based on theoretical and empirical 
considerations as well as the unique circumstances of each study. The answer to each 
domain was assigned a score of “high risk”, “low risk”, or “unclear risk”, and as per 
Cochrane guidelines,75 to ensure transparency in how assessments were made each 
domain was accompanied by a concise description on the basis of judgements and quotes 
supporting them.  
No modifications to the Cochrane Collaboration RoB tool were made. Despite the 
difficulty of blinding vitamin-K antagonists, the risks of performance bias and detection 
bias were fairly assessed in all included studies regardless of the interventions. We 
assessed incomplete outcome data separately for primary and secondary outcomes 
because a higher rate of loss to follow-up for assessment of SVG patency was expected 
during the study. 
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3.7 Selection of Data for Analysis 
3.7.1 Choice of interventions 
Each intervention included in this NMA forms a node in the network. We clustered 
different regimens (dose and frequency) of an antithrombotic agent in the same node as 
comparing intervention regimens is beyond the scope of this NMA. We assumed that 
there would be no systematic differences in intervention effects (beyond sampling error) 
between regimens. We also kept aspirin monotherapy as a single node, regardless of 
whether aspirin was started before or after CABG, since aspirin has been strongly 
recommended to be administered preoperatively and restarted within six hours after 
surgery,6 and regardless of whether aspirin was interrupted or continuously taken before 
CABG (7 to 10 days), since an unpublished meta-analysis failed to show a significant 
difference between the two groups.131 
3.7.2 Choice of time points 
As stated before, if studies were followed by another publication in the same population, 
data from studies with the longest duration of follow-up were included as a base case. 
3.7.3 Choice of units of analysis 
For the primary outcome, the choices for the units of analysis were the patient and the 
SVG/distal anastomosis. It is unclear whether the investigators in the included studies 
chose the unit of analysis based on clinical considerations or statistical efficiency. The 
patient approach may be more clinically relevant, as the interventions are naturally 
applied to the patient, and not the individual graft. Although patients generally received 
multiple grafts, studies that reported results expressed on a per patient basis typically 
presented SVG occlusion data as a proportion of patients with at least one occluded SVG. 
This outcome may have been chosen by investigators to avoid the issue of dependency 
between SVGs within a patient. In other words, this outcome may have been selected to 
satisfy the assumption of statistical independence, though at the expense of lower 
statistical power (inflated type II error).132  
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On the other hand, the per graft approach may have been preferred as it does not 
compromise power.132 SVG occlusion data reported as per graft however present a 
particular statistical challenge because grafts in the same patient tend to respond similarly 
with respect to failure compared to grafts between different people, possibly because they 
are under the same circulatory system.132 133 Clustering effects must be therefore 
considered in the analysis, as otherwise the assumption of statistical independence is 
violated and it may result in over precision (i.e., underestimated standard errors, narrower 
CIs, and inflated type I error) because the same patient is potentially counted more than 
once (across multiple grafts). There are several statistical approaches used to handle 
clustering effects in the context of a meta-analysis, such as the ratio-estimator approach 
or the adjusted Mantel-Haenszel test.134 To use one of these approaches, information such 
as the variance of the ratio estimate, intra-cluster correlation (ICC, the proportion of total 
variation in the outcome being measured at the patient level), and number of SVGs per 
patient are required. Due to limited individual patient-level data, we were unable to 
compute variance of the ratio estimate or ICC. However, we could calculate the effective 
sample size (ESS, defined as sample size after accounting for clustering effects) for each 
arm in studies that provided number of SVGs per patient. We considered it appropriate to 
use the ESS in the analysis rather than the original number of vein grafts provided by the 
included studies, as it accounts for the lack of independence. The ESS was estimated 
based on the design effect.135 The design effect was a correction factor that included ICC 
and average number of SVGs per patient. The ICC was obtained from a published 
study.133 Using Generalized Estimating Equation with an exchangeable correlation 
structure (i.e. the outcomes of the same patient are assumed equally correlated), the 
author estimated an ICC of 0.177 indicating a moderate degree of dependency. Then, the 
design effect was also applied to the number of events to obtain the number of occluded 
SVGs with clustering. As a result, the total number of SVGs and the number of occluded 
SVGs were reduced after correlation between SVGs was considered. We planned to use 
the originally reported outcome data if studies did not provide enough information. 
However, all studies provided sufficient data. 
Unfortunately, not all included studies reported SVGF rates on a per-patient basis. There 
were studies that reported results both on a per-patient basis and a per-graft basis, but a 
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few reported results only from a per-graft analysis. To address the issue of partial 
reporting, the unit of analysis of this NMA depended on the consistency of effect 
estimates between the per-patient (patient with at least one occluded SVGs) and per-graft 
(with clustering) meta-analyses across treatment comparisons. 
After conducting a separate meta-analysis for each unit of analysis, we found that the 
results between per patient and per graft were consistent (i.e., similar direction and large 
overlaps in the 95% CIs of effect sizes) in most comparisons. We therefore considered it 
appropriate to combine data from the two units of analysis: the patient and the SVG, for 
the NMA, assuming that there are no systematic differences between the units of 
analysis. In other words, we combined studies that reported the per-patient data with 
those that only reported the per-graft data and made an inference at the patient level (our 
base case). Inference at the patient level is highly preferable as treatments will be given 
on an individual basis. Unfortunately, we could not compare the consistency of results 
between the two levels using NMA as some studies did not provide sufficient data, which 
made it impossible to qualitatively compare results between NMAs with missing nodes. 
The credibility of this data-driven approach at the NMA level is unclear and therefore, 
the findings of the NMA should be interpreted with caution. 
3.8 Statistical Analysis 
Descriptive statistics were presented as percentages for categorical variables, and mean ± 
standard deviation (SD) or median (range or interquartile range, [IQR]) for continuous 
variables. We performed pairwise meta-analysis using Review Manager version 5.3 
(Nordic Cochrane Center, The Cochrane Collaboration) and NMA using the network 
command, a user-written command (Stata version 13.1).136 ITT was followed whenever 
possible. A two-tailed p-value of less than 0.05 was considered statistically significant. 
3.8.1 Direct treatment comparisons 
Pairwise meta-analyses were conducted to produce direct estimates needed to supplement 
the NMA results and to evaluate a potential violation against the coherence assumption of 
the network. The random-effects model with an inverse-variance method was chosen 
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over the fixed-effect model because we anticipated true variation in effects across 
studies.137 The included studies were clinically and methodologically similar, but not 
identical because they were conducted in different settings with different intervention 
regimens and patient characteristics. In addition, fixed-effect models are not 
recommended for common outcomes such as SVGF due to risk of over-precision.78  
Empirical studies have shown that, for binary outcomes, results using relative measures 
(e.g., OR and RR) are more consistent (i.e., less heterogeneous) than absolute measures 
(e.g., RD) due to their insensitivity to baseline risk.138 139 We therefore chose relative 
measures over absolute measures to ensure more consistent effect sizes across studies 
regardless of baseline risk, although absolute measures are better at communicating a 
clinical impact of the intervention. Compared to RRs, ORs are more commonly used in a 
NMA and preferable because of their mathematical properties (i.e., symmetric 
properties), which overcome inferential fallacies.140 141 An example of this fallacy is that 
a drug was suggested to both improve SVG patency and increase SVG occlusion. Given 
these considerations, the causal relationship between interventions and outcomes was 
estimated using OR and its corresponding 95% CI. For ease of comparison between 
direct and network estimates, ORs were also selected as the appropriate effect measure 
for the pairwise meta-analysis.  
The extent of clinical and methodological heterogeneity was evaluated through visual 
examination of important differences in patient/study characteristics (e.g., CABG type, 
clinical setting) and risk of bias between studies. In addition, we assessed the extent of 
statistical heterogeneity in the meta-analysis using the I2 index. An I2 of either 25%, 50%, 
and 75% indicates low, moderate, and high heterogeneity, respectively.86 
Whether studies with zero events in both arms should be excluded or not remains 
unclear.142-144 For transparency, we included studies with zero events in both study arms 
for all endpoints in the meta-analyses.144 A correction factor of 0.5 was applied when a 
study contained a zero event in one of the study arms, which is a widely acceptable 
approach to account for zero events.144 In each direct comparison, publication bias was 
assessed if sufficient (i.e., ≥10 studies per comparison) data were available.145 
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3.8.2 Indirect and mixed treatment comparisons 
NMA allowed us to compare multiple treatments within a single analytic framework by 
combining the direct and indirect evidence. However, before concluding that NMA was 
feasible, we assessed the two important assumptions: transitivity and homogeneity.  
First, we evaluated the transitivity assumption by considering the first four of its 
equivalent expressions (Chapter 2.2.2.2 Transitivity).74 After checking the assumption of 
transitivity and determining that transitivity was reasonable (see details in Chapter 4.6), 
we performed NMA. In terms of statistical framework, there is no consensus on whether 
a frequentist or Bayesian framework should be used for NMA. Despite the conceptual 
benefits of Bayesian approaches (see details in Chapter 2.2.3), because they require 
specification of priors, and because the study results may vary based on the chosen prior, 
we opted to use the frequentist approach to NMA in this research work. We also used the 
random-effects approach for the NMA to account for heterogeneity. To illustrate 
information on the data structure, we produced a network plot for outcomes with 
sufficient data (≥10 studies) including SVGF, mortality, and MI. In addition to these 
outcomes, major bleeding was also included in the NMA, though with <10 studies, 
because of its clinical relevance. We also produced the contribution matrix to summarize 
the contribution (in %) of each direct estimate to the network estimates.136 
Though there is no formal way to statistically test the transitivity assumption, we assessed 
the statistical manifestation of this assumption, known as coherence.94 The indirect 
comparison is valid when there is an agreement in treatment effects between direct and 
indirect estimates. For the comparative analysis to be possible, both direct and indirect 
estimates must be available together in a closed loop. We assessed the coherence 
assumption in two ways (globally and locally). The design-by-treatment interaction 
model was used to explore for evidence of incoherence in the entire network.100 This 
approach was chosen over the other methods (e.g., Lu and Ades model) because the 
presence of multi-arm studies would not influence the results.146 P-value <0.1 was 
considered to be statistically significant global incoherence. We also assessed the 
presence of local incoherence. The loop-specific approach was used to explore evidence 
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of local incoherence within a closed loop in a network, assuming a common loop-specific 
heterogeneity variance.147 This approach was chosen over the composite test because the 
composite test considers multiple closed loops whereas our networks had only a single 
closed loop. Moreover, though our chosen approach and the node-splitting method share 
similar strengths (e.g., generally unbiased) and limitations (e.g., low power and unable to 
account for correlation induced by multi-arm trials), the loop-specific approach is more 
straightforward and requires less computations.148 The IF and its corresponding 95% CI 
were estimated and reported. If the 95% CI excludes zero, local incoherence is detected 
statistically.147 
In addition to transitivity, we also assessed homogeneity. To evaluate the clinical and 
methodological heterogeneity, we visually compared the distribution of clinical 
characteristics and risk of bias across included studies. In terms of statistical 
heterogeneity, we obtained heterogeneity variance (τ2) by squaring the standard deviation 
of treatment effects estimated from the NMA model. We assumed a common 
heterogeneity variance (τ2) across all comparisons, as all treatments of interest are similar 
in a sense that they principally act to inhibit clotting factors.149 150 The magnitude of the 
estimated τ2 was then compared with the empirical distribution of between-study 
heterogeneity variances to investigate the extent of heterogeneity.151 An estimated τ2 of 
either <50%, 50% to 75%, and >75% quantile of the empirical distribution was 
considered low, moderate, and high heterogeneity, respectively.149  
Of note, when a treatment comparison is part of a closed loop, the network estimate is the 
weighted average of the two sources of evidence: direct and indirect evidence. When a 
treatment comparison provides either only direct evidence or only indirect evidence, the 
network estimate reflects only one of them. 
3.8.2.1 Treatment ranking 
We used the surface under the cumulative ranking (SUCRA) with 10,000 samples drawn 
from the distribution of summary treatment effects to calculate the mean rank for each 
intervention.136 We ranked the interventions for each of the four outcomes. A larger 
SUCRA value indicates a more effective treatment. 
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3.8.2.2 Small-study effects 
For outcomes that had sufficient data (≥10 placebo-controlled studies), a comparison 
adjusted funnel plot was created to explore the potential small-study effects in the 
network by comparing all active treatments against placebo/control.136 
3.9 GRADE 
As per protocol, we assessed the quality of evidence using the GRADE approach (see 
details in Chapter 2.3.2). In this NMA, the OIS for SVGF ranged between 434 and 905 
patients (in one arm), based on the following assumptions: alpha of 0.05, beta of 0.20, 10 
to 20% of patients with SVGF, and medically worthwhile treatment effect of 5 to 15%. 
For MI, the OIS was about 2,073 patients per arm (incidence of 6.6%152 and a 2% 
absolute reduction with the therapy). For mortality, the OIS was about 18,330 patients per 
arm  (rate of 0.5 to 14%152 and a 1% absolute reduction). 
3.10 Missing Outcome Data 
We tried to gather missing information by contacting the study authors. However, of 16 
authors whom were contacted for further information, four responded but no one 
provided data needed for the NMA. Obtaining missing outcome data from secondary 
sources was also attempted.  
In addition, we also used a statistical approach to handle missing data. Using empirical 
data, Spineli et al153 evaluated several different imputation assumptions: missing at 
random model, all missing failures model, all missing successes model, best-case model, 
worst-case model, common informative missing OR, treatment-specific informative 
missing OR (either on average missing at random, more missing failures, more missing 
successes, more failures in placebo, or more success in placebo). Compared with the 
other assumptions, the worst- and best- case models were found to increase heterogeneity 
markedly and were considered extreme assumptions. Moreover, this study found that the 
‘all missing failure’ model was robust to small changes in the uncertainty and the 
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SUCRA values. Given this consideration, we handled missing outcome data using the ‘all 
missing failure’ model, which assumes that all missing patients have a negative event. 
3.11 Sensitivity Analysis for SVGF 
We did not perform our preplanned sensitivity analyses because the analyses would result 
in removal of nodes from the network altering the geometry of the network. Previous 
studies found that changing the network pattern may substantially change the effect sizes 
and/or treatment rankings and increase the likelihood of incoherence.154-156 Therefore, 
comparing results between primary analyses and sensitivity analyses with different 
network geometries may not be meaningful. 
A series of post hoc sensitivity analyses was undertaken instead. First, we performed a 
sensitivity analysis including only per-graft data to determine the impact of unit of 
analysis on study findings. Another sensitivity analysis focused on duration of follow-up. 
The primary analyses for SVGF endpoint included studies with the longest follow-up 
data; however, this approach may lead to increased heterogeneity because the included 
studies had different lengths of follow-up. To explore the potential effect of duration of 
follow-up on treatment effects, a post hoc sensitivity analysis was performed by 
including only angiographic data that were collected closer to one year post CABG. In 
addition, we performed another post hoc sensitivity analysis excluding studies of OPCAB 
(only) surgery, a type of surgery that is less commonly used (~17%),157 to explore the 
impact of outlier on study findings. 
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Chapter 4  
 
4 Results 
4.1 Literature Search 
Figure 2 shows the study selection process. We identified a total of 2,917 titles and 
abstracts through the literature search. Of these, 125 articles were potentially eligible for 
inclusion and considered for full article review. One hundred and five articles were then 
excluded if they were duplicates or non-English, reported the wrong outcome (i.e., did 
not assess SVG patency), wrong interventions (e.g., combine aspirin with dipyridamole 
or ticlopidine), wrong patient population (e.g., randomization did not occur in proximity 
[seven days] to CABG), or wrong study design (e.g., subgroup analysis of RCTs), or if 
they were ongoing trials. Twenty articles describing 18 unique studies were deemed 
eligible and included. Of these, two articles were longer term follow-up of the original 
studies.64 158 The longest available follow-up for each of the 18 studies was used as our 
base case. The list of studies deemed to be excluded and the reasons for exclusion can be 
found in Supplementary Appendix eTable 7. 
 
 
 
 
 
 
 
48 
 
Figure 2. Study selection process 
 
Flow diagram based on PRISMA 
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elective setting, and five (28%) trials159 160 169 173 174 combined elective and urgent cases. 
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longest time of angiographic follow-up ranging from eight days to eight years (≤ three-
month follow-up from four studies,164 168 170 171 four- to 12-month follow-up from nine 
studies,159 161-163 167 169 172-174 and >12-month-follow-up from five studies64 158 160 165 166). In 
studies reporting duration of treatment (n=17 trials),64 158-168 170-174 the included patients 
received study medications as a single-dose 12 hours before CABG164 or a regular-dose 
for one to 12 months. All studies reported SVGF on a per-graft basis as an outcome 
measure, but only 12 studies64 159-167 171 175 reported the outcome on a per-patient basis 
and 13 studies158-161 163-166 170-174 reported at least one of major clinical endpoints (major 
bleeding, mortality, CVA and/or MI). Detailed information for trial characteristics is 
summarized in Table 1 and eTable 8. 
In studies that reported baseline characteristics, the mean age ranged from 44 to 83 years 
and 2,655 (89%) patients were male. A total of 528 (21%) patients underwent CABG 
without CPB and 2,596 (95%) were elective patients. There were 409 (18%) patients with 
diabetes, 824 (48%) with dyslipidemia, 1,445 (55%) with prior MI, 109 (14%) with prior 
PCI, 16 (3.7%) with prior CVA, and 1,361 (47%) with hypertension. Across studies, 
mean of SVGs per patient and percentage of male participants were comparable. The 
proportions of patients with at least one concomitant condition were also reasonably 
similar across studies. Overall, the included trials were deemed sufficiently similar in 
terms of observed demographic and clinical characteristics. 
Five active interventions included in this NMA were aspirin monotherapy, clopidogrel 
monotherapy, vitamin-K antagonists, dual-antiplatelet therapy with aspirin and 
clopidogrel, and dual-antiplatelet therapy with aspirin and ticagrelor. These agents were 
compared either with inactive control/placebo or each other. Across treatment 
comparisons, the percentage of males was similar. The distribution of other baseline 
characteristics was generally balanced across comparisons, except for CABG type and 
timing for the start of treatment. CCAB patients were more prevalent in comparisons that 
included earlier studies (before 2000). In general, the timing for the start of treatment 
varied across treatment comparisons ranging from seven preoperative days to four 
postoperative days. Detailed information for patient characteristics is summarized in 
Table 2 and eTable 9. 
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Table 1. Summary of characteristics of trials included in pairwise meta-analysis and 
NMA (n=18 RCTs) 
RCT Characteristics No. of RCTs (%) 
Year of publication  
    1979 – 1989 6 (33) 
    1990 – 2000  4 (22) 
    2001 – 2011 4 (22) 
    2012 - 2017 4 (22) 
Study type  
   Single center 9 (50) 
   Multicenter 6 (33) 
   Not reported 3 (17) 
Surgical setting  
   Elective 10 (56) 
   Urgent 0 (0) 
   Both 5 (28) 
   Not reported 3 (17) 
CABG type  
   CCAB 9 (50) 
   OPCAB 2 (11) 
   Both 3 (17) 
   Not reported 4 (22) 
Outcomes assessed*  
   Vein graft failure (Per patient) 12 (67) 
   Vein graft failure (Per graft) 18 (100) 
   Major bleeding 8 (44) 
   Mortality 11 (61) 
   Myocardial infarction 10 (56) 
   CVA 7 (39) 
Longest time of patency assessment 
   ≤3 months 4 (22) 
  >3 to 12 months 9 (50) 
   >12 months (up to 8 years) 5 (28) 
Control interventions*  
   Placebo/control 9 (50) 
   Aspirin (usual care) 9 (50) 
Length of treatment  
   <3 months 2 (11) 
   3 to 12 months 15 (83) 
   >12 months 0 (0) 
   Not reported 1 (5.6) 
*RCTs can report more than one outcome or comparator. 
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4.3 Risk of Bias 
Overall, the study-specific risk of bias ranged from low to high (eFigure 1 and eFigure 2). 
Most studies were judged to have a low risk of bias for random sequence generation 
(61%), blinding of patients (56%), blinding of outcome assessor (78%), selective 
reporting (78%), and other bias (94%). In terms of allocation concealment, 78% of 
studies did not report details.  
Of five (28%) studies159-161 166 170 that reported failure to blind, three159 160 166 explained 
that the need for International Normalized Ratio (INR) monitoring of vitamin-K 
antagonists therapy prevented them from blinding patients and personnel. Eleven (61%) 
studies64 158-164 166 167 171 were at high risk of bias related to incomplete patency data owing 
to the high proportion of loss to follow up (16% to 49%) and/or uneven proportions 
and/or reasons for loss to follow up between arms. Unlike the primary outcome, all 
studies contributing to the secondary outcomes were judged to have a low risk of bias for 
incomplete outcome data. A greater risk of bias for the primary outcome is not surprising, 
as not all patients could return for angiographic assessment for various reasons including 
refusal or development of contraindications for angiography during follow-up (e.g., renal 
failure). In terms of selective reporting, three studies162 168 169 were at unclear risk of bias 
as they did not report data on at least one of our secondary clinical outcomes, and one 
study167 was at high risk of bias because it did not report any clinical outcome data. In 
addition, only one trial162 had a high risk of bias due to other bias owing to the imbalance 
in a few clinical characteristics between study groups despite randomization. 
Through visual inspection, the comparison-adjusted funnel plot appears symmetric 
suggesting that there was no evidence for small-study effects for placebo-controlled trials 
assessing SVGF (eFigure 4). 
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Table 2. Summary of baseline characteristics of patients undergoing CABG across treatment comparisons (n=18 RCTs) 
Characteristics 
No. of 
RCTs 
with data 
Aspirin vs 
Control 
n=8 RCTs 
Vit K A vs 
Control 
n=2 RCTs 
Vit K A vs 
Aspirin 
n=2 RCTs 
ASA/Clo vs 
Aspirin 
n=6 RCTs 
ASA/Clo vs 
Clopidogrel 
n=1 RCT 
ASA/Tic vs 
Aspirin 
n=1 RCT 
Age (mean±SD) 14 58±7.72 53±8 58±8 61±8.16 62±9.94 62±8.67 
Male 15 1212/1278 
(95) 
129/148 
(87) 
632/722 
(88) 
599/736 
(81) 
163/197 
(83) 
61/70 
(87) 
DM 12 45/560 
(8) 
18/111 
(16) 
74/722 
(10) 
168/756 
(22) 
108/197 
(55) 
21/70 
(30) 
HTN 14 528/1218 
(43) 
20/111 
(18) 
250/722 
(35) 
417/756 
(55) 
125/197 
(64) 
54/70 
(77) 
Dyslipidemia 8 27/116 
(23) 
NR 271/616 
(44) 
426/736 
(58) 
41/197 
(21) 
59/70 
(84) 
Prior MI 12 703/1076 
(65) 
74/111 
(67) 
401/722 
(56) 
253/623 
(41) 
105/197 
(53) 
12/70 
(17) 
Prior PCI 4 NR NR NR 77/524 
(15) 
24/197 
(12) 
8/70 
(11) 
Prior CVA 3 NR NR NR 16/436 
(3.7) 
NR NR 
CCAB 14 862/862 
(100) 
37/37 
(100) 
616/616 
(100) 
321/776 
(41) 
124/197 
(63) 
NR 
Antifibrinolytic 
use 
2 NR NR NR 399/399 
(100) 
NR NR 
Elective surgery 15 932/1006 
(93) 
73/145 
(50) 
695/755 
(92) 
776/776 
(100) 
186/197 
(94) 
47/70 
(67) 
Time of drug 18 7 preop to 5 3 to 4 postop 12 preop hours Immediately 1 day 58 to 59 
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initiation 
(range) 
postop days days to 4 postop 
days 
postop to 48 
hours 
postop hours 
Values presented as n/N (%) unless stated otherwise. All information was obtained from first publications. ASA/Clo: Dual-antiplatelet 
therapy with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. NR: Not reported. Preop: 
preoperative. Postop: postoperative. Vit K A: Vitamin-K antagonists.
54 
 
4.4 Direct Estimates 
4.4.1 Primary outcome 
A pairwise meta-analysis of eight RCTs (n= 1,182 patients) showed that dual-antiplatelet 
therapy with aspirin and clopidogrel significantly reduced SVGF compared to aspirin 
monotherapy (OR: 0.60; 95% CI: 0.42-0.88). In a separate meta-analysis of six RCTs (n= 
1,085 patients), aspirin monotherapy significantly decreased the odds of SVGF by 38% 
(OR: 0.62; 95% CI: 0.43-0.90) relative to placebo/control. Furthermore, there was no 
evidence of significant differences among other treatment comparisons. The direct 
estimates were consistent in magnitude and direction between base case analyses and per-
graft analyses for all comparisons (eTable 10). 
4.4.2 Secondary outcomes 
In a pairwise meta-analysis of four RCTs, of 506 patients assigned to aspirin 
monotherapy group, 34 (6.72%) patients underwent re-exploration for bleeding, and of 
485 patients assigned to placebo/control group, 9 (1.86%) patients had the event (OR: 
3.59; 95% CI: 1.67-7.73; eTable 10). No significant differences between interventions in 
major bleeding, mortality, MI, CVA, repeat revascularization, minor bleeding, and 
MACCE were found (eTable 10). 
4.5 Network Estimates, Treatment Ranking, and 
Contribution of Direct Evidence 
4.5.1 Primary outcome 
Figure 3 shows the network of evidence for SVGF. Eighteen studies64 158-174 with six 
treatment arms including 15 unique treatment comparisons were included in a NMA for 
SVGF. Of the 15 comparisons, four were statistically significant with three treatments 
were found to be more effective than placebo/control and one treatment was superior to 
aspirin monotherapy. More specifically, when compared with placebo/control, dual-
antiplatelet therapy with aspirin and clopidogrel (OR: 0.40; 95% CI: 0.24-0.69), dual-
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antiplatelet therapy with aspirin and ticagrelor (OR: 0.25; 95% CI: 0.07-0.94), and aspirin 
alone (OR: 0.64; 95% CI: 0.47-0.88) significantly reduced the odds of SVGF. In addition, 
dual-antiplatelet therapy with aspirin and clopidogrel had a statistically significant benefit 
in preventing SVGF relative to aspirin alone (OR: 0.63; 95% CI: 0.41-0.97). The network 
estimates were consistent in magnitude and direction between base case analyses and per-
graft analyses for all comparisons, except for the network estimate of vitamin-K 
antagonists versus placebo/control (eTable 11).  The difference is likely owing to a 
greater statistical power with the per-graft data (i.e., larger number of occluded SVGs and 
larger sample size in the two direct comparisons contributing to the network estimate) 
than with the base-case data. The direct and network estimates for all treatment 
comparisons can be found in Figure 4. 
eTable 12 presents the SUCRA value for all interventions. According to the SUCRA, 
dual-antiplatelet therapy with aspirin and ticagrelor was ranked the best in preventing 
SVGF with a SUCRA of 89, followed by dual-antiplatelet therapy with aspirin and 
clopidogrel (SUCRA=80), vitamin-K antagonists (SUCRA=46), aspirin monotherapy 
(SUCRA=44), clopidogrel monotherapy (SUCRA=33), and placebo/control 
(SUCRA=8.4). The numerical values of SUCRA between the base-case analysis and the 
per-graft analysis were similar (eTable 12). 
Lastly, the direct comparison of aspirin monotherapy and dual-antiplatelet therapy with 
aspirin and clopidogrel had the largest contribution to the network analyses (27.7%). 
Detailed information for contributions of direct evidence in the entire network can be 
found in eTable 13. 
 
 
 
 
56 
 
Figure 3. Network of RCTs comparing the effect of antithrombotic agents on 
saphenous vein graft failure (A), major bleeding (B), mortality (C), and myocardial 
infarction (D) 
 
The size of the nodes (circles) and edges (lines) are proportional to the number of studies 
evaluating a particular treatment and the number of patients who contribute to the direct 
comparison, respectively. 
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Figure 4. Summary of direct and network estimates for SVGF 
 
Estimates are presented as OR and its corresponding 95% CI. The bolded estimates are 
statistically significant. 
 
4.5.2 Secondary outcomes 
Figure 1 shows the network of treatment comparisons for secondary outcomes. Each 
outcome involves five arms with an identical set of interventions. Unlike the primary 
outcome, clopidogrel monotherapy was not part of the network for the secondary 
outcomes as the only study169 evaluating clopidogrel monotherapy did not report data on 
any of our secondary outcomes. 
In the NMA, there were eight studies158 160 165 166 171-174 including 1,690 patients for major 
bleeding, eleven studies158-161 163 165 166 170-173 including 2,396 patients for mortality, and 
ten studies158 160 164-166 170-174 including 2,644 patients for MI. For each of these secondary 
outcomes, there were 10 unique treatment comparisons in a network with no evidence of 
any statistically significant differences among these comparisons (eFigure 3 and eTable 
11). 
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clopidogrel (SUCRA=60), aspirin monotherapy (SUCRA=47), dual-antiplatelet with 
aspirin and ticagrelor (SUCRA=46), and vitamin-K antagonists (SUCRA=14). In 
addition, dual-antiplatelet therapy with aspirin and clopidogrel (SUCRA=71) was most 
effective in preventing MI, but dual-antiplatelet therapy with aspirin and ticagrelor 
(SUCRA=66) was best for improving survival (eTable 12). 
Lastly, the direct comparison of vitamin-K antagonists and aspirin monotherapy had the 
largest contribution to the network analysis for major bleeding and MI (34% and 37%, 
respectively, eTable 13). Dual-antiplatelet therapy with aspirin and clopidogrel versus 
aspirin monotherapy was the comparison with the most contribution to the entire network 
for mortality (24%). 
4.6 Assessment of Transitivity, Homogeneity, and 
Coherence 
We assessed the transitivity assumption using its own four expressions: 
1. First, we suspected that not all treatments were sufficiently similar across trials. 
While trials investigating the effect of dual-antiplatelet therapy with aspirin and 
clopidogrel used similar regimens, higher aspirin doses were given to patients 
who participated in earlier studies. Also, for control arms, two trials159 161 
provided no study medications to patients, while the remaining studies 
administered matching placebo. Therefore, the control arms in the vitamin-K 
antagonists studies may not be similar to control arms in earlier studies or in the 
aspirin monotherapy studies. 
2. Second, we felt it is appropriate to conclude that the choice of comparator may 
not be influenced by the authors’ expectations in the magnitude and/or direction 
of treatment effects. In early days, placebo was used as a comparator; but after the 
benefit of aspirin was established in published trials, most trials compared the 
intervention of interest with aspirin monotherapy. Hence, it may be justifiable to 
assume that the missing arms were missing at random. 
3. Third, we visually inspected the network plot and qualitatively examined the 
comparability of the distribution of potential effect modifiers, which were pre-
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specified, across treatment contrasts. We assumed that the effect modifiers were 
not systematically different between treatment comparisons (Table 2). Although 
the proportion of CCAB and the timing for the start of treatment varied across 
comparisons, we felt these differences may not have enough strength to 
substantially influence treatment effects. Due to limited data on antifibrinolytic 
use, it was not possible to compare the distribution of this variable across 
comparisons in this network.  
4. Fourth, we felt it was appropriate to assume that the type of participants included 
in these studies could conceivably have been eligible to be randomized to any of 
the included interventions. Patients with a history of bleeding were excluded in all 
studies, thus, equipoise between participating in a vitamin-K antagonist trial and 
participating in a non-vitamin-K antagonist trial would equally apply, despite the 
known bleeding risk of vitamin-K antagonists. 
In summary, though we could not definitively rule out the possibility of intransitivity, we 
judged that the assumption of transitivity sufficiently holds based on the current evidence 
since there was no good evidence to the contrary. 
In terms of the homogeneity assumption, we identified low to moderate heterogeneity (I2 
of <75%) for all outcomes based on pairwise meta-analyses. In the network, the between-
trial variance (tau2) was 0.047, 5.38×10-22, 1.93×10-17, and 1.08×10-14 for SVGF, major 
bleeding, mortality, and MI, respectively (see eTable 11). The estimated tau2 for SVGF 
was lower than the 50% quantile of heterogeneity estimates (up to 1.10) obtained from an 
empirical meta-analysis for a subjective outcome.149 Similarly, the heterogeneity variance 
for all-cause mortality was lower than the corresponding 50% quantile of the empirical 
tau2 (up to 0.007). Lastly, the heterogeneity variance for semi-objective outcomes (i.e., 
major bleeding and MI) was also lower than the 50% quantile of the empirical 
distribution (up to 0.016). Overall, we identified low heterogeneity in our networks, 
which suggests that heterogeneity is probably less likely to threaten internal validity. 
With regards to the coherence assumption, there was a lack of evidence of local 
incoherence for all outcomes: SVGF (IF: 0.25 (95% CI: 0.00-1.42)), major bleeding (IF: 
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0.30 (95% CI: 0.00-1.12)), mortality (IF: 0.85 (95% CI: 0.00-5.22)), and MI (IF: 3.33 
(95% CI: 0.00-7.06); see eTable 14). In addition, the design-by-treatment interaction 
model found no evidence of incoherence in the entire network for SVGF (P= 0.834), 
major bleeding (P= 0.632), mortality (P=0.476), and MI (P=0.191; see eTable 15). 
4.7 Quality of Evidence 
For the primary outcome, no serious risk of bias and no inconsistency was detected for all 
direct comparisons, except for those involving vitamin-K antagonists, in which blinding 
was a challenge. All direct comparisons were at risk of indirectness due to: 1) the use of 
aspirin at doses higher than the currently recommended (75 to 100 mg/day)21; 2) the use 
of a surrogate outcome (SVGF), which has not yet been validated for its relationship to 
the outcomes that matter, including acute MI and death; and 3) the short duration of 
treatment (e.g., one month) and follow-up (e.g., eight days) for SVGF, which are not very 
applicable to the real-world situation, where long term treatment and data are of interest. 
In addition, the evidence was rated down for imprecision because of the wide 95% CIs 
with small number of events and sample size for most direct comparisons. The overall 
quality of the direct evidence therefore ranged from very low to moderate, in which the 
comparisons of aspirin monotherapy versus placebo/control and dual-antiplatelet therapy 
with aspirin and clopidogrel versus aspirin monotherapy were of moderate quality. In 
terms of network evidence, the overall quality of evidence was very low, ranging from 
very low to moderate, primarily due to the wide 95% CIs of network estimates and the 
probable intransitivity. In the network, we found eight comparisons (53% of all 
comparisons) of very low quality, three (20%) of low quality, four (27%) of moderate 
quality. Notably, the network evidence for most comparisons of active drugs versus 
placebo/control was moderate quality because the magnitude of significant effect sizes 
reached <0.5, and the only head-to-head comparison with moderate quality was dual-
antiplatelet therapy with aspirin and clopidogrel versus aspirin monotherapy. 
For secondary outcomes, there was no serious risk of bias and inconsistency for most 
direct comparisons, except for those studies using vitamin-K antagonists. Comparisons of 
any drugs versus aspirin monotherapy were at risk of indirectness as aspirin was 
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administered at higher doses than those that are currently used. For all direct 
comparisons, evidence was rated down for imprecision because the 95% CIs crossed the 
clinical decision threshold. The overall quality of direct evidence was therefore low, 
ranging from very low to moderate, in which the comparison of dual-antiplatelet therapy 
with aspirin and ticagrelor versus aspirin monotherapy was rated at moderate quality. In 
terms of network evidence, the overall quality was very low, ranging from very low to 
moderate, primarily due to the wide 95% CIs of network estimates and the possibility of 
intransitivity. In each of the networks, we found six comparisons (60% of all 
comparisons) of very low quality, three (30%) of low quality, one (10%) of moderate 
quality. Although the evidence for dual-antiplatelet therapy with aspirin and ticagrelor 
versus aspirin monotherapy was moderate quality, it is important to note that there was 
only one study available for this comparison. Detailed information regarding quality of 
direct and network evidence can be found in eTable 16 and eTable 17, respectively. 
4.8 Post-hoc Sensitivity Analyses 
To explore the potential impact of missing outcome data in the analyses, we conducted a 
sensitivity analysis for SVGF. eTable 18 and eTable 19 present the results of sensitivity 
analyses accounting for loss to follow-up. The results obtained from our primary analysis 
were similar to those from the ‘all missing failure’ models with respect to the effect 
estimates and the treatment rankings.  
There were two studies with multiple follow-up data.158 160 When we included SVGF data 
that were collected closer to 1-year of CABG (a shorter follow-up i.e. up to two years) 
from these studies, the conclusions did not change substantially in terms of effect sizes, 
treatment rankings, and coherence (eTable 20). 
Lastly, we performed another sensitivity analysis excluding studies168 172 that included 
only patients undergoing CABG without CPB (OPCAB) and found that the results were 
consistent with those obtained from the primary analyses (eTable 20), except for the 
comparison of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin 
monotherapy, which did not reach statistical significance. This may be owing to the 
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smaller sample size (i.e., lower statistical power) because of study removal or could be 
related to clinical differences in likelihood of SVGF in the context of OPCAB relative to 
CABG with CPB. 
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Chapter 5  
5 Discussion 
The aims of this chapter are to summarize the study findings, to compare them to the 
existing literature, and to discuss the limitations and the conclusions of the current NMA, 
including its implications for clinical practice and research. 
5.1 Summary of Study Findings 
A NMA was conducted to synthesize results from RCTs that assessed efficacy of 
different antithrombotic therapies in the prevention of SVGF to provide evidence-based 
guidance for optimal prophylactic management. In this NMA of 18 unique RCTs (n= 
3,413 patients), we included six interventions for patients undergoing CABG and found 
that, based on moderate-quality evidence, patients receiving dual-antiplatelet therapy 
with aspirin and clopidogrel, a second-best treatment, had significantly lower odds of 
developing SVGF compared to either aspirin alone or placebo/control. Furthermore, 
though ranked the most effective agent, dual-antiplatelet therapy with aspirin and 
ticagrelor only significantly reduced SVGF relative to placebo/control, but not in 
comparison with any other interventions. Additionally, moderate-quality evidence 
showed that aspirin monotherapy was protective against SVGF relative to 
placebo/control. Besides the aforementioned comparisons, there were no significant 
differences found in any other treatment comparisons. These results (effect sizes and 
treatment rankings) were generally consistent across different units of analysis (base case 
versus per graft) and different durations of follow-up (longer [up to 8 years] versus 
shorter follow-up [up to 2 years]). 
Our secondary objective was to conduct a NMA to assess the relative effects of 
antithrombotic agents on clinical outcomes. The present NMA could not demonstrate any 
significant differences in major cardiovascular adverse events (MI and mortality) and 
major bleeding amongst antithrombotic therapies. 
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5.2 Comparison to the Existing Literature 
The current study is the first NMA to simultaneously evaluate the effect of various 
antithrombotic agents on SVGF; however, a number of pairwise meta-analyses 
comparing a subset of these agents had been previously published. Fremes et al and 
Henderson et al published the earliest meta-analyses in the late 1980s and early 1990s 
and found aspirin to be superior in reducing SVG occlusion among patients undergoing 
CABG over placebo.71 176 Our findings are consistent with these early meta-analyses. 
Additionally, an antiplatelet meta-analysis in 1994 demonstrated that the use of 
postoperative aspirin (75 to 325 mg/day) reduced the odds of any graft occlusion by 44% 
relative to control, although the proportion of occluded vein grafts was not reported.177 In 
terms of duration of treatment, it has been suggested that the use of aspirin for longer 
than 1 year post CABG did not improve SVG patency.178 Due to insufficient data, the 
current NMA could not confirm the benefits of long-term antithrombotic therapy use. In 
contrast to our results, Fremes et al and Henderson et al found a reduction in SVGF with 
anticoagulation. It is important to note that one of the three anticoagulation studies 
included in these meta-analyses (which was excluded from our analysis) provided an 
uninterrupted antiplatelet therapy with dipyridamole for seven days post CABG, an agent 
that is no longer used for SVGF prevention.179 In 2013, Deo et al published a pairwise 
meta-analysis of five RCTs involving 1,419 SVGs and showed that the postoperative use 
of dual-antiplatelet therapy with aspirin and clopidogrel significantly reduced SVG 
occlusion compared with aspirin alone,72 which was congruent with the results observed 
in our NMA. In addition, the significant reduction remained when considering only 
patients undergoing CABG without CPB.72 Due to the lack of data, a sensitivity analysis 
including only OPCAB studies was not possible to confirm this reduction.  
In terms of clinical outcomes, Fremes et al failed to demonstrate the survival benefits of 
aspirin monotherapy as well as anticoagulation, which was consistent with our study.71 
Furthermore, a meta-analysis of 11 RCTs and observational studies involving 25,728 
CABG patients showed that dual-antiplatelet therapy with aspirin and clopidogrel was 
associated with a significant reduced risk of 30-day mortality.72 Despite this association, 
a causative role of antithrombotic agents in reducing mortality in this population remains 
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unknown. A more recent meta-analysis examining the clinical effects of postoperative 
antithrombotic therapy in five RCTs (979 patients undergoing elective CABG) reported 
that there were no significant differences in mortality, MI, stroke, and major bleeding 
events between monotherapy with aspirin and dual-antiplatelet therapy with aspirin and 
clopidogrel.180 Similar conclusions were also observed in our study. In summary, there 
have been no previously published NMAs of antithrombotic agents for SVG patency. 
However, the direct comparison findings within our NMA were generally in agreement 
with the previous pairwise meta-analyses in terms of SVGF and clinical outcomes. 
5.2.1 Other comparisons 
In this NMA, we did not observe any significant effect of vitamin-K antagonists on either 
SVGF or clinical outcomes. The low sample size may be mainly responsible for the non-
significant results. Though increasing the power of the study is one solution to this 
statistical issue, warfarin has typically been used less frequently to prevent SVGF due to 
its association with increased bleeding and the need for regular testing of the INR.  
Our NMA was also underpowered to detect significant differences in the incidence of 
SVGF or adverse events between monotherapy with clopidogrel169 or dual-antiplatelet 
therapy with aspirin and ticagrelor173  and other antithrombotic agents as currently there 
is only one published trial available for each comparison. It is hoped that the two trials 
(DACAB trial; ClinicalTrials.gov No. NCT02201771 and TICAB Trial; 
ClinicalTrials.gov No. NCT01755520) that are currently in progress can provide 
additional data on the use of dual-antiplatelet therapy with aspirin and ticagrelor among 
patients undergoing CABG. 
5.3 Strengths and Limitations 
The following are the main strengths of the current NMA: 1) its comprehensive 
systematic search that considered all available RCTs, published or unpublished, of 
antithrombotic therapies assessing the patency of SVGs as an outcome of interest.  The 
eligibility criteria were pre-specified and stringent, which was purposefully done to 
reduce heterogeneity and risk of bias; 2) The use of a well-defined protocol. The protocol 
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was prepared to provide background information to the readers, to serve as a working 
outline, and most importantly, to  enhance the integrity of the current study promoting 
transparency in scientific research;181 3) The use of the GRADE approach to evaluate the 
quality of the evidence for individual trials and in aggregate. Understanding not only the 
magnitude and direction of treatment effects, but also the quality of evidence is important 
to avoid the over-reliance on statistical significance and treatment ranking; 4) Lastly, the 
use of NMA methodology for secondary analysis of existing studies. A NMA is useful to 
estimate network estimates with greater precision while simultaneously considering all 
relevant treatment options, even when some of the treatments have never been compared 
previously. 
Despite these strengths, the results of this study should be interpreted in light of the 
following limitations. First, we encountered several challenges in evaluating the 
transitivity, homogeneity, and coherence assumptions of NMA. Although we felt it was 
appropriate to conclude that our networks did not transgress the transitivity assumption, 
the judgment was limited by the lack of global evidence and extent of clinical 
understanding of treatment-effect modification. Consequently, the choice of study-level 
effect modifiers was necessarily somewhat arbitrary, based on our best knowledge of 
clinical expectations rather than on empirical evidence (which does not yet exist). We 
also could not confirm whether it was appropriate to treat these covariates equally across 
outcomes and comparisons as potentially they could have different effects across 
different outcomes and comparisons. Even if there was sufficient pre-existing evidence to 
inform these relationships a priori, the assessment would still be limited if the effect 
modifiers were not measured or the information was not reported by each study report. 
These concerns are not unique to our NMA, and have been frequently discussed by 
authors and methodologists in previous NMA publications.141 182 183 Future research is 
therefore needed to better understand treatment-effect modification. Notably, this NMA 
used a qualitative approach to assess the transitivity assumption, which can be subjective. 
Another method has been recently proposed by Kabali and Ghazipura to evaluate the 
assumption using causal graphs and transport formulae.183 However, a detailed 
description and application of this approach is beyond the scope of this NMA. Regarding 
coherence, our network is sparsely populated with only one closed loop provided by 
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direct comparison studies; therefore, we were not able to assess incoherence for the other 
parts of network. It is also important to note that lack of evidence of statistical 
incoherence does not necessarily mean evidence of coherence. There may be several 
factors contributing to the absence of this evidence in our NMA, such as the low power 
of tests for detecting local and global incoherence and the unexplained heterogeneity that 
may further reduce the power. In terms of the homogeneity assumption, although the 
statistical heterogeneity was found to be low or moderate, the power of the tests to 
quantify the extent of heterogeneity was limited by the relatively few studies and small 
sample size in the networks. Importantly, the inadequate data on baseline characteristics 
and the lack of patient-level data also preclude carrying out a full, comprehensive 
assessment of clinical and methodological heterogeneity and performing further analyses 
such as subgroup analysis or meta-regression to explore potential sources of 
heterogeneity or to adjust for the unbalanced distribution of effect modifiers. If factors 
influencing SVGF varied markedly across comparisons, the estimated treatment effects 
may be biased. While the results after we performed sensitivity analyses (to explore the 
impact of missing outcome data, differing duration of follow-up, and varied units of 
analysis) remained robust across different scenarios, it is important to highlight that the 
sensitivity analyses were also severely limited in power to detect differences.  
Second, since our inclusion criteria for eligible RCTs was restricted to a single outcome 
(SVGF), the analyses of other clinically-relevant outcomes were very limited by the 
amount of data reported in the SVGF study reports. As expected, several interventions 
were compared in a relatively few studies and sample size. Hence, drawing definitive 
conclusions regarding the clinically-relevant impact on the ultimate outcomes of interest 
including MI and need for cardiac reintervention was not possible, which puts the current 
study at risk of type II error (failure in finding a significant result when in truth there is 
one). Most importantly, although the balance between health benefits and safety is an 
important aspect that influences the choice of intervention, assessing the balance of 
benefit and harms of antithrombotic therapies is not possible in this study due to limited 
data. Therefore, future research is needed to expand our knowledge and depth of 
understanding of the benefit:risk ratio. Third, although the chance is small, the possibility 
of drawing erroneous conclusions of statistical differences between comparisons cannot 
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be ruled out (type I error). Theoretically speaking, of 111 (direct, indirect, and network) 
statistical tests that we performed on four different endpoints using an alpha of 0.05, a 
total of six statistically significant differences (false positives) would be expected, and 
therefore our significant outcomes might be explained by chance alone.  
Fourth, it is unknown whether different doses lead to clinically important differences in 
the patency of SVG. In this current study, we did not control for dose and our results may 
be confounded by it. Fifth, our NMA included studies which were published over a 38-
year period, and thus, patient characteristics (i.e., risk factors and disease complexity), 
surgical techniques, advances in imaging, treatment regimens used in earlier studies may 
differ from those included in more recent studies (such as broad use of statins) and may 
not reflect the current clinical practice. Due to the small number of trials in each 
comparison, we are unable to perform a sensitivity analysis investigating the impact of 
year of publication (before and after year 2000). Sixth, substantial heterogeneity in the 
definition of SVGF exists in the included studies. Of those that reported clear definitions 
of SVGF, one study performed angiographic assessments in surviving patients only,158 
one study evaluated the patency of SVG post mortem,160 and the remaining were 
unknown. Many studies also did not describe whether grafts or distal anastomoses were 
being counted. In addition, studies measured SVGF at different times and it is unclear 
whether these studies excluded perioperative (early) SVGF. Early SVGF is often a result 
of technical factors, regardless of the antithrombotic therapy received. The inclusion of 
early SVGF may underestimate the efficacy of antithrombotic agents themselves for SVG 
failure after CABG. Collectively, considerable heterogeneity in definitions of SVGF may 
therefore threaten internal validity. Furthermore, although the results from base case 
analysis and per graft analysis were similar, combining data from two different units of 
analysis may challenge the interpretation of the base case analysis. Seventh, follow-up 
period and length of treatment may be potential sources of heterogeneity. Many of these 
studies did not follow up patients for adequate number of years to allow for a fair 
indication of whether differences in SVGF would arise, and pooling studies with different 
lengths of treatment may reduce the relevance of the study findings. Eighth, women 
(11%) were underrepresented in all included studies, which may limit the generalizability 
of the results. Lastly, due to insufficient information, it is unclear whether studies 
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presented the data based on ITT analysis, an analysis that preserves the benefits of 
randomization in the presence of reasonable rate of missing data ensuring unbiased 
estimates.184 The study findings therefore should be interpreted with caution due to the 
potential selection bias induced by the high rate of loss to angiographic follow-up (with 
patients having certain characteristics that are associated with treatment effects or side 
effects of treatment forgoing further angiographic follow-up), which occurred in most of 
the included studies, and by death as a competing event in SVGF analysis. The large loss 
to follow up indicates that our results remain unstable. Hence, the answers remain 
unknown, and demand future adequately controlled trials of sufficient duration to 
measure these outcomes. 
5.4 Implications for Clinical Practice 
Experts have recognized the importance of rating the quality of evidence in the process of 
making clinical decisions. According to the GRADE system, high quality of evidence is 
considered most desirable, followed by moderate quality of evidence since the observed 
treatment effect and our confidence in it are unlikely to alter as more studies emerge.185 
In this NMA, there are four comparisons with moderate quality of evidence on reducing 
SVGF but no comparison with high quality of evidence. The four comparisons are dual-
antiplatelet therapy with aspirin and clopidogrel versus placebo/control, dual-antiplatelet 
therapy with aspirin and ticagrelor versus placebo/control, monotherapy with aspirin 
versus placebo/control, and dual-antiplatelet therapy with aspirin and clopidogrel versus 
monotherapy with aspirin; of these, all reached statistical significance. However, the first 
three comparisons included placebo/control, in which its use is not of interest. Indeed, it 
is unethical to give patients placebo when a strategy known to be efficacious exists and is 
recommended by clinical guidelines.  Considering a placebo-controlled trial in the light 
of superiority evidence may therefore raise ethical concerns.186 187 This concern leaves us 
with the last comparison, which is dual-antiplatelet therapy with aspirin and clopidogrel 
versus monotherapy with aspirin, to discuss. 
In the context of SVG patency, aspirin monotherapy is the current standard prophylactic 
treatment.6 However, there is growing evidence showing that the suboptimal performance 
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of aspirin alone is not uncommon among CABG patients.188 189 As briefly discussed in 
Chapter 1.3.3.2, this phenomenon is known as aspirin resistance, which affects 30 to 42% 
of patients undergoing CABG.188 189 Studies have shown that aspirin resistance was 
associated with an increased risk of cardiovascular adverse events and was more 
prevalent in patients with SVGF.67 190 191 Some argue that a higher (up to 325 mg daily) 
aspirin dose should be administered to prevent aspirin resistance.6 However, aspirin 
resistance is unlikely to be affected by higher doses of aspirin. Aspirin resistance is 
mainly caused by decreased bioavailability of some enteric-coated formulations and drug 
interactions with low-dose aspirin.192 193 Alternatively, the addition of clopidogrel to 
aspirin has been proposed to further reduce the risk of occlusion. Based on moderate-
quality evidence, our study findings supported this hypothesis and showed that the use of 
dual-antiplatelet therapy with aspirin and clopidogrel reduced SVGF compared to aspirin 
alone. Although providing a recommendation with lower quality of evidence (Class IIb, 
Level of Evidence B-NR), the 2016 ACC/AHA guidelines on dual-antiplatelet therapy 
with aspirin and clopidogrel70, also suggest that the addition of clopidogrel to aspirin (75 
to 100 mg daily) for 12 postoperative months may improve the patency of SVGs. The 
findings of our NMA provide further support for this recommendation.  
Furthermore, the beneficial effect of dual-antiplatelet with aspirin and clopidogrel on 
SVGF may have important impacts on the healthcare system as it may lead to a decrease 
in the rate of SVG-related repeat revascularization, which was found to be ~5.7% 
between 2004 and 2009 for SVG-related PCI and 1.3% at 10 year post initial CABG for 
re-do CABG, and a reduction in costs associated with these procedures.194 195 However, 
further studies are needed to ascertain whether the dual-antiplatelet therapy with aspirin 
and clopidogrel will lead to cost-effectiveness.  
As important as it may seem, quality of evidence alone is not sufficient in making 
recommendations. There are many other aspects that should be considered including 
balance between beneficial and harmful effects, values and preferences, and cost-
effectiveness, as they are also important factors that influence the choice of 
antithrombotic agents.185 Due to insufficient information on clinical outcomes, we could 
not confirm whether the benefits related to SVGF of the dual-antiplatelet therapy with 
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aspirin and clopidogrel outweigh the harms or whether the beneficial effects will translate 
into long-term improvements in overall health. 
It is important to note that though dual-antiplatelet therapy with aspirin and ticagrelor 
was the best-ranked treatment in preventing SVGF, treatment rankings derived from 
NMA cannot be interpreted clinically as SUCRA is not intended as a clinical ranking 
measure. Moreover, SUCRA does not account for the magnitude and uncertainty of 
differences in effect estimates between interventions, the quality of the network evidence, 
nor the contribution of each direct estimate to the network estimates. Consequently, it 
would be difficult to decide whether being the best is clinically and statistically different 
from being the second best as the difference may occur due to chance.196 
5.5 Implications for Research 
The following are several important evidence gaps, which should be addressed by future 
research. First, SVGF is itself presumably a surrogate for more important clinical 
outcomes such as acute MI and death, however, there is little research evaluating the 
relationship between SVGF and these patient-important outcomes. Surrogate endpoints 
are useful in clinical trials to understand the mechanism of action of a drug and often 
used because trials can use smaller sample sizes and shorter follow-up periods to generate 
sufficiently powered results.197 However, to appropriately use SVGF as a surrogate, the 
relationship between SVGF and the hard outcomes needs to be established. As practice 
patterns and patient demographics change, it is particularly important to understand its 
validity and reliability as a surrogate endpoint for describing the patterns. Second, many 
studies did not report data on cardiovascular adverse events as they were not designed to 
demonstrate the potential cardiovascular risk with antithrombotic agents. As a result, we 
were unable to adequately measure the clinical outcomes due to lack of statistical power 
owing to the few studies that reported on clinical outcomes. Therefore, well-designed 
studies (e.g., pragmatic RCTs) are needed to evaluate both SVGF and clinical outcomes 
to ascertain the balance between potential health benefits and safety. Third, research 
should focus on treatment-effect modification as identifying true effect modifiers is of 
clinical and research importance; it may help clinicians focus on the specific needs of 
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patients across different subgroups and may aid researchers in better evaluating the 
validity of NMA findings through transitivity and homogeneity assessment. 
5.6 Conclusions 
A NMA of RCTs was conducted to simultaneously assess the relative effects of various 
oral antithrombotic agents on SVGF and clinical outcomes among patients undergoing 
CABG. Based on very low to moderate quality of evidence, no significant differences in 
the incidence of major bleeding, mortality, and myocardial infarction post CABG across 
antithrombotic comparisons were found, owing to low number of events and small 
sample size. Compared to placebo/control, three active medications (aspirin 
monotherapy, dual-antiplatelet therapy with aspirin and clopidogrel, and dual-antiplatelet 
therapy with aspirin and ticagrelor) significantly reduced SVGF. Importantly, based on 
moderate-quality evidence, dual-antiplatelet therapy with aspirin and clopidogrel was the 
only intervention that improved the SVG patency compared to aspirin monotherapy. Our 
results may, therefore, help clarify whether the current guidelines should be revisited to 
more compellingly recommend the use of dual-antiplatelet therapy with aspirin and 
clopidogrel in patients undergoing CABG. Certainly, optimal antithrombotic therapy 
options should be individualized based on a multidisciplinary evaluation that incorporates 
considerations of comorbidity burden, perception of risks, and patient values and 
preferences informed by the evidence and its remaining uncertainties.  
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Appendix A: eFigures 
 
 
 
 
 
eFigure 1. Risk of bias assessments for SVGF 
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eFigure 2. The overall risk of bias graph for SVGF 
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eFigure 3. Summary of direct and network estimates for major bleeding (A), 
mortality (B), and MI (C) 
 
Estimates are presented as OR and its 95% CI. 
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eFigure 4. Comparison-adjusted funnel plot of placebo-controlled trials for SVGF 
 
Treatment 1: Aspirin, 4: Vitamin K antagonists, 6: Control. The yellow line is the 
linear regression of the comparison-specific differences (i.e., the difference between the 
individual study-level effect size and the summary effect estimate for each comparison, 
x-axis) on the standard error of the summary estimate of each study (y-axis)  
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Appendix B: eTables 
eTable 1: Ovid MEDLINE search strategy 
# Searches (November 13, 2016) Results 
1 exp Coronary Artery Bypass/ 50665 
2 ((aortocoronary or aorto-coronary or coronary) adj2 (bypass or by-pass or graft* or 
saphenous or radial or vein or venous or internal mammar*)).mp. 
68443 
3 (CABG or "coronary artery bypass").mp.  62608 
4 1 or 2 or 3 69629 
5 fibrinolytic agents/ or aspirin/ or ticlopidine/ 73496 
6 platelet aggregation inhibitors/ or aspirin/ or aspirin, dipyridamole drug combination/ 
or dipyridamole/ or prasugrel hydrochloride/ or ticlopidine/ 
72898 
7 anticoagulants/ or acenocoumarol/ or phenprocoumon/ or warfarin/ or antithrombins/ 
or exp factor xa inhibitors/ 
79011 
8 (antithrombotic* or anti-thrombotic* or anticoagula* or anti-coagula* or antiplatelet* 
or anti-platelet*).mp. 
139797 
9 ((platelet or thromboxane or adenosine diphosphate receptor or ADP receptor or 
thienopyridine or cyclo-oxygenase or cyclooxygenase or cyclic GMP 
phosphodiesterase type V enzyme or vitamin K or vitamin-K or direct thrombin or 
direct factor Xa) adj1 (antagonist* or inhibitor*)).mp. 
28064 
10 (aspirin or acetylsalicylic acid or acylpyrin or aloxiprimuma or colfarit or dispril or 
easprin or ecotrin or endosprin or magnecyl or micristin or polopirin or polopiryna or 
solprin or solupsan or zorprin).mp. 
65552 
11 exp Dipyridamole/ 7772 
12 (dipyridamole or persantine or antistenocardin or cerebrovase or cleridium or curantil 
or curantyl or dipyramidole or kurantil or miosen or novo-dipiradol or persantin or 
persantine).mp.   
10587 
13 (clopidogrel or Plavix or clopilet or grepid or iscover or zopya or zylagren or 
zylit).mp. 
12243 
14 Prasugrel Hydrochloride/ or (prasugrel or effient or efient).mp. 1814 
15 (ticagrelor or brilinta or brilique or possia).mp. 1480 
16 (indobufen or ibustrin).mp. 171 
17 (warfarin or adoisine or athrombin or befarin or carfin or circuvit or coumadan or 
coumadin or coumadine or coumafene or coumaphene or dagonal or farin or jantoven 
or aldocumar or kumatox or maforan or marevan or orgarin or panwarfarin or 
panwarfin or prothromadin or sofarin or tintorane or uniwarfin or wafarin or waran or 
warfarine or warfilone or warnerin or marevan or tedicumar or warfant).mp. 
7024 
18 (acenocoumarol or acenocoumarin or acenocoumarine or acenocoumarole or 
acenocoumarolum or acenocumarol or acenocumarolo or acenocumerol or 
acenokumarin or acitrom or neo sintrom or neosintrom or neositron or nicoumalone or 
nicumalon or nitrovarfarin or nitrowarfarin or sincoumar or sincumar or sinkumar or 
sinthrom or sinthrome or sintrom or sintroma or sintron or syncoumar or syncumar or 
syntrom or synthrom or trombostop or zotil or mini sintrom or mini-sintrom or 
minisintrom).mp. 
1674 
19 (phenprocoumon or falithrom or falithrome or fenprocoumon or liquamar or 
marcoumar or marcumar or phenprocouman or phenprocoumalol or phenprocoumarol 
or phenprocoumon or phenprocoumom or phenprocumarol or phenprogramma).mp. 
1272 
20 (Ticlopidine or agulan or anagregal or antigreg or aplaket or cartrilet or cenpidine or 
clotidone or crodin or declot or desitic or goclid or licodin or nufaclapide or panaldine 
or siclot or tacron or ticard or ticdine or ticlid or ticlidil or ticlodine or ticlodix or 
ticlodone or ticlomed or ticlon or ticuring or tikleen or tiklid or tiklyd or tikol or 
tilodene or tiodin or tipidin or tipidine or tyklid or viladil).mp. 
10455 
21 (Rivaroxaban or xarelto).mp. 3088 
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22 (Dabigatran or pradax or pradaxa or prazaxa or rendix).mp. 3543 
23 (Apixaban or eliques or eliquis).mp. 1903 
24 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 
21 or 22 or 23 
256464 
25 4 and 24 4778 
26 ("randomized controlled trial" or "controlled clinical trial").pt. 559642 
27 (random* or placebo* or single-blind* or double-blind* or triple-blind* or "single 
blind*" or "double blind*" or "triple blind*").ti,ab. 
1051974 
28 clinical trials as topic.sh. 189460 
29 26 or 27 or 28 353315 
30 exp animals/ not humans.sh. 4668056 
31 29 not 30 1237283 
32 25 and 31 1211 
33 ("graft paten*" or "graft occlu*" or "occlu* graft*" or "graft fail*" or "fail* graft*" or 
“patency rate*” or paten* or “total occlu*”).mp. 
27036 
34 ("string sign" or stenosis or Fitzgibbon or "TIMI flow").mp 175704 
35 ("cardiac revasculari$ation" or revasculari$ation or "repeat CABG" or "repeat 
coronary artery bypass" or "redo CABG" or "redo coronary artery bypass" or "re-do 
CABG" or "re-do coronary artery bypass" or PCI or "percutaneous coronary 
intervention").mp.    
33226 
36 33 or 34 or 35 300192 
37 32 and 36 494 
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eTable 2: Ovid EMBASE search strategy 
# Searches (November 13, 2016) Results 
1 exp Coronary Artery Bypass/ 66277 
2 ((aortocoronary or aorto-coronary or coronary) adj2 (bypass or by-pass or graft* or 
saphenous or radial or vein or venous or internal mammar*)).mp. 
92637 
3 (CABG or "coronary artery bypass").mp. 90465 
4 1 or 2 or 3 98265 
5 antithrombocytic agent/ 36964 
6 acetylsalicylic acid plus clopidogrel/ 406 
7 exp prasugrel/ or exp antithrombocytic agent/ or exp ticlopidine/ or exp acetylsalicylic 
acid/ or exp dipyridamole/ or exp ticagrelor/ or exp clopidogrel/ or exp anticoagulant 
agent/ 
605804 
8 (antithrombotic* or anti-thrombotic* or anticoagula* or anti-coagula* or antiplatelet* 
or anti-platelet*).mp. 
225540 
9 ((platelet or thromboxane or adenosine diphosphate receptor or ADP receptor or 
thienopyridine or cyclo-oxygenase or cyclooxygenase or cyclic GMP 
phosphodiesterase type V enzyme or vitamin K or vitamin-K or direct thrombin or 
direct factor Xa) adj1 (antagonist* or inhibitor*)).mp. 
18919 
10 (aspirin or acetylsalicylic acid or acylpyrin or aloxiprimuma or colfarit or dispril or 
easprin or ecotrin or endosprin or magnecyl or micristin or polopirin or polopiryna or 
solprin or solupsan or zorprin).mp. 
198403 
11 (dipyridamole or persantine or antistenocardin or cerebrovase or cleridium or curantil 
or curantyl or dipyramidole or kurantil or miosen or novo-dipiradol or persantin or 
persantine).mp.   
24832 
12 (clopidogrel or Plavix or clopilet or grepid or iscover or zopya or zylagren or 
zylit).mp. 
48978 
13 (prasugrel or effient or efient).mp. 6079 
14 (ticagrelor or brilinta or brilique or possia).mp. 4772 
15 (indobufen or ibustrin).mp. 492 
16 (warfarin or adoisine or athrombin or befarin or carfin or circuvit or coumadan or 
coumadin or coumadine or coumafene or coumaphene or dagonal or farin or jantoven 
or aldocumar or kumatox or maforan or marevan or orfarin or panwarfarin or 
panwarfin or prothromadin or sofarin or tintorane or uniwarfin or wafarin or waran or 
warfarine or warfilone or warnerin or marevan or tedicumar or warfant).mp. 
80901 
17 (acenocoumarol or acenocoumarin or acenocoumarine or acenocoumarole or 
acenocoumarolum or acenocumarol or acenocumarolo or acenocumerol or 
acenokumarin or acitrom or neo sintrom or neosintrom or neositron or nicoumalone or 
nicumalon or nitrovarfarin or nitrowarfarin or sincoumar or sincumar or sinkumar or 
sinthrom or sinthrome or sintrom or sintroma or sintron or syncoumar or syncumar or 
syntrom or synthrom or trombostop or zotil or mini sintrom or mini-sintrom or 
minisintrom).mp. 
5736 
18 (phenprocoumon or falithrom or falithrome or fenprocoumon or liquamar or 
marcoumar or marcumar or phenprocouman or phenprocoumalol or phenprocoumarol 
or phenprocoumon or phenprocoumom or phenprocumarol or phenprogramma).mp.                             
13870 
19 (Ticlopidine or agulan or anagregal or antigreg or aplaket or cartrilet or cenpidine or 
clotidone or crodin or declot or desitic or goclid or licodin or nufaclapide or panaldine 
or siclot or tacron or ticard or ticdine or ticlid or ticlidil or ticlodine or ticlodix or 
ticlodone or ticlomed or ticlon or ticuring or tikleen or tiklid or tiklyd or tikol or 
tilodene or tiodin or tipidin or tipidine or tyklid or viladil).mp. 
4922 
20 (Rivaroxaban or xarelto).mp. 9305 
21 (Dabigatran or pradax or pradaxa or prazaxa or rendix).mp. 10004 
22 (Apixaban or eliques or eliquis).mp. 5968 
23 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 
21 or 22 
660898 
24 4 and 23 15137 
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25 ("randomized controlled trial" or "controlled clinical trial").pt. 0 
26 (random* or placebo* or single-blind* or double-blind* or triple-blind* or "single 
blind*" or "double blind*" or "triple blind*").ti,ab. 
1281645 
27 25 or 26 1281645 
28 24 and 27 2402 
29 ("graft paten*" or "graft occlu*" or "occlu* graft*" or "graft fail*" or "fail* graft*" or 
"patency rate*" or paten* or "total occlu*").mp. 
171788 
30 ("string sign" or stenosis or Fitzgibbon or "TIMI flow").mp. 265679 
31 ("cardiac revasculari$ation" or revasculari$ation or "repeat CABG" or "repeat 
coronary artery bypass" or "redo CABG" or "redo coronary artery bypass" or "re-do 
CABG" or "re-do coronary artery bypass" or PCI or "percutaneous coronary 
intervention").mp 
75778 
32 29 or 30 or 31 483433 
33 28 and 32 1114 
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eTable 3: CINAHL search strategy 
# Searches (November 13, 2016) Results 
1 (MH "Coronary Artery Bypass+") 7115 
2 “coronary artery bypass” or “coronary bypass” or “aortocoronary bypass” or 
“aortocoronary saphenous” or “aortocoronary vein” or “saphenous vein graft*” or 
CABG 
8615 
3 S1 OR S2 8657 
4 (MH "Platelet Aggregation Inhibitors+") 10826 
5 Antiplatelet* or anti-platelet* 2779 
6 (MH "Anticoagulants+") 14670 
7 Anticoagulant* or anti-coagulant* 11709 
8 “platelet antagonist*” or ‘platelet inhibitor*” or “thromboxane antagonist*” or 
“thromboxane inhibitor*” or “adenosine diphosphate receptor antagonist*” or 
“adenosine diphosphate receptor inhibitor*” or “ADP receptor antagonist*” or “ADP 
receptor inhibitor*” or “thienopyridine antagonist*” or “thienopyridine inhibitor*” or 
“cyclo-oxygenase antagonist*” or “cyclo-oxygenase inhibitor*” or “cyclooxygenase 
antagonist*” or ‘cyclooxygenase inhibitor*” or “cyclic GMP phosphodiesterase type V 
enzyme antagonist*” or “cyclic GMP phosphodiesterase type V enzyme inhibitor*” or 
“vitamin K antagonist*” or “vitamin K inhibitor*” or “vitamin-K antagonist*” or 
“vitamin-K inhibitor*” or “direct thrombin antagonist*” or “direct thrombin 
inhibitor*” or “direct factor Xa antagonist*” or “direct factor Xa inhibitor*” 
779 
9 (MH "Aspirin") 6415 
10 aspirin or acetylsalicylic acid or acylpyrin or aloxiprimuma or colfarit or dispril or 
easprin or ecotrin or endosprin or magnecyl or micristin or polopirin or polopiryna or 
solprin or solupsan or zorprin 
8489 
11 dipyridamole or persantine or antistenocardin or cerebrovase or cleridium or curantil 
or curantyl or dipyramidole or kurantil or miosen or novo-dipiradol or persantin or 
persantine 
544 
12 clopidogrel or Plavix or clopilet or grepid or iscover or zopya or zylagren or zylit 2327 
13 prasugrel or effient or efient 304 
14 ticagrelor or brilinta or brilique or possia 265 
15 indobufen or ibustrin 6 
16 warfarin or adoisine or athrombin or befarin or carfin or circuvit or coumadan or 
coumadin or coumadine or coumafene or coumaphene or dagonal or farin or jantoven 
or aldocumar or kumatox or maforan or marevan or orfarin or panwarfarin or 
panwarfin or prothromadin or sofarin or tintorane or uniwarfin or wafarin or waran or 
warfarine or warfilone or warnerin or marevan or tedicumar or warfant 
5257 
17 acenocoumarol or acenocoumarin or acenocoumarine or acenocoumarole or 
acenocoumarolum or acenocumarol or acenocumarolo or acenocumerol or 
acenokumarin or acitrom or neo sintrom or neosintrom or neositron or nicoumalone or 
nicumalon or nitrovarfarin or nitrowarfarin or sincoumar or sincumar or sinkumar or 
sinthrom or sinthrome or sintrom or sintroma or sintron or syncoumar or syncumar or 
syntrom or synthrom or trombostop or zotil or mini sintrom or mini-sintrom or 
minisintrom 
42 
18 phenprocoumon or falithrom or falithrome or fenprocoumon or liquamar or 
marcoumar or marcumar or phenprocouman or phenprocoumalol or phenprocoumarol 
or phenprocoumon or phenprocoumom or phenprocumarol or phenprogramma 
29 
19 Rivaroxaban or xarelto 525 
20 Dabigatran or pradax or pradaxa or prazaxa or rendix 722 
21 Apixaban or eliques or eliquis 292 
22 S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR 
S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 
28599 
23 random* or placebo* or "single-blind*" or "double-blind*" or "triple-blind*" or 
"single blind*" or "double blind*" or "triple blind*" 
186004 
24 ("graft paten*" or "graft occlu*" or "occlu* graft*" or "graft fail*" or "fail* graft*" or 7088 
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"patency rate*" or paten* or "total occlu*").mp. 
25 ("string sign" or stenosis or Fitzgibbon or "TIMI flow").mp. 12034 
26 ("cardiac revasculari$ation" or revasculari$ation or "repeat CABG" or "repeat 
coronary artery bypass" or "redo CABG" or "redo coronary artery bypass" or "re-do 
CABG" or "re-do coronary artery bypass" or PCI or "percutaneous coronary 
intervention").mp 
4806 
27 S24 OR S25 OR S26 22912 
28 S3 AND S22 AND S23 AND S27 42 
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eTable 4: Web of Science search strategy 
# Searches (November 13, 2016) Results 
1 “coronary artery bypass” or “coronary bypass” or “aortocoronary bypass” or 
“aortocoronary saphenous” or “aortocoronary vein” or “saphenous vein graft*” or 
CABG 
45358 
2 Antithrombotic* or anti-thrombotic* 17850 
3 Antiplatelet* or anti-platelet* or anticoagula* or anti-coagula* 96184 
4 “platelet antagonist*” or ‘platelet inhibitor*” or “thromboxane antagonist*” or 
“thromboxane inhibitor*” or “adenosine diphosphate receptor antagonist*” or 
“adenosine diphosphate receptor inhibitor*” or “ADP receptor antagonist*” or “ADP 
receptor inhibitor*” or “thienopyridine antagonist*” or “thienopyridine inhibitor*” or 
“cyclo-oxygenase antagonist*” or “cyclo-oxygenase inhibitor*” or “cyclooxygenase 
antagonist*” or ‘cyclooxygenase inhibitor*” or “cyclic GMP phosphodiesterase type V 
enzyme antagonist*” or “cyclic GMP phosphodiesterase type V enzyme inhibitor*” or 
“vitamin K antagonist*” or “vitamin K inhibitor*” or “vitamin-K antagonist*” or 
“vitamin-K inhibitor*” or “direct thrombin antagonist*” or “direct thrombin 
inhibitor*” or “direct factor Xa antagonist*” or “direct factor Xa inhibitor*” 
6260 
5 aspirin or acetylsalicylic acid or acylpyrin or aloxiprimuma or colfarit or dispril or 
easprin or ecotrin or endosprin or magnecyl or micristin or polopirin or polopiryna or 
solprin or solupsan or zorprin 
56834 
6 dipyridamole or persantine or antistenocardin or cerebrovase or cleridium or curantil 
or curantyl or dipyramidole or kurantil or miosen or novo-dipiradol or persantin or 
persantine 
8316 
7 clopidogrel or Plavix or clopilet or grepid or iscover or zopya or zylagren or zylit 14390 
8 prasugrel or effient or efient 2177 
9 ticagrelor or brilinta or brilique or possia 1538 
10 indobufen or ibustrin 194 
11 warfarin or adoisine or athrombin or befarin or carfin or circuvit or coumadan or 
coumadin or coumadine or coumafene or coumaphene or dagonal or farin or jantoven 
or aldocumar or kumatox or maforan or marevan or orfarin or panwarfarin or 
panwarfin or prothromadin or sofarin or tintorane or uniwarfin or wafarin or waran or 
warfarine or warfilone or warnerin or marevan or tedicumar or warfant 
25997 
12 acenocoumarol or acenocoumarin or acenocoumarine or acenocoumarole or 
acenocoumarolum or acenocumarol or acenocumarolo or acenocumerol or 
acenokumarin or acitrom or neo sintrom or neosintrom or neositron or nicoumalone or 
nicumalon or nitrovarfarin or nitrowarfarin or sincoumar or sincumar or sinkumar or 
sinthrom or sinthrome or sintrom or sintroma or sintron or syncoumar or syncumar or 
syntrom or synthrom or trombostop or zotil or mini sintrom or mini-sintrom or 
minisintrom 
1047 
13 phenprocoumon or falithrom or falithrome or fenprocoumon or liquamar or 
marcoumar or marcumar or phenprocouman or phenprocoumalol or phenprocoumarol 
or phenprocoumon or phenprocoumom or phenprocumarol or phenprogramma 
957 
14 Rivaroxaban or xarelto 3512 
15 Dabigatran or pradax or pradaxa or prazaxa or rendix 4340 
16 Apixaban or eliques or eliquis 1887 
17 #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 
OR #14 OR #15 OR #16 
174560 
18 #1 AND #17 2835 
19 controlled trial* OR clinical trial* OR comparative stud* OR OR prospective stud* 
OR random* OR placebo* OR (single blind*) OR (double blind*) 
2430123 
20 #18 AND #19 1214 
21 "graft paten*" or "graft occlu*" or "occlu* graft*" or "graft fail*" or "fail* graft*" or 
"patency rate*" or paten* or "total occlu*" 
105834 
22 "string sign" or stenosis or Fitzgibbon or "TIMI flow" 127165 
23 "cardiac revasculari$ation" or revasculari$ation or "repeat CABG" or "repeat coronary 85164 
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artery bypass" or "redo CABG" or "redo coronary artery bypass" or "re-do CABG" or 
"re-do coronary artery bypass" or PCI or "percutaneous coronary intervention" 
24 #21 OR #22 OR #23 295412 
25 #21 AND #20 705 
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eTable 5: Cochrane Library search strategy 
# Searches (October 31, 2016) Results 
1 MeSH descriptor: [Coronary Artery Bypass] explode all trees 5397 
2 “coronary artery bypass” or “coronary bypass” or “aortocoronary bypass” or 
“aortocoronary saphenous” or “aortocoronary vein” or “saphenous vein graft*” or 
CABG:ti,ab,kw 
9174 
3 #1 OR #2 9194 
4 MeSH descriptor: [Anticoagulants] explode all trees 4532 
5 MeSH descriptor: [Platelet Aggregation Inhibitors] 3505 
6 Anticoagula* or anti-coagula*:ti,ab,kw 9419 
7 Antiplatelet* or anti-platelet*:ti,ab,kw 3542 
8 MeSH descriptor: [Aspirin] 4816 
9 aspirin or acetylsalicylic acid or acylpyrin or aloxiprimuma or colfarit or dispril or 
easprin or ecotrin or endosprin or magnecyl or micristin or polopirin or polopiryna or 
solprin or solupsan or zorprin:ti,ab,kw 
11585 
10 dipyridamole or persantine or antistenocardin or cerebrovase or cleridium or curantil 
or curantyl or dipyramidole or kurantil or miosen or novo-dipiradol or persantin or 
persantine:ti,ab,kw 
1179 
11 clopidogrel or Plavix or clopilet or grepid or iscover or zopya or zylagren or 
zylit:ti,ab,kw 
3135 
12 prasugrel or effient or efient:ti,ab,kw 480 
13 ticagrelor or brilinta or brilique or possia:ti,ab,kw 417 
14 indobufen or ibustrin:ti,ab,kw 85 
15 warfarin or adoisine or athrombin or befarin or carfin or circuvit or coumadan or 
coumadin or coumadine or coumafene or coumaphene or dagonal or farin or jantoven 
or aldocumar or kumatox or maforan or marevan or orfarin or panwarfarin or 
panwarfin or prothromadin or sofarin or tintorane or uniwarfin or wafarin or waran or 
warfarine or warfilone or warnerin or marevan or tedicumar or warfant:ti,ab,kw 
3116 
16 acenocoumarol or acenocoumarin or acenocoumarine or acenocoumarole or 
acenocoumarolum or acenocumarol or acenocumarolo or acenocumerol or 
acenokumarin or acitrom or neo sintrom or neosintrom or neositron or nicoumalone or 
nicumalon or nitrovarfarin or nitrowarfarin or sincoumar or sincumar or sinkumar or 
sinthrom or sinthrome or sintrom or sintroma or sintron or syncoumar or syncumar or 
syntrom or synthrom or trombostop or zotil or mini sintrom or mini-sintrom or 
minisintrom:ti,ab,kw 
224 
17 phenprocoumon or falithrom or falithrome or fenprocoumon or liquamar or 
marcoumar or marcumar or phenprocouman or phenprocoumalol or phenprocoumarol 
or phenprocoumon or phenprocoumom or phenprocumarol or 
phenprogramma:ti,ab,kw 
189 
18 Rivaroxaban or xarelto:ti,ab,kw 547 
19 Dabigatran or pradax or pradaxa or prazaxa or rendix:ti,ab,kw 430 
20 Apixaban or eliques or eliquis:ti,ab,kw 316 
21 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR 
#15 OR #16 OR #17 OR #18 OR #19 OR #20 
24362 
22 #3 AND #21 1088 
23 "controlled trial*" or "clinical trial*" or "comparative stud*" or "prospective stud*" or 
random* or placebo* or "single blind*" or "double blind*" or “triple blind*” or 
"single-blind*" or "double-blind*" or "triple-blind*":ti,ab,kw 
704157 
24 #23 AND #22 952 
25 "graft paten*" or "graft occlu*" or "occlu* graft*" or "graft fail*" or "fail* graft*" or 
"patency rate" or paten* or "total occlu*":ti,ab,kw 
5963 
26 "string sign" or stenosis or Fitzgibbon or "TIMI flow":ti,ab,kw 7223 
27 "cardiac revasculari$ation" or revasculari$ation or "repeat CABG" or "repeat coronary 
artery bypass" or "redo CABG" or "redo coronary artery bypass" or "re-do CABG" or 
"re-do coronary artery bypass" or PCI or "percutaneous coronary 
6052 
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intervention":ti,ab,kw 
28 #27 or #28 or #29 17746 
29 #24 AND #30 432 
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eTable 6: Grey literature search strategy 
Sources (August 29, 2016) 
ClinicalTrials.gov 
International Clinical Trials Registry Platform (ICTRP): Australian (ANZCTR), India (CTRI), UK 
(EU-CTR), Chinese (ChiCTR), Dutch (NTR), German (DRKS), Japanese (UMIN CTR), Korean (CRiS), 
Persian (IRCT), Portuguese (ReBec), Spanish (PRCEC), Pan African (PACTR), Sri Lanka (SLCTR), 
Thai (TCTR) 
Other clinical trial registries: AstraZeneca, Bayer, Bristol-Myers Squibb 
USA Food and Drug Administration (FDA) 
Electronic Theses Online Service  
Gray Matters (https://www.cadth.ca/resources/finding-evidence/grey-matters) 
Key terms used for grey literature: 
CABG: coronary artery bypass, coronary bypass, CABG 
Antithrombotic agents: antithrombotic, antiplatelet, anticoagulation, aspirin, acetylsalicylic 
acid, clopidogrel, Plavix, prasugrel, effient, ticagrelor, brilinta, indobufen, Ibustrin, dipyridamole, 
persantine, warfarin, Coumadin, jantoven, acenocoumarol, sinthrome, phenprocoumon, 
marcumar, ticlopidine, Ticlid, rivaroxaban, Xarelto, apixaban, eliquis, dabigatran, pradaxa. 
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eTable 7: List of selected excluded studies (after full-text retrieval) 
No. Reference Reason for 
Exclusion 
1 ClinicalTrias.gov: NCT02201771; Compare the Efficacy of Different 
Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft 
Surgery (DACAB-1) 
Ongoing Trial 
2 ClinicalTrials.gov: NCT01560780; Prasugrel for Prevention of Early 
Saphenous Vein Graft Thrombosis –  
Ongoing Trial 
3 ClinicalTrials.gov: NCT01598337; The Effect of Antiplatelets Therapy 
on Saphenous Vein Coronary Artery Bypass Graft Patency  
Ongoing Trial 
4 ClinicalTrials.gov: NCT00330772; Preoperative Aspirin and 
Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The 
PAPA CABG Study (PAPA CABG)  
Ongoing Trial 
5 ClinicalTrials.gov: NCT01268917; The Effect of Preoperative Aspirin 
on Graft Patency and Cardiac Events in Off-pump Coronary Artery 
Bypass 
Ongoing Trial 
6 ClinicalTrials.gov: NCT02352402; The Effect of Ticagrelor on 
Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery 
Bypass Grafting Surgery (POPular CABG) 
Ongoing Trial 
7 de Waha A, Sandner S, von Scheidt M.... A randomized, parallel group, 
double-blind study of ticagrelor compared with aspirin for prevention of 
vascular events in patients undergoing coronary artery bypass graft 
operation: Rationale and design of the Ticagrelor in CABG (TiCAB) 
trial: An Investigator-Initiated trial. Am Heart J. 2016 Sep;179:69-76. 
Ongoing Trial 
8 Rafiq S, Johansson PI, Kofoed KF, Lund JT, Olsen PS, Bentsen S, 
Steinbrüchel DA. Thrombelastographic hypercoagulability and 
antiplatelet therapy after coronary artery bypass surgery (TEG-CABG 
trial): a randomized controlled trial. Platelets. 2017 Feb 22:1-8 
Highly selected 
group of patients 
(patients with 
hypercoagulable 
states) 
9 Kolluri R, Plessa AL, Sanders MC, Singh NK, Lucore C. A randomized 
study of the safety and efficacy of fondaparinux versus placebo in the 
prevention of venous thromboembolism after coronary artery bypass 
graft surgery. Am Heart J. 2016 Jan;171(1):1-6. 
Wrong 
intervention 
(heparin and 
fondapariux) and 
wrong outcome 
10 El Messaoudi S, Wouters CW, van Swieten HA, …. Effect of 
dipyridamole on myocardial reperfusion injury: A double-blind 
randomized controlled trial in patients undergoing elective coronary 
artery bypass surgery. Clin Pharmacol Ther. 2016 Apr;99(4):381-9 
Wrong 
intervention 
(dipyridamole) 
and Wrong 
outcome 
11 Paikin JS, Hirsh J, Ginsberg JS, Weitz JI, Chan NC, Whitlock RP, Pare 
G, Johnston M, Eikelboom JW. Multiple daily doses of acetyl-salicylic 
acid (ASA) overcome reduced platelet response to once-daily ASA after 
coronary artery bypass graft surgery: a pilot randomized controlled trial. 
Wrong outcome 
(did not assess 
VGF; did not 
report repeat 
revascularization) 
and only assess 
aspirin 
12 Thopte OS, Patil SP, Deshmukh RS. A study of aspirin plus clopidogrel 
versus aspirin alone on saphenous vein graft patency after coronary 
artery bypass graft surgery-an angiographic follow-up after three 
months. Indian Heart Journal. 2014;66:S22. 
Results are not 
reported 
(published) 
13 Ebrahimi R, Bakaeen FG, Uberoi A... Effect of clopidogrel use post 
coronary artery bypass surgery on graft patency. Ann Thorac Surg. 
Wrong study 
design (subgroup 
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2014 Jan;97(1):15-21 analysis of RCT) 
14 Gasparovic H, Petricevic M, Kopjar T, Djuric Z, Svetina L, Biocina B. 
Impact of dual-antiplatelet therapy on outcomes among aspirin-resistant 
patients following coronary artery bypass grafting. Am J Cardiol. 2014 
May 15;113(10):1660-7 
Wrong outcome 
(did not assess 
VGF nor repeat 
revascularization) 
15 Wang X, Gong X, Zhu T, Zhang Q, Zhang Y, Wang X, Yang Z, Li C. 
Clopidogrel improves aspirin response after off-pump coronary artery 
bypass surgery. J Biomed Res. 2014 Mar;28(2):108-13 
Duplication: Wang XZ, Gong XX, Zhu TT, Li CJ, Yang ZJ. [Effect of 
aspirin plus clopidogrel therapy on aspirin resistance after off-pump 
coronary artery bypass surgery]. Zhongguo Yi Xue Ke Xue Yuan Xue 
Bao. 2013 Oct;35(5):495-502.  
Wrong outcome 
(did not assess 
VGF; did not 
report repeat 
revascularization) 
16 Suwalski G, Smoczycski R, Banach M, Gryszko L, Szaaacski P, 
Krawczyk K, Hendzel P. Aspirin versus clopidogrel after off-pump 
coronary artery bypass grafting: Prospective, randomized head-to-head 
trial. In: 15th Annual Meeting of the International Society for 
Minimally Invasive Cardiothoracic Surgery. vol. 7. Los Angeles; 2012: 
138. 
Results are not 
reported 
(published) 
17 Deja MA, Kargul T, Domaradzki W, Stącel T, Mazur W, Wojakowski 
W, Gocoł R, Gaszewska-Żurek E, Żurek P, Pytel A, Woś S. Effects of 
preoperative aspirin in coronary artery bypass grafting: a double-blind, 
placebo-controlled, randomized trial. J Thorac Cardiovasc Surg. 2012 
Jul;144(1):204-9. 
Wrong outcome 
(did not assess 
VGF; did not 
report repeat 
revascularization 
as an independent 
endpoint) 
18 Veeger NJ, Zijlstra F, Hillege HL, van der Meer J, CABADAS 
Research Group of the Interuniversity Cardiology Institute of The 
Netherlands. Fourteen-year follow-up from CABADAS: vitamin K 
antagonists or dipyridamole not superior to aspirin. The Annals of 
thoracic surgery. 2010 Nov 30;90(5):1515-21. 
Wrong outcome 
(unclear definition 
of repeat 
revascularization) 
19 Tetik S, Ak K, Isbir S, Eksioglu-Demiralp E, Arsan S, Iqbal O, 
Yardimci T. Clopidogrel provides significantly greater inhibition of 
platelet activity than aspirin when combined with atorvastatin after 
coronary artery bypass grafting: a prospective randomized study. 
Clinical and Applied Thrombosis/Hemostasis. 2010 Apr;16(2):189-98. 
Wrong outcome 
20 Kayacioglu I, Gunay R, Saskin H…The role of clopidogrel and 
acetylsalicylic acid in the prevention of early-phase graft occlusion due 
to reactive thrombocytosis after coronary artery bypass operation. Heart 
Surg Forum. 2008;11:E152–157. 
Did not measured 
graft patency in 
all participants, 
but only in those 
who have positive 
exercise tests 
21 Nielsen AB, Bochsen L, Steinbruchel DA. Hypercoagulability and 
platelet inhibition after OPCAB. Randomized intervention with 
clopidogrel. Scand Cardiovasc J. 2007;41:325–30. 
Wrong outcome 
22 Morawski W, Sanak M, Cisowski M, Szczeklik M, Szczeklik W, 
Dropinski J, Waclawczyk T, Ulczok R, Bochenek A. Prediction of the 
excessive perioperative bleeding in patients undergoing coronary artery 
bypass grafting: role of aspirin and platelet glycoprotein IIIa 
polymorphism. J Thorac Cardiovasc Surg. 2005 Sep;130(3):791-6 
Wrong outcome 
23 Lim E, Cornelissen J, Routledge T, Kirtland S, Charman SC, Bellm S, 
Munday H, Khan O, Masood I, Large S. Clopidogrel did not inhibit 
platelet function early after coronary bypass surgery: A prospective 
randomized trial. J Thorac Cardiovasc Surg. 2004 Sep;128(3):432-5 
Wrong outcome 
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Duplication: Lim E, Cornelissen J, Routledge T… Biological efficacy 
of low versus medium dose aspirin after coronary surgery: results from 
a randomized trial [NCT00262275]. BMC medicine. 2006 May 
22;4(1):12.  
24 Shennib H, Endo M, Benhameid O. A feasibility study of the safety and 
efficacy of a combined clopidogrel and aspirin regimen following off-
pump coronary artery bypass grafting. Heart Surg Forum. 
2003;6(5):288-91. 
Wrong study 
design 
25 David JL, Limet R. Antiplatelet activity of clopidogrel in coronary 
artery bypass graft surgery patients. Thromb Haemost. 1999 
Nov;82(5):1417-21. 
Wrong outcome & 
Wrong 
intervention 
26 Hashimoto K, Onoguchi K, Sasaki T… Strategy for balancing 
anticoagulation and hemostasis in aortocoronary bypass surgery: blood 
conservation and graft patency. Jpn Circ J. 1999 Mar;63(3):165-9. 
Wrong 
intervention 
27 Post Coronary Artery Bypass Graft Trial Investigators. The effect of 
aggressive lowering of low-density lipoprotein cholesterol levels and 
low-dose anticoagulation on obstructive changes in saphenous-vein 
coronary-artery bypass grafts. N Engl J Med. 1997 Jan 16;336(3):153-
62. 
Wrong patient 
population ( 
randomization 
occurred 1-11 
years post-CABG) 
28 van der Meer J, Brutel de la Rivière A, van Gilst WH... Effects of low 
dose aspirin (50 mg/day), low dose aspirin plus dipyridamole, and oral 
anticoagulant agents after internal mammary artery bypass grafting: 
patency and clinical outcome at 1 year. CABADAS Research Group of 
the Interuniversity Cardiology Institute of The Netherlands. Prevention 
of Coronary Artery Bypass Graft Occlusion by Aspirin, Dipyridamole 
and Acenocoumarol/Phenprocoumon Study. J Am Coll Cardiol. 1994 
Nov 1;24(5):1181-8. 
Wrong outcome 
(IMA patency) 
and Wrong study 
design (Subgroup 
analysis of 
CABADAS trial) 
29 Mulder BJ, Van der Doef RM, Van der Wall EE... Effect of various 
antithrombotic regimens (aspirin, aspirin plus dipyridamole, 
anticoagulants) on the functional status of patients and grafts one year 
after coronary artery bypass grafting. European heart journal. 1994 Aug 
1;15(8):1129-34. 
Wrong study 
design (subgroup 
analysis of 
CABADAS trial) 
30 Goldman S, Copeland J, Moritz T…Long-term graft patency (3 years) 
after coronary artery surgery. Effects of aspirin: results of a VA 
Cooperative study. Circulation. 1994 Mar 1;89(3):1138-43. 
Double counting 
31 Rajah SM, Nair U, Rees M…Effects of antiplatelet therapy with 
indobufen or aspirin-dipyridamole on graft patency one year after 
coronary artery bypass grafting. The Journal of Thoracic and 
Cardiovascular Surgery. 1994 Apr 1;107(4):1146-53. 
Wrong 
intervention 
(indobufen and 
dipyridamole) 
32 Rohn V, Pirk J, Mach T. The effect of indobufen on aortocoronary 
bypass patency after 1 week and after 1 year. Cor et vasa. 1992 
Dec;35(4):162-4. 
Wrong 
intervention 
(indobufen and 
dipyridamole) and 
Study not in 
English 
33 Yamaguchi A, Kitamura N, Miki T, Tatebayashi T, Kawashima M, 
Otaki M, Tamura H. [Comparative study of anticoagulant management 
after coronary artery bypass surgery--warfarin versus dipyridamole]. 
Nihon Kyobu Geka Gakkai Zasshi. 1992 Apr;40(4):485-9. 
Wrong 
intervention 
(dipyridamole) 
and Study not in 
English 
34 Agnew TM, French JK, Neutze JM, Whitlock RM, Brandt PW, Kerr 
AR, Webber BJ, Rutherford JD. The role of dipyridamole in addition to 
low dose aspirin in the prevention of occlusion of coronary artery 
Wrong 
intervention 
(dipyridamole) 
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bypass grafts. Aust N Z J Med. 1992 Dec;22(6):665-70. 
35 Yli-Māyry S, Huikuri Hv, Korhonen Ur, Airaksinen K, Ikāheimo M, 
Linnaluoto MK, Takkunen JT. Efficacy And Safety Of Anticoagulant 
Therapy Started Pre-Operatively In Preventing Coronary Vein Graft 
Occlusion. European Heart Journal. 1992 Sep 1;13(9):1259-64. 
Wrong 
intervention 
(dipyridamole) 
36 Rovelli F, Cataldo G, Pellegrini A, Mannucci P, Marubini E, Degaetano 
G, Orzan F, Lavezzari M, Petroccione A, Pirotta N, Bertele V. 
Indobufen Versus Aspirin Plus Dipyridamole After Coronary-Artery 
Bypass-Surgery. Coronary Artery Disease. 1991;2(8):897-906. 
Wrong 
intervention 
(indobufen and 
dipyridamole) 
37 Ollivier JP. [Permeability of aortocoronary bypass after 6 months. A 
multicenter French study]. Arch Mal Coeur Vaiss. 1991 Apr;84(4):537-
42. 
Wrong 
intervention 
(dipyridamole) 
and Study not in 
English 
38 Ekeström SA, Gunnes S, Brodin UB. Effect of Dipyridamole 
(Persantin®) on Blood Flow and Patency of Aortocoronary Vein 
Bypass Grafts. Scandinavian journal of thoracic and cardiovascular 
surgery. 1990 Jan 1;24(3):191-6. 
Wrong 
intervention 
(dipyridamole) 
39 Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, 
Kern KB, Sethi G, Sharma GV, Khuri S, et al. Internal mammary artery 
and saphenous vein graft patency. Effects of aspirin. Circulation. 1990 
Nov;82(5 Suppl):IV237-42. 
Wrong outcome 
(IMA patency) 
and Wrong study 
design (subgroup 
analysis of RCT) 
40 Pfisterer M, Burkart F, Jockers G, Meyer B, Regenass S, Burckhardt D, 
Schmitt HE, Müller-Brand J, Skarvan K, Stulz P, Hasse J. Prevention of 
aortocoronary vein bypass graft occlusion: Which antithrombotic 
treatment and for how long?. Thrombosis Research. 1990 Jan 1;57:11-
21. 
First Duplication: Pfisterer M, Jockers G, Regenass S, … [How long 
should antithrombotic therapy be continued following aortocoronary 
bypass surgery?]. Schweiz Med Wochenschr. 1989 Oct 
28;119(43):1518-20. 
Second Duplication: Pfisterer 1989.  Duration of thrombolytic treatment 
after coronary artery bypass surgery. Schweiz Med Wochenschr 
Third Duplication: Pfisterer M, Jockers G, Meier B, … [Anticoagulants 
vs. low-dose aggregation inhibitors in the prevention of perioperative 
occlusion of aortocoronary bypass grafts. Preliminary results of a 
prospective randomized study]. Helv Chir Acta. 1987 Feb;53(4):497-
500. 
Fourth Duplication: Pfisterer M, Burkart F, Jockers G, … Trial of low-
dose aspirin plus dipyridamole versus anticoagulants for prevention of 
aortocoronary vein graft occlusion. Lancet. 1989 Jul 1;2(8653):1-7. 
Wrong 
intervention 
(OAC 12 mth vs 
OAC 3 mth) 
41 Sanz G, Pajaron A, Alegría E, Coello I, Cardona M, Fournier JA, 
Gómez-Recio M, Ruano J, Hidalgo R, Medina A. Prevention of early 
aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. 
Grupo Espanol para el Seguimiento del Injerto Coronario (GESIC). 
Circulation. 1990 Sep 1;82(3):765-73. 
Duplication: Sanz G. Does low-dose aspirin prevent aortocoronary vein 
bypass graft occlusion?. Thrombosis research. 1990 Jan 1;57:23-6. 
Wrong patient 
population (in all 
patients, 
dipyridamole was 
used before study 
medications were 
administered) 
42 Sethi GK, Copeland JG, Goldman S, Moritz T, Zadina K, Henderson 
WG. Implications of preoperative administration of aspirin in patients 
undergoing coronary artery bypass grafting. Journal of the American 
College of Cardiology. 1990 Jan 1;15(1):15-20. 
Wrong study 
design (subgroup 
analysis of 
Goldman 1988’s 
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RCT), Wrong 
intervention and 
Wrong outcome 
43 Weber MA, Hasford J, Taillens C, ... Low-dose aspirin versus 
anticoagulants for prevention of coronary graft occlusion. Am J Cardiol. 
1990 Dec 15;66(20):1464-8  
Duplication: Weber Meister. Br. J clin. Pharmac. 1984, 17, 703-11 
Wrong 
intervention 
(heparin) 
44 Pirk J, Rohn V, Peregrin J. The effect of ibustrin on early aortocoronary 
bypass patency. Cor Vasa. 1990;32(3):258-62. 
Wrong 
intervention 
(dipyridamole) 
45 Guiteras P, Altimiras J, Arís A, Augé JM, Bassons T, Bonal J, Caralps 
JM, Castellarnau C, Crexells C, Masotti M, et al. Prevention of 
aortocoronary vein-graft attrition with low-dose aspirin and triflusal, 
both associated with dipyridamole: a randomized, double-blind, 
placebo-controlled trial. Eur Heart J. 1989 Feb;10(2):159-67. 
Wrong 
intervention 
(dipyridamole) 
46 Gershlick AH, Lyons JP, Wright JE, …Long term clinical outcome of 
coronary surgery and assessment of the benefit obtained with 
postoperative aspirin and dipyridamole. Br Heart J. 1988 
Aug;60(2):111-6. 
Wrong 
intervention 
(dipyridamole) 
47 Thaulow E, Frøysaker T, Dale J, Vatne K. Failure of combined 
acetylsalicylic acid and dipyridamole to prevent occlusion of 
aortocoronary venous bypass graft. Scand J Thorac Cardiovasc Surg. 
1987;21(3):215-20. 
Wrong 
intervention 
(dipyridamole) 
48 Limet R, David JL, Magotteaux P, Larock MP, Rigo P. Prevention of 
aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine 
on early and late patency rates of venous coronary bypass grafts: a 
double-blind study. J Thorac Cardiovasc Surg. 1987 Nov;94(5):773-83 
Wrong 
intervention 
(Ticlopidine) 
49 Pirk J, Vojácek J, Kovác J. Improvement of aortocoronary bypass 
patency by antiplatelet drug administration. Preliminary 
communication. Cor Vasa. 1986;28(3):177-80. 
Duplication: Pirk J, Vojácek J, Kovác J, .... Improved patency of the 
aortocoronary bypass by antithrombotic drugs. Ann Thorac Surg. 1986 
Sep;42(3):312-4. 
Wrong 
intervention 
(dipyridamole) 
50 Brooks N, Wright J, Sturridge M, Pepper J, Magee P, Walesby R, 
Layton C, Honey M, Balcon R. Randomised placebo controlled trial of 
aspirin and dipyridamole in the prevention of coronary vein graft 
occlusion. Br Heart J. 1985 Feb;53(2):201-7. 
Wrong 
intervention 
(dipyridamole) 
51 Rothlin ME, Pfluger N, Speiser K, .... Platelet inhibitors versus 
anticoagulants for prevention of aorto-coronary bypass graft occlusion. 
Eur Heart J. 1985 Feb;6(2):168-75. 
Wrong 
intervention 
(ticlopidine) 
52 Rajah SM, Salter MC, Donaldson DR, … Acetylsalicylic acid and 
dipyridamole improve the early patency of aorta-coronary bypass grafts. 
A double-blind, placebo-controlled, randomized trial. J Thorac 
Cardiovasc Surg. 1985 Sep;90(3):373-7. 
Wrong 
intervention 
(dipyridamole) 
53 Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes 
DR Jr, Bardsley WT, Pluth JR, Wallace RB, Puga FJ, et al. Effect of 
dipyridamole and aspirin on late vein-graft patency after coronary 
bypass operations. N Engl J Med. 1984 Jan 26;310(4):209-14. 
Wrong 
intervention 
(dipyridamole) 
54 Chevigné M, David JL, Rigo P, Limet R. Effect of ticlopidine on 
saphenous vein bypass patency rates: a double-blind study. Ann Thorac 
Surg. 1984 May;37(5):371-8. 
Wrong 
intervention 
(ticlopidine) 
55 Chesebro JH, Clements IP, Fuster V…A platelet-inhibitor-drug trial in 
coronary-artery bypass operations: benefit of perioperative 
Wrong 
intervention 
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dipyridamole and aspirin therapy on early postoperative vein-graft 
patency. N Engl J Med. 1982 Jul 8;307(2):73-8. 
(dipyridamole) 
56 Mayer JE Jr, Lindsay WG, Castaneda W, Nicoloff DM. Influence of 
aspirin and dipyridamole on patency of coronary artery bypass grafts. 
Ann Thorac Surg. 1981 Mar;31(3):204-10. 
Wrong 
intervention 
(dipyridamole) 
57 Dale J. Prevention of closure of aorto-coronary venous bypass grafts. 
Scand J Haematol Suppl. 1981;38:131-41. 
Protocol (No 
results) 
58 Gohlke H, Gohlke-Bärwolf C, Stürzenhofecker P…Improved graft 
patency with anticoagulant therapy after aortocoronary bypass surgery: 
a prospective, randomized study. Circulation. 1981 Aug;64(2 Pt 2):II22-
7 
Duplication: Gohlke H, Gohlke-Bärwolf C, Stürzenhofecker P, 
Görnandt L, Ritter B, Reichelt M, Buchwalsky R, Schmuziger M, 
Roskamm H. [Improved flow through aortocoronary venous bypasses 
after anticoagulant therapy. A prospective randomized study]. Schweiz 
Med Wochenschr. 1981 Nov 7;111(45):1722-4. 
Wrong patient 
population (in all 
patients, 
dipyridamole was 
administered) 
59 Gohlke H, Gohlke C, Sturzenhofecker P…Influence Of Marcumar On 
Flow Through Aortocoronary Bypass-Prospective, Randomized Study. 
Inzeitschrift Fur Kardiologie 1979 Jan 1 (Vol. 68, No. 9, Pp. 651-651). 
C/O Springer-Verlag, Heidelberger Platz 3, 1000 Berlin 33, Germany: 
Dr Dietrich Steinkopff Verlag. 
Study not in 
English 
60 Thaneeru P.; Gamel A.E.; Harding S.; Galvin S.; Hamilton F.; Kirk M.;  
Devlin G. IMPACT: Improving Coronary Graft Patency with 
Postoperative Aspirin and Clopidogrel Versus Aspirin and Ticagrelor. 
2017. (conference abstract) 
Abstract (cannot 
extract relevant 
information) 
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eTable 8. Characteristics of included studies in the systematic review and network meta-analysis 
Study, 
Year 
Location 
Overall 
sample 
size 
No. of 
eligible 
arms 
Antithrombotic status prior 
random; antifibrinolytic use; 
heparin use 
Patency assess-
ment method 
(unit of analysis) 
Time from 
random to 
patency 
assessment 
Overall loss 
of patency 
follow-up  
CABG 
type; 
setting 
Pantely, 
1979 
US 47 2 NR; NR; NR Angiography (per 
patient+per graft) 
6 mth 21.3% CCAB; 
Elective + 
Urgent 
McEnany, 
1982 
US 216 3 NR; NR; NR Angiography (per 
patient+per graft) 
21.5 mth (range: 
1 to 47 mth) 
48.6% NR; 
Elective + 
Urgent 
Sharma, 
1983 
US 116 2 NR; NR; NR Angiography (per 
patient+per graft) 
12 mth 19.0% CCAB; NR 
Lorenz, 
1984 
DE 60 2 NR; NR; Yes during operation Cineangiography 
(per patient+per 
graft) 
4 mth 23.3% CCAB; NR 
Brown, 
1985 
US 98 2 NR; NR; NR Angiography (per 
patient+per graft) 
12 mth 16.3% CCAB; 
Elective 
Goldman, 
1988 
US 307 2 Stopped ASA ≥7 d pre-study 
entry; NR; NR 
Angiography (per 
patient+per graft) 
9 d (range: 6 to 
60 d) 
20.7% NR; 
Elective 
Goldman, 
1989* 
US 307 2 Stopped ASA ≥7 d pre-study 
entry; NR; NR 
Angiography (per 
patient+per graft) 
367 d (range: 62 
to 527 d) 
33.5% NR; 
Elective 
Goldman, 
1991 
US 489 2 Stopped ASA ≥5 d pre-CABG; 
NR; NR 
Angiography (per 
patient+per graft) 
8 d (range: 4 to 
58 d) 
28.2% CCAB; 
Elective 
Gavaghan 
1991 
AU 237 2 Stopped ASA or other 
antiplatelet agents ≥7 d pre-
CABG; NR; Yes during 
operation 
Angiography (per 
patient+per graft) 
363 d (range: 222 
to 430 d) 
7.6% CCAB; NR 
Van der 
Meer, 1993 
NL, DE, 
CH 
635 2 Stopped antiplatelet ≥14 d pre-
CABG or OAC ≥5 d pre-
CABG; NR; Yes during 
Angiography (per 
patient+per graft) 
371 d 15.9% CCAB; 
Elective 
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operation 
Hockings, 
1993 
AU 140 2 Stopped aspirin or platelet 
active drug ≥7 d pre-CABG; 
NR; NR 
Angiography (per 
patient) 
6 mth 27.1% NR; 
Elective 
Mujanovic, 
2009 
NO 20 2 All patients were on aspirin 
pre-CABG; NR; Yes during 
operation 
Angiography (per 
graft) 
3 mth 0% OPCAB; 
Elective 
Gao, 2009 CN 197 2 Stopped antiplatelet ≥5-7 d 
pre-CABG; NR 
64-Multislice CT 
Angiography (per 
graft) 
12 mth 0% CCAB + 
OPCAB; 
Elective + 
Urgent 
Kulik, 2010 CA 113 2 Aspirin was not withheld pre-
CABG; NR; NR 
Angiography (per 
patient + per graft) 
12 mth 18.6% CCAB + 
OPCAB; 
Elective 
Hage, 
2017* 
CA 113 2 Aspirin was not withheld pre-
CABG; NR; NR 
CT Angiography 
(per graft) 
8 y 41.6% CCAB + 
OPCAB; 
Elective 
Gao, 2010 CN 249 2 Stopped clopidogrel or aspirin 
≥7 d pre-CABG; NR; NR 
Multislice CT 
Angiography (per 
graft) 
3 mth 10.0% CCAB + 
OPCAB; 
Elective 
Sun, 2010 CA 99 2 NR; Y; NR Cardiac CT 
angiography (per 
patient) 
50 d 22.0% CCAB; 
Elective 
Mannacio, 
2012 
IT 300 2 Stopped antiplatelet ≥15 d pre-
CABG; Yes during peri-op, but 
not during first 15 d post-op; 
Yes during peri-op but not 
during first 15 d post-op 
64-slice 
multidetector CT 
angiography (per 
graft)  
12 mth 4% OPCAB; 
Elective 
Saw, 2016 CA 70 2 All patients were on aspirin 
pre-CABG; NR; NR 
320-detector or 
128-slice dual 
source CT scanner 
(per graft)  
12 mth 24.3% NR; 
Elective + 
Urgent 
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Slim, 2016 NR 20 2 NR; NR; NR 128-slice dual-
source scanner 
(per graft) 
12 mth 0% CCAB + 
OPCAB; 
Elective 
*Long-term follow-up of the originally published study. ASA: aspirin. CA: Canada. CH: Switzerland. CCAB: On-pump CABG. CN: 
China. CT: computed tomography. d: day(s). DE: Germany. DK: Denmark. IT: Italy. mth: month(s). NL: Netherlands. NO: Norway. 
NR: Not reported. OAC: oral anticoagulation. OD: once daily. OPCAB: Off-pump CABG. Random: randomization. Vit K A: Vitamin 
K Antagonists. y: year. 
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eTable 9. Demographic and clinical characteristics of patients enrolled in the included studies 
Study, Year 
Time of drug 
initiation 
post-CABG 
Treatment 
duration 
Relevant study arms Age (y) 
Male 
(%) 
DM 
(%) 
HTN 
(%) 
Prior 
MI 
(%) 
No. of any 
graft/vein 
per patient 
Pantely, 1979 +3 d 6 mth 
Vit K A: warfarin (INR target: 
NR) 
56±8 69.2 - - - 2.85/2.85 
Control: No study medication 52±8 83.3 - - - 2.54/2.54 
 
McEnany, 1982 
 
+3 to 4 d 12 mth 
Vit K A: warfarin (INR target: 
1.5-2) 
- 92.9 19.6 16.1 69.6 1.91/1.91 
Aspirin: 600 mg BID - 82.0 14.0 26.0 58.0 2.03/2.03 
Control: Matching placebo - 87.3 12.7 20.0 63.6 2.00/2.00 
Sharma, 1983 +3 to 5 d 12 mth 
Aspirin: 325 mg TID - 100 23.4 25.0 57.8 2.20/2.20 
Control: No study medication - 100 19.2 23.1 67.3 2.20/2.20 
Lorenz, 1984 +24 h 4 mth 
Aspirin: 100 mg OD 55±10 82.8 - - 58.6 2.69/2.69 
Control: Matching placebo 55±6 90.3 - - 77.4 3.35/3.35 
Brown, 1985 +67 ± 27 h 12 mth 
Aspirin: 325 mg TID - - - - - 3.10/3.10 
Control: Matching placebo - - - - - 3.30/3.30 
Goldman, 1988 -12 h <2 mth 
Aspirin: 325 mg OD 58±8 100 - 47.4 55.8 
-/3.20 
Control: Matching placebo 58±7 100 - 49.0 56.9 
Goldman, 1989* -12 h 12 mth 
Aspirin: 325 mg OD 59±8 100 - 45.2 52.9 
-/3.20 
Control: Matching placebo 58±8 100 - 49.5 57.0 
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Goldman, 1991 -12 h 0 h 
Aspirin: 325 mg OD 60±8 100 - 56.0 62.0 -/2.60 
Control: Matching placebo 60±7 100 - 50.0 60.0 -/2.60 
Gavaghan 1991 +1 h 12 mth 
Aspirin: 324 mg OD 56±8 86.6 0.0 45.0 56.7 -/3.40 
Control: Matching placebo 56±7 83.6 0.0 39.0 60.9 -/3.60 
Van der Meer, 1993 
-12 h; 
24 h 
12 mth 
Vit K A: 4 mg Acenocoumarol or 
6 mg Phenprocoumon (INR 
Target: 2.8-4.8) 
58±8 88.0 10.1 40.1 52.1 -/3.10 
Aspirin: 50 mg OD 58±8 87.0 8.1 34.0 56.0 -/2.80 
Hockings, 1993 -7 d 6 mth 
Aspirin: 100 mg OD 60±9 94.0 6.0 50.0 - 3.14/2.56 
Control: Matching placebo 60±9 92.3 5.8 30.8 - 3.48/2.79 
Mujanovic, 2009 
Immediately 
post-op 
3 mth 
Aspirin & Clopidogrel: 100 and 
75 mg OD, respectively 
58±8.5 - - - - 2.9±0.99/1.9 
Aspirin: 100 mg OD 60±8.5 - - - - 2.7±0.48/1.7 
Gao, 2009 +1 d Unclear 
Aspirin & Clopidogrel: 100 and 
75 mg OD, respectively 
61±10 82.1 60.0 62.1 58.9 
2.66±0.75/ 
1.71±0.94 
Clopidogrel: 75 mg OD 62±9.9 83.3 50.0 64.7 48.0 
2.49±0.72/ 
1.51±0.85 
Kulik, 2010 0 d 12 mth 
Aspirin & Clopidogrel: 162 and 
75 mg OD, respectively 
65±7.5 91.1 25.0 48.2 - 3.6±0.8/2.30 
Aspirin: 162 mg OD and 
matching placebo 
68±7.4 87.7 33.3 52.6 - 3.4±0.6/2.24 
Hage 2017* 0 d 12 mth 
Aspirin & Clopidogrel: 162 and 
75 mg OD, respectively 
72±7.7 92.2 33.3 64.7 - 3.6±0.8/2.30ǂ 
Aspirin: 162 mg OD and 
matching placebo 
75±7.6 87.5 45.8 83.3 - 3.4±0.6/2.24ǂ 
Gao, 2010 ≤ +48 h 3 mth 
Aspirin & Clopidogrel: 100 and 
75 mg OD, respectively 
58±8.3 82.3 39.8 61.9 49.6 3.18/2.14 
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Aspirin: 100 mg OD 60±7.9 83.8 40.5 56.8 44.1 3.11/2.09 
Sun, 2010 +6 to 7 h 1 mth 
Aspirin & Clopidogrel: 81 and 75 
mg OD, respectively 
66±9.4 93.9 36.7 69.4 46.9 4.04/2.35 
Aspirin: 81 mg OD 65±9.3 86.0 34.0 70.0 32.0 3.94/2.30 
Mannacio, 2012 
+28 ± 12 h 
 
12 mth 
 
Aspirin & Clopidogrel: 100 and 
75 mg OD, respectively 
59±7.7 73.3 0.0 47.3 38.0 3.1±0.6/1.78 
Aspirin: 100 mg OD 59±8.3 75.3 0.0 45.3 34.7 3.2±0.6/1.87 
Saw, 2016 
+58 to 59 h 
 
3 mth 
 
Aspirin & Ticagrelor: 81 mg OD 
and 90 mg BID, respectively 
62±7.5 85.7 31.4 74.3 14.3  3.49/1.14 
Aspirin: 81 mg OD and matching 
placebo 
63±9.7 88.6 28.6 80.0 20.0 3.71/1.69 
Slim, 2016 +6 h 8 mth 
Aspirin & Clopidogrel: 81 and 75 
mg OD, respectively 
- - 41.7 100 - 3.00/2.00 
Aspirin: 81 mg OD and matching 
placebo 
- - 62.5 87.5 - 3.38/2.38 
*Long-term follow-up of the originally published study. INR: International Normalized Ratio. ǂfrom a secondary source.72
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eTable 10. Pairwise meta-analyses of antithrombotic agents 
Intervention, 
by outcome 
Comparator 
No. 
of 
RCTs 
No. of events/Total 
OR (95% CI) 
I2 
(%) Intervention Comparator 
SVGF (Base case analysis) 
   Aspirin Control 8 138/599 182/583 0.62 (0.43-0.90) 41 
   Vit K A Control 2 15/47 25/61 0.68 (0.30-1.51) 0 
   Vit K A Aspirin 2 79/291 88/310 0.94 (0.66-1.35) 0 
   ASA/Clo Aspirin 6 56/546 83/539 0.60 (0.42-0.88) 0 
   ASA/Clo Clopidogrel 1 5/145 9/141 NE NA 
   ASA/Tic Aspirin 1 4/39 12/53 NE NA 
SVGF (Per graft analysis) 
   Aspirin Control 8 130/1243 194/1236 0.63 (0.49-0.80) 0 
   Vit K A Control 2 15/84 26/111 0.72 (0.33-1.59) 17 
   Vit K A Aspirin 2 85/637 100/643 0.84 (0.62-1.15) 0 
   ASA/Clo Aspirin 6 58/618 81/574 0.61 (0.42-0.88) 0 
   ASA/Clo Clopidogrel 1 5/145 9/141 NE NA 
   ASA/Tic Aspirin 1 4/39 12/53 NE NA 
Major bleeding 
   Aspirin Control 2 1/198 0/187 2.62 (0.11-64.98) NA 
   Vit K A Control 1 4/68 0/71 NE NA 
   Vit K A Aspirin 2 29/375 16/380 2.26 (0.56-9.12) 30 
   ASA/Clo Aspirin 4 6/262 8/256 0.76 (0.25-2.31) 0 
   ASA/Clo Clopidogrel 0 NR NR NR NA 
   ASA/Tic Aspirin 1 0/35 0/35 NE NA 
Mortality 
   Aspirin Control 4 5/309 3/290 1.54 (0.36-6.66) 0 
   Vit K A Control 2 1/81 0/101 3.44 (0.14-85.97) NA 
   Vit K A Aspirin 2 4/375 8/380 0.65 (0.10-4.10) 32 
   ASA/Clo Aspirin 4 4/374 6/373 0.67 (0.20-2.30) 0 
   ASA/Clo Clopidogrel 0 NR NR NR NA 
   ASA/Tic Aspirin 1 0/35 1/35 NE NA 
Myocardial infarction 
   Aspirin Control 3 4/374 5/362 0.97 (0.03-27) 70 
   Vit K A Control 1 1/68 5/77 NE NA 
   Vit K A Aspirin 2 25/375 26/380 0.97 (0.55-1.71) 0 
   ASA/Clo Aspirin 5 6/386 8/381 0.69 (0.23-2.04) 0 
   ASA/Clo Clopidogrel 0 NR NR NR NA 
   ASA/Tic Aspirin 1 0/35 0/35 NE NA 
Cerebrovascular accident 
   Aspirin Control 2 1/223 1/226 1.09 (0.07-17.89) NA 
   Vit K A Control 0 NR NR NR NA 
   Vit K A Aspirin 1 3/307 1/309 NE NA 
   ASA/Clo Aspirin 3 5/250 8/248 0.60 (0.19-1.87) 0 
   ASA/Clo Clopidogrel 0 NR NR NR NA 
   ASA/Tic Aspirin 1 0/35 0/35 NE NA 
Repeat revascularization 
   Aspirin Control 0 NR NR NR NA 
   Vit K A Control 0 NR NR NR NA 
   Vit K A Aspirin 0 NR NR NR NA 
   ASA/Clo Aspirin 2 7/201 9/198 0.72 (0.25-2.05) 0 
   ASA/Clo Clopidogrel 0 NR NR NR NA 
   ASA/Tic Aspirin 1 0/35 1/35 NE NA 
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Re-exploration for bleeding 
   Aspirin Control 4 34/506 9/485 3.59 (1.67-7.73) 0 
   Vit K A Control 0 NR NR NR NA 
   Vit K A Aspirin 1 18/307 10/309 NE NA 
   ASA/Clo Aspirin 1 0/49 1/50 NE NA 
   ASA/Clo Clopidogrel 0 NR NR NR NA 
   ASA/Tic Aspirin 0 NR NR NR NA 
Minor bleeding 
   Aspirin Control 0 NR NR NR NA 
   Vit K A Control 0 NR NR NR NA 
   Vit K A Aspirin 0 NR NR NR NA 
   ASA/Clo Aspirin 4 10/262 11/256 0.89 (0.36-2.18) 0 
   ASA/Clo Clopidogrel 0 NR NR NR NA 
   ASA/Tic Aspirin 1 11/35 1/35 NE NA 
MACCE 
   Aspirin Control 0 NR NR NR NA 
   Vit K A Control 0 NR NR NR NA 
   Vit K A Aspirin 1 52/307 43/309 NE NA 
   ASA/Clo Aspirin 3 6/330 8/332 0.75 (0.25-2.25) 0 
   ASA/Clo Clopidogrel 0 NR NR NR NA 
   ASA/Tic Aspirin 0 NR NR NR NA 
Not estimable because of zero events in both arms or insufficient data (<2 studies). ASA: 
Aspirin. ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. ASA/Tic: Dual-
antiplatelet therapy with aspirin and ticagrelor. Control: Placebo/control. MACCE: Major 
adverse cardiac and cerebrovascular event. NE: Not estimable. NR: Not reported. NA: 
Not applicable. SVGF: Saphenous vein graft failure. Vit K A: Vitamin K Antagonists. 
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eTable 11. Summary of direct, indirect, and network estimates for primary and 
secondary outcomes 
Treatment, by 
outcome 
Comparator 
Direct OR  
(95% CI) 
Indirect OR  
(95% CI) 
NMA OR  
(95% CI) 
SVGF (Base case analysis) 
   ASA/Clo Control - 0.40 (0.24-0.69) 0.40 (0.24-0.69) 
   ASA/Tic Control - 0.25 (0.07-0.94) 0.25 (0.07-0.94) 
   Vit K A Control 0.68 (0.30-1.51) 0.58 (0.28-1.21)  0.63 (0.37-1.06) 
   Aspirin Control 0.62 (0.43-0.90) 0.79 (0.19-3.41) 0.64 (0.47-0.88) 
   Clopidogrel Control - 0.77 (0.21-2.86) 0.77 (0.21-2.86) 
   ASA/Clo Aspirin 0.60 (0.42-0.88) Not estimable 0.63 (0.41-0.97) 
   ASA/Tic Aspirin 0.39 (0.12-1.32) Not estimable 0.39 (0.11-1.42) 
   Vit K A Aspirin 0.94 (0.66-1.35) 1.49 (0.42-5.21) 0.98 (0.61-1.57) 
   ASA/Clo Clopidogrel 0.52 (0.17-1.60) Not estimable 0.52 (0.16-1.73) 
   ASA/Tic Clopidogrel - 0.32 (0.05-1.98) 0.32 (0.05-1.98) 
   Vit K A Clopidogrel - 0.81 (0.21-3.15) 0.81 (0.21-3.15) 
   Aspirin    Clopidogrel - 0.83 (0.23-2.96) 0.83 (0.23-2.96) 
   ASA/Clo Vit K A - 0.64 (0.34-1.22) 0.64 (0.34-1.22) 
   ASA/Tic Vit K A - 0.40 (0.10-1.57) 0.40 (0.10-1.57) 
   ASA/Clo ASA/Tic - 1.62 (0.41-6.31) 1.62 (0.41-6.31) 
The estimated common between-study variance (tau2) = 0.2162 = 0.047 
SVGF (Per graft analysis) 
   ASA/Clo Control - 0.39 (0.25,0.61) 0.39 (0.25,0.61) 
   ASA/Tic Control - 0.25 (0.07-0.87) 0.25 (0.07-0.87) 
   Vit K A Control 0.72 (0.33-1.59) 0.53 (0.35-0.81) 0.57 (0.40-0.82) 
   Aspirin Control 0.63 (0.49-0.80) 1.04 (0.37-2.96) 0.65 (0.51-0.82) 
   Clopidogrel Control - 0.75 (0.22-2.49) 0.75 (0.22-2.49) 
   ASA/Clo Aspirin 0.61 (0.42-0.88) Not estimable 0.61 (0.42-0.88) 
   ASA/Tic Aspirin 0.39 (0.12-1.32) Not estimable  0.39 (0.12-1.32) 
   Vit K A Aspirin 0.84 (0.62-1.15) 1.47 (0.56-3.86) 0.89 (0.66-1.20) 
   ASA/Clo Clopidogrel 0.52 (0.17-1.60) Not estimable  0.52 (0.17-1.60) 
   ASA/Tic Clopidogrel - 0.34 (0.06-1.84) 0.34 (0.06-1.84) 
   Vit K A Clopidogrel - 0.77 (0.23-2.59) 0.77 (0.23-2.59) 
   Aspirin    Clopidogrel - 0.86 (0.27-2.81) 0.86 (0.27-2.81) 
   ASA/Clo Vit K A - 0.68 (0.42-1.11) 0.68 (0.42-1.11) 
   ASA/Tic Vit K A - 0.44 (0.13-1.54) 0.44 (0.13-1.54) 
   ASA/Clo ASA/Tic - 1.56 (0.43-5.56) 1.56 (0.43-5.56) 
The estimated common between-study variance (tau2) = (3.61×10-10)2 = 1.30×10-19 
Major bleeding (no Clopidogrel monotherapy) 
   ASA/Clo Control - 2.84 (0.25-32.26) 2.84 (0.25-32.26) 
   ASA/Tic Control - 3.75 (0.04-341.19) 3.75 (0.04-341.19) 
   Vit K A Control 9.98 (0.53-188.92) 2.50 (0.13-48.51) 6.70 (0.75-59.62) 
   Aspirin Control 2.62 (0.11-64.98) Not estimable 3.75 (0.42-33.28) 
   ASA/Clo Aspirin 0.76 (0.25-2.31) Not estimable  0.76 (0.26-2.20) 
   ASA/Tic Aspirin Not estimable Not estimable 1.00 (0.02-51.80) 
   Vit K A Aspirin 2.26 (0.56-9.12) Not estimable 1.79 (0.95-3.35) 
   ASA/Clo Vit K A - 0.42 (0.12-1.46) 0.42 (0.12-1.46) 
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   ASA/Tic Vit K A - 0.56 (0.01-30.44) 0.56 (0.01-30.44) 
   ASA/Clo ASA/Tic - 0.76 (0.01-45.19) 0.76 (0.01-45.19) 
The estimated common between-study variance (tau2) = (2.32×10-11)2 = 5.38×10-22 
Mortality (no Clopidogrel monotherapy) 
   ASA/Clo Control - 1.19 (0.21-6.71) 1.19 (0.21-6.71) 
   ASA/Tic Control - 0.57 (0.02-18.18) 0.57 (0.02-18.18) 
   Vit K A Control 3.44 (0.14-85.97) 0.53 (0.08-3.57) 1.04 (0.23-4.72) 
   Aspirin Control 1.54 (0.36-6.66) Not estimable 1.77 (0.52-5.99) 
   ASA/Clo Aspirin 0.67 (0.20-2.30) Not estimable  0.67 (0.20-2.30) 
   ASA/Tic Aspirin 0.32 (0.01-8.23) Not estimable 0.32 (0.01-8.23) 
   Vit K A Aspirin 0.65 (0.10-4.10) Not estimable 0.59 (0.19-1.87) 
   ASA/Clo Vit K A - 1.14 (0.21-6.17) 1.14 (0.21-6.17) 
   ASA/Tic Vit K A - 0.55 (0.02-17.09) 0.55 (0.02-17.09) 
   ASA/Clo ASA/Tic - 2.07 (0.07-66.02) 2.07 (0.07-66.02) 
The estimated common between-study variance (tau2) = (4.40×10-9)2 = 1.93×10-17 
Myocardial Infarction (no Clopidogrel monotherapy) 
   ASA/Clo Control - 0.38 (0.07-2.12) 0.38 (0.07-2.12) 
   ASA/Tic Control - 0.53 (0.01-34.71) 0.53 (0.01-34.71) 
   Vit K A Control 0.21 (0.02-1.89) 1.74 (0.19-15.92) 0.49 (0.12-2.00) 
   Aspirin Control 0.97 (0.03-27) Not estimable 0.52 (0.13-2.10) 
   ASA/Clo Aspirin 0.69 (0.23-2.04) Not estimable  0.71 (0.25-2.02) 
   ASA/Tic Aspirin NA Not estimable 1.00 (0.02-51.80) 
   Vit K A Aspirin 0.97 (0.55-1.71) Not estimable  0.92 (0.52-1.62) 
   ASA/Clo Vit K A - 0.77 (0.23-2.54) 0.77 (0.23-2.54) 
   ASA/Tic Vit K A - 1.09 (0.02-58.80) 1.09 (0.02-58.80) 
   ASA/Clo ASA/Tic - 0.71 (0.01-42.40) 0.71 (0.01-42.40) 
The estimated common between-study variance (tau2) = (1.04×10-7)2 = 1.08×10-14 
Not estimable because of zero events in all study arms or because a second direct 
comparison needed to contribute to that specific indirect comparison is not available. 
Bold estimates indicate statistically significant differences. ASA/Clo: Dual-antiplatelet 
with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and 
ticagrelor. Control: Placebo/control. Vit K A: Vitamin K Antagonists. 
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eTable 12. Treatment rankings according to SUCRA curves 
Treatment by outcome SUCRA 
SVGF (Base case analysis)  
   ASA/Tic 89.3 
   ASA/Clo 79.9 
   Vit K A 45.6 
   Aspirin 43.5 
   Clopidogrel 33.3 
   Control 8.4 
SVGF (Per graft analysis)  
   ASA/Tic 89.7 
   ASA/Clo 81.1 
   Vit K A 52.0 
   Aspirin 37.7 
   Clopidogrel 32.8 
   Control 6.7 
Major Bleeding (no Clopidogrel monotherapy) 
   Control 83.3 
   ASA/Clo 59.6 
   Aspirin 47.3 
   ASA/Tic 45.9 
   Vit K A 13.9 
Mortality (no Clopidogrel monotherapy) 
   ASA/Tic 66.4 
   Control 56.5 
   Vit K A 55.9 
   ASA/Clo 49.1 
   ASA 22.1 
Myocardial Infarction (no Clopidogrel monotherapy) 
   ASA/Clo 71.4 
   Vit K A 57.7 
   ASA/Tic 50.7 
   Aspirin 48.9 
   Control 21.3 
ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet 
therapy with aspirin and ticagrelor. Control: Placebo/control. SUCRA: Surface Under the 
Cumulative Ranking. Vit K A: Vitamin K Antagonists. Larger SUCRA values indicates 
better interventions. 
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eTable 13. Contribution percentage (%) of direct evidence to the entire network 
Outcome ASA/Clo 
vs ASA 
ASA/Tic 
vs ASA 
Vit K A 
vs ASA 
Aspirin vs 
Control 
ASA/Clo 
vs Clo 
Vit K A vs 
Control 
SVGF  
(base case 
analysis) 
27.7 17.3 16.4 16.2 17.3 5.1 
Major 
bleeding 
31.3 NE 33.7 16.7 NA 18.3 
Mortality 24.0 23.9 20.5 23.3 NA 8.3 
MI 30.9 NE 37.4 9.9 NA 21.8 
NE: not estimated because of zero events in all arms. NA: not applicable because 
outcome data were not reported. ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. 
ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. Clo: Clopidogrel 
monotherapy. Control: Placebo/control. Vit K A: Vitamin K Antagonists. 
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eTable 14. Local inconsistency tests assuming a common loop-specific heterogeneity 
estimated using the method of moments. 
Closed loop of evidence Inconsistency factor 
(IF, 95% CI) 
Loop heterogeneity,  
tau2 
SVGF (Base case analysis) 
   Aspirin-Vit K A-Control 0.25 (0.00-1.42) 0.098 
SVGF (Per graft analysis) 
   Aspirin-Vit K A-Control 0.30 (0.00-1.12) 0.000 
Major Bleeding 
   Aspirin-Vit K A-Control 0.85 (0.00-5.25) 0.000 
Mortality 
   Aspirin-Vit K A-Control 1.48 (0.00-5.22) 0.000 
Myocardial Infarction 
   Aspirin-Vit K A-Control 3.33 (0.00-7.06) 0.000 
Control: Placebo/control. Vit K A: Vitamin-K Antagonists. If the 95% CI excludes zero, 
incoherence is detected statistically. 
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eTable 15. Global inconsistency using the design-by-treatment interaction model 
Outcomes of interest Chi-square Global inconsistency, p-value 
SVGF (Base case analysis) 0.86 (df=3) 0.8341 
SVGF (Per graft analysis) 1.72 (df=3) 0.6323 
Major bleeding 1.49 (df=2) 0.4759 
Mortality 1.92 (df=3) 0.5899 
Myocardial infarction 3.31 (df=2) 0.1910 
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eTable 16. Quality of direct evidence assessment 
Comparison No. of RCTs Risk of bias Inconsistency Indirectness Imprecision Publication bias OR 
(95% CI) 
Quality of 
evidence 
Vein graft failure (Base case analysis) 
Aspirin vs Control 8 Not Serious1 Not Serious2 Serious3 Not  
Serious4 
Unclear5 0.62 (0.43-0.90) Moderate 
Vit K A vs Control 2 Serious6 Not Serious2 Serious3 Serious7 Unclear5 0.68 (0.30-1.51) Very Low 
Vit K A vs Aspirin 2  Serious8 Not Serious2 Serious3  Serious7 Unclear5 0.94 (0.66-1.35)  Very Low 
ASA/Clo vs Aspirin 6  Not Serious9  Not Serious2 Serious3 Not  
Serious4 
Unclear5 0.60 (0.42-0.88) Moderate 
ASA/Clo vs Clo 1  Not Serious NA10 Serious3 Serious7 Unclear5 0.52 (0.17-1.60) Low 
ASA/Tic vs Aspirin 1  Not Serious  NA10 Serious3 Serious7 Unclear5 0.39 (0.12-1.32) Low 
Major bleeding 
Aspirin vs Control 2 Not Serious NA10 Serious3  Serious7 NA11 2.62 (0.11-65)  Low  
Vit K A vs Control 1 Serious12 NA10 Not Serious   Serious7 NA11 9.98 (0.53-189) Low 
Vit K A vs Aspirin 2 Serious12 Not Serious2 Serious3  Serious7 NA11 2.26 (0.56-9.12) Very Low 
ASA/Clo vs Aspirin 4 Not Serious Not Serious2 Serious3  Serious7 NA11 0.76 (0.25-2.31) Low 
ASA/Tic vs Aspirin 1 Not Serious NA10 Not Serious  Serious13 NA11 Not estimable Moderate 
All-cause mortality 
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Aspirin vs Control 4 Not Serious Not Serious2  Serious3  Serious7 NA11 1.54 (0.36-6.66) Low 
Vit K A vs Control 2 Serious12 NA10 Not Serious Serious7 NA11 3.44 (0.14-86) Low 
Vit K A vs Aspirin 2 Serious12 Not Serious2 Serious3 Serious7 NA11 0.65 (0.10-4.10) Very Low 
ASA/Clo vs Aspirin 4 Not Serious Not Serious2 Serious3 Serious7 NA11 0.67 (0.20-2.30) Low 
ASA/Tic vs Aspirin 1 Not Serious NA10 Not Serious  Serious7 NA11 0.32 (0.01-8.23) Moderate 
All myocardial infarction 
Aspirin vs Control 3  Not Serious Not Serious2  Serious3 Serious7 NA11 0.97 (0.03-27) Low 
Vit K A vs Control 1 Serious12 NA10 Not Serious  Serious7 NA11 0.21 (0.02-1.89)  Low 
Vit K A vs Aspirin 2 Serious12  Not Serious2 Serious3 Serious7 NA11 0.97 (0.55-1.71) Very Low 
ASA/Clo vs Aspirin 5 Not Serious Not Serious2 Serious3 Serious7 NA11 0.69 (0.23-2.04) Low 
ASA/Tic vs Aspirin 1 Not Serious NA10 Not Serious  Serious13 NA11 Not estimable Moderate 
NA: Not applicable 
1Eight studies have incomplete patency data (range: 16% to 48.6%). Of these, three studies reported comparable missing rates and 
similar reasons for missing outcome across arms. Of six studies that reported in sufficient detail, adequate generation of a randomized 
sequence was performed in all of the studies and blinding was likely effective in all of them. No studies adequately described 
allocation concealment. 
2Low heterogeneity (I2 <75%). 
3At least one study used aspirin at doses higher than those that are currently used (75-100 mg/day) and/or SVGF is a surrogate 
outcome as well as the short duration of treatment and follow-up for SVGF are not very applicable to the real-world situation. 
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4The 95% confidence interval is narrow, does not cross the clinical decision threshold, and OIS is met. 
5As per protocol, the funnel plot or Egger’s test was not performed because of insufficient information (<10 studies). 
6No blinding in one study and incomplete blinding in another study. Both studies have incomplete patency data (range: 21% to 
48.6%), and the proportion of missing data was not balanced between arms in one study. 
7The confidence interval crosses the clinical decision threshold with small number of events and sample size. 
8Both studies failed to blind patients and personnel and had incomplete patency data (range: 15.9% to 48.6%). The proportion of 
missing data was not balanced between arms in one study.  
9Of six studies, one study did not blind patient and personnel and missing data (41.6%) was not balanced in another study. 
10Unable to assess because there are <2 studies available with non-zero events in both arms. 
11This NMA was designed to include studies that evaluated SVGF. Many studies reporting only clinical outcomes were excluded as a 
result of the design. Therefore, it is not possible to explore the impact of publication bias for clinical outcomes. 
12All studies failed to blind patients and personnel completely.  
13Small number of events and sample size. 
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eTable 17. Quality of network evidence assessment  
Comparison 
Direct Evidence Indirect Evidence Network Meta-Analysis* 
OR (95% CI) Quality of Evidence OR (95% CI) Quality of Evidence OR (95% CI) Quality of Evidence 
SVGF (Base case analysis) 
ASA/Clo vs Control - - 0.40 (0.24-0.69) Moderate1,3,5 0.40 (0.24-0.69) Moderate 
ASA/Tic vs Control - - 0.25 (0.07-0.94) Moderate1,3,6 0.25 (0.07-0.94) Moderate 
Vit K A vs Control 0.68 (0.30-1.51) Very Low 0.58 (0.28-1.21)  Very Low2,8 0.63 (0.37-1.06) Very Low 
Aspirin vs Control 0.62 (0.43-0.90) Moderate 0.79 (0.19-3.41) Very Low2,10 0.64 (0.47-0.88) Moderate 
Clopidogrel vs Control - - 0.77 (0.21-2.86) Very Low1,2,5 0.77 (0.21-2.86) Very Low 
ASA/Clo vs Aspirin 0.60 (0.42-0.88) Moderate Not estimable Not estimable 0.63 (0.41-0.97) Moderate 
ASA/Tic vs Aspirin 0.39 (0.12-1.32) Low Not estimable Not estimable 0.39 (0.11-1.42) Low 
Vit K A vs Aspirin 0.94 (0.66-1.35) Very Low 1.49 (0.42-5.21) Very Low2,4,7 0.98 (0.61-1.57) Very Low 
ASA/Clo vs Clopidogrel 0.52 (0.17-1.60) Low Not estimable Not estimable 0.52 (0.16-1.73) Low 
ASA/Tic vs Clopidogrel - - 0.32 (0.05-1.98) Very Low1,2,7 0.32 (0.05-1.98) Very Low 
Vit K A vs Clopidogrel - - 0.81 (0.21-3.15) Very Low1,2,7 0.81 (0.21-3.15) Very Low 
Aspirin vs Clopidogrel - - 0.83 (0.23-2.96) Low2,7 0.83 (0.23-2.96) Low 
ASA/Clo vs Vit K A - - 0.64 (0.34-1.22) Very Low1,2,5 0.64 (0.34-1.22) Very Low 
ASA/Tic vs Vit K A - - 0.40 (0.10-1.57) Very Low1,2,6 0.40 (0.10-1.57) Very Low 
ASA/Clo vs ASA/Tic - - 1.62 (0.41-6.31) Very Low2,5 1.62 (0.41-6.31) Very Low 
Major Bleeding 
ASA/Clo vs Control - - 2.84 (0.25-32.26) Very Low1,2,6 2.84 (0.25-32) Very Low 
ASA/Tic vs Control - - 3.75 (0.04-341.19) Very Low1,2,8 3.75 (0.04-341) Very Low 
Vit K A vs Control 9.98 (0.53-189) Low 2.50 (0.13-48.51) Very Low1,2,8 6.70 (0.75-60) Low 
Aspirin vs Control 2.62 (0.11-65) Low Not estimable Not estimable 3.75 (0.42-33) Low 
ASA/Clo vs Aspirin 0.76 (0.25-2.31) Low Not estimable  Not estimable 0.76 (0.26-2.20) Low 
ASA/Tic vs Aspirin NA Moderate Not estimable Not estimable 1.00 (0.02-52) Moderate 
Vit K A vs Aspirin 2.26 (0.56-9.12) Very Low Not estimable Not estimable 1.79 (0.95-3.35) Very Low 
ASA/Clo vs Vit K A - - 0.42 (0.12-1.46) Very Low1,2,6 0.42 (0.12-1.46) Very Low 
ASA/Tic vs Vit K A - - 0.56 (0.01-30.44) Very Low1,2,9 0.56 (0.01-30) Very Low 
ASA/Clo vs ASA/Tic - - 0.76 (0.01-45.19) Very Low2,4,8 0.76 (0.01-45) Very Low 
Mortality 
ASA/Clo vs Control - - 1.19 (0.21-6.71) Very Low1,2,6 1.19 (0.21-6.71) Very Low 
ASA/Tic vs Control - - 0.57 (0.02-18.18) Very Low1,2,5 0.57 (0.02-18) Very Low 
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Vit K A vs Control 3.44 (0.14-86) Low 0.53 (0.08-3.57) Very Low1,2,8 1.04 (0.23-4.72) Low 
Aspirin vs Control 1.54 (0.36-6.66) Low Not estimable Not estimable 1.77 (0.52-5.99) Low 
ASA/Clo vs Aspirin 0.67 (0.20-2.30) Low Not estimable  Not estimable 0.67 (0.20-2.30) Low 
ASA/Tic vs Aspirin 0.32 (0.01-8.23) Moderate Not estimable Not estimable 0.32 (0.01-8.23) Moderate 
Vit K A vs Aspirin 0.65 (0.10-4.10) Very Low Not estimable Not estimable 0.59 (0.19-1.87) Very Low 
ASA/Clo vs Vit K A - - 1.14 (0.21-6.17) Very Low1,2,8 1.14 (0.21-6.17) Very Low 
ASA/Tic vs Vit K A - - 0.55 (0.02-17.09) Very Low1,2,5 0.55 (0.02-17) Very Low 
ASA/Clo vs ASA/Tic - - 2.07 (0.07-66.02) Very Low2,4,8 2.07 (0.07-66) Very Low 
Myocardial Infarction 
ASA/Clo vs Control - - 0.38 (0.07-2.12) Very Low1,2,6 0.38 (0.07-2.12) Very Low 
ASA/Tic vs Control - - 0.53 (0.01-34.71) Very Low1,2,8 0.53 (0.01-35) Very Low 
Vit K A vs Control 0.21 (0.02-1.89) Low 1.74 (0.19-15.92) Very Low1,2,8 0.49 (0.12-2.00) Low 
Aspirin vs Control 0.97 (0.03-27) Low Not estimable Not estimable 0.52 (0.13-2.10) Low 
ASA/Clo vs Aspirin 0.69 (0.23-2.04) Low Not estimable  Not estimable 0.71 (0.25-2.02) Low 
ASA/Tic vs Aspirin NA Moderate Not estimable Not estimable 1.00 (0.02-52) Moderate 
Vit K A vs Aspirin 0.97 (0.55-1.71) Very Low Not estimable  Not estimable 0.92 (0.52-1.62) Very Low 
ASA/Clo vs Vit K A - - 0.77 (0.23-2.54) Very Low1,2,6 0.77 (0.23-2.54) Very Low 
ASA/Tic vs Vit K A - - 1.09 (0.02-58.80) Very Low1,2,9 1.09 (0.02-59) Very Low 
ASA/Clo vs ASA/Tic - - 0.71 (0.01-42.40) Very Low2,4,8 0.71 (0.01-42) Very Low 
ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. Control: 
Placebo/control. Vit K A: Vitamin-K Antagonists. Not estimable because a second direct comparison needed to contribute to that 
specific indirect comparison is not available. Indirect estimates were obtained using the node-splitting approach. 
*𝜏𝑁𝑀𝐴
2  <50% quantiles of the empirical distribution (i.e., low heterogeneity) and lack of evidence of incoherence. 
1. Probable intransitivity (more CCAB patients and/or earlier drug administration in one of the direct comparisons). 
2. Imprecision (wide 95% CI) 
3. Effect size is <0.5 and statistically significant. 
4. Probable intransitivity (more elective patients and/or earlier drug administration in one of the direct comparisons). 
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5. The rating of the direct comparison with a stronger contribution is moderate. 
6. The rating of the direct comparison with a stronger contribution is low. 
7. Both direct comparisons have equal contributions to the indirect evidence, but the rating of the one with a larger sample size is 
moderate. 
8. Both direct comparisons have equal contributions to the indirect evidence, but the rating of the one with a larger sample size is low. 
9. Both direct comparisons have equal contributions to the indirect evidence, but the rating of the one with a larger sample size is very 
low. 
10. The rating of the direct comparison with a stronger contribution is very low. 
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eTable 18. Imputation analysis: SVGF 
Treatment Comparator 
Pairwise 
OR (95% CI) 
NMA 
OR (95% CI) 
Base Case All missing failure 
   ASA/Clo Control - 0.40 (0.24-0.69) 0.53 (0.36-0.80) 
   ASA/Tic Control - 0.25 (0.07-0.94) 0.28 (0.08-0.99) 
   Vit K A Control 0.68 (0.30-1.51) 0.63 (0.37-1.06) 0.80 (0.54-1.17) 
   Aspirin Control 0.62 (0.43-0.90) 0.64 (0.47-0.88) 0.71 (0.55-0.92) 
   Clopidogrel Control - 0.77 (0.21-2.86) 1.02 (0.30-3.43) 
   ASA/Clo Aspirin 0.60 (0.42-0.88) 0.63 (0.41-0.97) 0.75 (0.55-1.02) 
   ASA/Tic Aspirin 0.39 (0.12-1.32) 0.39 (0.11-1.42) 0.39 (0.11-1.35) 
   Vit K A Aspirin 0.94 (0.66-1.35) 0.98 (0.61-1.57) 1.12 (0.80-1.56) 
   ASA/Clo Clopidogrel 0.52 (0.17-1.60) 0.52 (0.16-1.73) 0.52 (0.17-1.65) 
   ASA/Tic Clopidogrel - 0.32 (0.05-1.98) 0.27 (0.05-1.52) 
   Vit K A Clopidogrel - 0.81 (0.21-3.15) 0.78 (0.23-2.69) 
   Aspirin    Clopidogrel - 0.83 (0.23-2.96) 0.70 (0.21-2.30) 
   ASA/Clo Vit K A - 0.64 (0.34-1.22) 0.67 (0.42-1.05) 
   ASA/Tic Vit K A - 0.40 (0.10-1.57) 0.35 (0.10-1.26) 
   ASA/Clo ASA/Tic - 1.62 (0.41-6.31) 1.92 (0.53-6.90) 
ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. Control: 
Placebo/control. Vit K A: Vitamin-K Antagonists.  
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eTable 19. SUCRA values for SVGF after accounting for loss to follow-up 
Treatment by outcome Base case All Missing Failure 
SUCRA SUCRA 
   ASA/Tic 89.3 92.6 
   ASA/Clo 79.9 79.1 
   Vit K A 45.6 37.2 
   Aspirin 43.5 51.4 
   Clopidogrel 33.3 26.2 
   Control 8.4 13.4 
ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. Control: 
Placebo/control. SUCRA: Surface Under the Cumulative Ranking. Vit K A: Vitamin-K Antagonists. 
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eTable 20. Sensitivity analyses: SVGF 
Treatment Comparator 
Pairwise 
OR (95% CI) 
NMA 
OR (95% CI) 
Base Case 
Closer to 1-year 
follow-up 
Without OPCAB 
studies 
   ASA/Clo Control - 0.40 (0.24-0.69) 0.38 (0.22-0.66) 0.50 (0.26-0.96) 
   ASA/Tic Control - 0.25 (0.07-0.94) 0.24 (0.06-0.93) 0.25 (0.06-0.97) 
   Vit K A Control 0.68 (0.30-1.51) 0.63 (0.37-1.06) 0.58 (0.32-1.04) 0.63 (0.36-1.09) 
   Aspirin Control 0.62 (0.43-0.90) 0.64 (0.47-0.88) 0.62 (0.44-0.86) 0.64 (0.46-0.89) 
   Clopidogrel Control - 0.77 (0.21-2.86) 0.72 (0.19-2.75) 0.95 (0.24-3.80) 
   ASA/Clo Aspirin 0.60 (0.42-0.88) 0.63 (0.41-0.97) 0.62 (0.39-0.96) 0.78 (0.44-1.39) 
   ASA/Tic Aspirin 0.39 (0.12-1.32) 0.39 (0.11-1.42) 0.39 (0.11-1.44) 0.39 (0.10-1.46) 
   Vit K A Aspirin 0.94 (0.66-1.35) 0.98 (0.61-1.57) 0.93 (0.55-1.57) 0.98 (0.59-1.63) 
   ASA/Clo Clopidogrel 0.52 (0.17-1.60) 0.52 (0.16-1.73) 0.52 (0.16-1.76) 0.52 (0.15-1.78) 
   ASA/Tic Clopidogrel - 0.32 (0.05-1.98) 0.33 (0.05-2.09) 0.26 (0.04-1.74) 
   Vit K A Clopidogrel - 0.81 (0.21-3.15) 0.79 (0.20-3.21) 0.66 (0.16-2.80) 
   Aspirin    Clopidogrel - 0.83 (0.23-2.96) 0.85 (0.23-3.10) 0.67 (0.17-2.61) 
   ASA/Clo Vit K A - 0.64 (0.34-1.22) 0.66 (0.33-1.32) 0.79 (0.37-1.71) 
   ASA/Tic Vit K A - 0.40 (0.10-1.57) 0.42 (0.10-1.71) 0.40 (0.10-1.63) 
   ASA/Clo ASA/Tic - 1.62 (0.41-6.31) 1.58 (0.40-6.26) 1.99 (0.47-8.41) 
ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. Control: 
Placebo/control. OPCAB: Off-pump CABG. Vit K A: Vitamin-K Antagonists.
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eTable 21. Description of outcomes used in RCTs included in the present NMA 
Study, by outcome Description of outcome 
VEIN GRAFT FAILURE 
   Pantely 1979 
Measured at six postoperative months using coronary angiography and 
expressed per patient. A graft was defined as occluded if the contrast 
agent failed to flow through it and into the grafted artery. 
   McEnany 1982 
Measured at 21.5 postoperative months using coronary angiography 
and expressed per graft and per patient, including post-mortem. 
   Sharma 1983 
Measured at 12 postoperative months. Expressed per patient. Vein 
grafts were “opacified by selective cannulation or aortic root 
angiography.” 
   Lorenz 1984 
Measured at four postoperative months using coronary angiography 
and expressed per patient. Contrast was selectively injected into each 
vein graft bypass. 
   Brown 1985 
Measured at 12 postoperative months. Expressed per patient. Grafts 
(distal anastomoses) fully visualized to supply the distal artery during 
selective injection were called “patent”; otherwise they were 
considered occluded.  
   Goldman 1989 
Measured at 367 postoperative days. Expressed per patient. A single 
vein graft was defined as occluded if the contrast agent failed to flow 
through it and into the grafted artery. Each distal anastomotic site is 
counted as a single graft 
   Goldman 1991 
Measured at eight postoperative days. Expressed per patient. A graft 
was defined as occluded if the contrast agent failed to flow through it 
and into the grafted artery. Each distal anastomotic site is counted as a 
single graft 
   Gavaghan 1991 
Measured at 363 postoperative days using angiography with the 
transfemoral Judkin's technique. Vein graft occlusion (or patency) 
rates were expressed per patient (with one or more distal anastomoses 
occluded). A graft was defined as occluded if the contrast agent failed 
to flow through it and into the grafted artery. 
   Van der Meer  
   1993 
Measured at 371 postoperative days. Expressed per patient. A graft 
was defined as occluded “if the contrast agent failed to flow through 
the graft, or one or more distal anastomoses were occluded. A distal 
anastomosis was defined as occluded if contrast did not flow from the 
proximal graft into the grafted native artery.” 
   Hockings 1993 
Measured at six postoperative months using invasive angiography. 
Expressed per patient. 
   Mujanovic 2009 
Measured at three postoperative months using angiography. 
Fitzgibbons method of classification was used. Expressed per graft.  
   Gao 2009 
Measured at 12 postoperative months using 64-Multislice Computed 
Tomography Angiography (MSCTA) and expressed per graft. 
   Kulik 2010 
Measured at 12 postoperative months using angiography and 
expressed per patient. 
   Hage 2017 
Measured at eight postoperative years using CCTA and expressed per 
graft in surviving patients. 
   Gao 2010 
Measured at three postoperative months using multislice computed 
tomography angiography (MSCTA) and expressed per graft. A graft 
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was considered occluded if a conduit did not fill with contrast at all. 
   Sun 2010 
Measured at 50 postoperative days using cardiac CT angiography and 
expressed Per patient. “Stenosed grafts without diffuse luminal 
narrowing were considered to be patent” 
   Mannacio 2012 
Measured at 12 postoperative months using 64-slice multidetector CT 
angiography. The quality of the anastomosis and conduits was graded 
according to Fitzgibbon.  
   Saw 2016 
Measured at 12 postoperative months using 320-detector or 128-slice 
dual source CT scanner. A graft was defined as occluded if there was 
lack of contrast flow in the graft segment from the proximal 
anastomosis 
   Slim 2016 
Measured at 12 postoperative months using a 128-slice dual-source 
scanner (failure is defined as stenosis ≥50%) and expressed per graft. 
MAJOR BLEEDING 
   McEnany 1982 No definition 
   Gavaghan 1991 GI bleeding 
   Van der Meer  
   1993 
If life threatening or fatal and if blood transfusion or surgery was 
necessary 
   Kulik 2010 As per CURE trial definition 
   Hage 2017 
A follow-up Case Report Form was designed to collect long-term 
clinical data and was sent to patients via mail.  
   Sun 2010 
Intracranial hemorrhage… bleeding causing death, or bleeding 
requiring transfusion of >1 unit of RBC 
   Mannacio 2012 Defined according to the CURE trial 
   Saw 2016 
Bleeding events were defined as per PLATO study. Major bleeding 
was defined as “bleeding that led to clinically significant disability, or 
bleeding with haemoglobin drop ≥ 3.0 g/dL but <5.0 g/dL or requiring 
2-3 units of transfusion” 
   Slim 2016 Bleeding events were defined as per TIMI study 
MORTALITY 
   Pantely 1979 All cause mortality at 6 months 
   McEnany 1982 Mortality at 34 months 
   Sharma 1983 All cause mortality at 12 months 
   Brown 1985 All cause mortality at 12 months 
   Gavaghan 1991 All cause mortality at 12 months 
   Van der Meer     
   1993 
All cause mortality at 12 months 
   Mujanovic No definition at 3 months 
   Kulik 2010 All cause mortality at 12 months 
   Hage 2017 
Cardiac Mortality. A follow-up Case Report Form was designed to 
collect long-term clinical data and was sent to patients via mail.  
   Gao 2010 All cause mortality at 3 months 
   Sun 2010 All cause mortality at 1 month 
   Mannacio 2012 Cardiac death at 12 months 
   Saw 2016 
Cardiovascular death defined as “any death from cardiovascular or 
cerebrovascular cause, and any death without another known cause at 
12 months” 
MYOCARDIAL INFARCTION (MI) 
   McEnany 1982 Fatal and non-fatal MI at 24 months 
   Goldman 1991 Assessed during postoperative catherization (60 days) 
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   Gavaghan 1991 Peri-operative new Q wave infarction 
   Van der Meer   
   1993 
Diagnosed according to strict ECG criteria… at 12 months 
   Kulik 2010 Assessed at 12 months 
   Hage 2017 
Collected at 8 years. A follow-up Case Report Form was designed to 
collect long-term clinical data and was sent to patients via mail.  
   Sun 2010 
30-day MI defined as “creatine kinase-MB >10 times the upper limit 
of normal or >5 times the upper limit of normal with new Q waves 
>30 msec in 2 contiguous leads on electrocardiogram of a new wall 
abnormality” 
   Mannacio 2012 
Assessed at 12 months. According to the joint ESC/ACCF/AHA/WHF 
definition 
   Saw 2016 
Assessed at 12 months. In accordance with the universal definition198. 
MI with CABG was defined as “>5 times normal reference elevation 
of tropinin-I within 72 h after CABG…” 
   Slim 2016 Unknown. Assessed at 12 months 
Cerebrovascular Accidents (CVA) 
   Brown 1985 CVA at 12 months 
   Goldman 1991 CVA during postoperative catherization (60 days)  
   Van der Meer  
   1993 
Ischemic stroke at 12 months 
   Kulik 2010 CVA at 12 months 
   Hage 2017 
Ischemic stroke at 8 years. A follow-up Case Report Form was 
designed to collect long-term clinical data and was sent to patients via 
mail.  
   Sun 2010 Stroke at 30 days 
   Mannacio 2012 Stroke at 12 months 
   Saw 2016 
Assessed at 12 months. Stroke defined as “focal loss of neurological 
function caused by an ischaemic or haemorrhagic event…lasting ≥24 h 
or leading to death” 
CARDIAC RE-INTERVENTION 
   Veeger 2010 Need for repeat revascularization at 14 years 
   Kulik 2010 Need for coronary intervention at 12 months 
   Hage 2017 
Coronary reintervention (PCI) at 8 years. A follow-up Case Report 
Form was designed to collect long-term clinical data and was sent to 
patients via mail.  
   Mannacio 2012 Repeat revascularization (PCI or repeat CABG) at 12 months 
   Saw 2016 Repeat Revascularization (PCI or repeat CABG) at 12 months 
HEART FAILURE 
   Van der Meer  
   1993 
Assessed at 12 months 
SURGICAL RE-EXPLORATION FOR BLEEDING 
   Goldman 1988 Re-operation 
   Goldman 1991 Re-operation 
   Gavaghan 1991 Re-operation 
   Van der Meer  
   1993 
Re-operation for bleeding 
   Hockings 1993 Re-operation for bleeding 
   Sun 2010 Re-operation 
MACCE 
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   Van der Meer  
   1993 
MI, stroke, TIA, DVT, PE, major bleeding, death at 12 months 
   Kulik 2010 
Cardiovascular death, MI, CVA, hospitalization for coronary 
ischemia, need for coronary intervention at 12 months 
   Gao 2010 
Cardiovascular mortality, MI, and need for revascularization at 3 
months 
   Mannacio 2012 
Cardiac death, MI, repeat revascularization (PCI or repeat CABG), 
stroke at 12 months 
ADMISSION DUE TO CARDIOVASCULAR CAUSE 
   Kulik 2010 Hospitalization for coronary ischemia at 12 months 
MINOR BLEEDING 
   Kulik 2010 As per CURE trial definition 
   Hage 2017 
Data collected at 8 years. A follow-up Case Report Form was designed 
to collect long-term clinical data and was sent to patients via mail.  
   Sun 2010 
“Bleeding requiring modification of antithrombotic drug regimens or 
transfusion of 1 unit of RBC” 
   Mannacio 2012 Defined according to the CURE trial 
   Saw 2016 
“Bleeding that led to clinically significant disability, or bleeding with 
haemoglobin drop ≥ 3.0 g/dL but <5.0 g/dL or requiring 2-3 units of 
transfusion” 
   Slim 2016 Defined according to the TIMI trial 
DVT: deep vein thrombosis. GI: Gastrointestinal. PE: pulmonary embolism. PLATO: 
Platelet Inhibition and Patient Outcomes. RBC: red blood cells. TIMI: Thrombolysis in 
Myocardial Infarction. CURE: Clopidogrel in Unstable Angina to Prevent Recurrent 
Events. 
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eTable 22. Matrix indicating which outcomes that were and were not reported in included studies 
Study ID SVGF Major 
Bleed 
Mortality CVA MI Cardiac re-
intervention 
Heart 
Failure 
Surgical re-
exploration 
Minor 
bleeding 
Admission 
to hospital 
Pantely, 1979 √ (PP)  √        
McEnany, 1982 √ (PP) √ √  √      
Sharma, 1983 √ (PP)  √        
Lorenz, 1984 √ (PP)          
Brown, 1985 √ (PP)  √ √       
Goldman, 1988 √ (PP)       √   
Goldman, 1989 √ (PP)          
Goldman, 1991 √ (PP)   √ √   √   
Gavaghan 1991 √ (PP) √ √  √   √   
Van der Meer, 
1993 
√ (PP) √ √ √ √  √ √   
Hockings, 1993 √ (PP)       √   
Mujanovic, 2009 √ (PG)          
Gao, 2009 √ (PG)          
Kulik, 2010 √ (PP) √ √ √ √ √   √ √ 
Hage, 2017 √ (PG) √ √ √ √ √   √  
Gao, 2010 √ (PG)  √  √      
Sun, 2010 √ (PP) √ √ √ √   √ √  
Mannacio, 2012 √ (PG) √ √ √ √ √   √  
Saw, 2016 √ (PG) √ √ √ √ √   √  
Slim, 2016 √  PG) √   √    √  
√: Reported. PP: per patient. PG: per graft.
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eTable 23. Study-specific and comparison-specific risk of bias: SVGF  
Comparison 
No of 
studies 
Study ID 
Study-specific risk 
of bias 
Comparison-
specific risk of 
bias 
Aspirin vs 
Control 
8 
McEnany 1982,  
Sharma 1983,  
Lorenz 1984,  
Brown 1985,  
Goldman 1989,  
Goldman 1991,  
Gavaghan 1991,  
Hockings 1993 
High,  
High,  
High,  
Uncertain,  
Uncertain,  
Uncertain,  
Low,  
High 
Moderate (not 
serious) 
Vit K A vs 
Control 
2 
Pantely 1979,  
McEnany 1982 
High,  
High 
High (serious) 
Vit K A vs 
Aspirin 
2 
McEnany 1982,  
Van der Meer 
1993 
High,  
High High (Serious) 
ASA/Clo vs 
Aspirin 
6 
Mujanovic 2009,  
Hage 2017,  
Gao 2010,  
Sun 2010,  
Mannacio 2012,  
Slim 2016 
Low,  
Uncertain,  
Uncertain,  
Uncertain,  
Low,  
Low 
Low (serious) 
ASA/Clo vs  
Clo 
1 
Gao 2009 Low 
Low (serious) 
ASA/Tic vs 
Aspirin 
1 
Saw 2016 Low 
Low (serious) 
Bold texts indicate studies with larger sample sizes. ASA/Clo: Dual-antiplatelet with 
aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. 
Clo: Clopidogrel monotherapy. Control: Placebo/control. Vit K A: Vitamin-K 
Antagonists. 
Study-specific risk of bias assessment: low (if low risk of bias in all domains); uncertain 
(if high risk of bias in 1 domain); and high (if high risk of bias in ≥2 domains). 
Comparison-specific risk of bias assessment: low (if all studies with larger sample size 
are at low risk of bias); moderate (if studies with larger sample size are either at low or 
unclear risk of bias and no studies with high risk of bias); high (if ≥1 studies with larger 
sample size are at high risk of bias).  
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